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ABSTRACT 
 
Cancer is so widespread and lethal that it can be considered the biggest health problem of 
our century. Cancer drug development is a real challenge. Efforts outlined in this work 
were directed towards showing solid evidence that casein kinase 2 inhibitors can be used 
as a starting point for the development of potential cancer therapy. We first studied the 
effect of a specific CK2 inhibitor, DMAT, in a malignant megakaryoblastic leukemia cell 
line (MEG-01). Treated cells grew at a significantly lower rate than non-treated cells. 
Apoptosis was induced by DMAT in MEG-01 cells, dose and time dependent. When 
stimulated with DMAT, MEG-01 cells produced platelets in vitro and in vivo. These 
platelets were found to have a normal phenotype and normal function. MEG-01 tumor 
bearing mice had tumor growth inhibition due to DMAT. These mice had MEG-01 cells 
spleen infiltration, splenomegaly and high platelets counts. An in vivo pilot toxicity study 
showed that DMAT is not toxic to mice. Breast cancer, colon cancer and melanoma cells 
were treated with DMAT. We observed that in vitro DMAT induces significant 
proliferation arrest and apoptosis at a similar level in all the cancer cell lines tested. All 
the tumor bearing mice treated with DMAT showed tumor growth inhibition but this was 
dependent oh hormone level for breast cancer and varied with the type of cancer 
analyzed. 
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CHAPTER I 
INTRODUCTION 
1.1. COMPREHENSIVE LITERATURE REVIEW 
1.1.1. Cancer and casein kinase 2  
Cancer is so widespread and lethal that it can be considered the biggest health 
problem of our century. Cancer rates could increase by 50%, to 15 million new cases, in 
the year 2020 worldwide according to the World Cancer Report. Various unknown 
causes, diverse genetic and protein abnormalities as well as very different and complex 
molecular mechanisms make cancer drug development a real challenge. Harmful side-
effects are another problem that needs to be overcome in the search for possible cancer 
therapies. 
Efforts outlined in this work were directed towards showing solid evidence that 
casein kinase 2 (CK2) inhibitors can be used as a starting point for the development of 
potential cancer therapy. 
Why targeting casein kinase 2? 
 1 
 
 
In different cancers, including leukemia, a kinase, named casein kinase 2 (CK2), 
was found to be constitutively activated, over-expressed and to serve as an oncoprotein 
[1-7]. CK2 is a pleiotropic, ubiquitous kinase that phosphorylates Serine, Threonine, and 
Tyrosine amino acid residues. The protein is a heterotetramer with two catalytic subunits, 
α and α’, and two regulatory β subunits [8]. Each subunit was shown to be able to 
execute specific functions by itself or in the holoenzyme form, the αα’β2 (or α2β2) 
tetramer [9, 10]. CK2 was found to have both nuclear and cytoplasmic localization. It 
seems that CK2 is also characterized by the capability to undergo nucleo-cytoplasmic 
shuttling [3-5, 7, 11]. 
A combined effect from both nuclear and cytoplasmic CK2 will promote survival 
in cancer, see figure 1.1. In cancer cells, CK2 is deregulated (is hyperactive and elevated 
3- to 7- folds) [7]. The up-regulation and hyperactivity of CK2 has an anti-apoptotic 
effect and is correlated with aggressive tumor behavior in different cancer types 
examined and results in abnormal platelet counts in leukemia [12].  
Silencing of the CK2 alpha subunit was studied in vivo, in murine prostate cancer 
xenografts. A very interesting observation following this study showed that CK2 
inhibition affects the tumors (by inducing apoptosis and tumor ablation), but does not 
affect the normal surrounding tissue [3, 7]. A differential response to CK2 inhibition 
(with specific CK2 inhibitor, DRB and antisense nucleotides against CK2α mRNA) in 
different normal and benign cell lines (in vitro) was observed [6, 13]. Therefore it seems 
that normal and benign cells are less sensitive to the CK2 inhibition.  
CK2 elevation in nuclear matrix in cancerous cells is related to cell growth, 
survival and even resistance to apoptosis [5, 7, 11]. Nuclear localization of CK2 in 
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malignant versus normal tissues was observed on histological analysis of normal tissues 
and neck squamos carcinoma tissues [3, 14]. The effects of nuclear CK2 are due to the 
action of CK2 on cell cycle and nuclear proteins like MPF (cdc2/cyclin B), cdc 25, 
topoisomerase II, surviving and p53 just to mention a few. 
Inhibition of CK2 hinders angiogenesis in oxygen induced retinopathy, most 
probably due to the action of CK2 on AKT kinase [15]. CK2 is a positive regulator of 
AKT kinase [16, 17]. PI3K-AKT pathway deregulation is important in tumor 
development and tumor response to anti-cancer treatment. CK2α inhibition with antisense 
nucleotides against CK2α mRNA, potentates the effect of specific inhibition of PI3K-
AKT signaling pathway. CK2 forms a complex with AKT, and also phosphorylates AKT 
[16, 17]. This makes CK2 an angiogenic protein and thus by promoting angiogenesis will 
also promote tumor growth. 
CK2 phosphorylates pro-apoptotic Bid protein making it less sensitive to caspase-
8 cleavage and by this action, CK2 promotes cell survival by inhibiting apoptosis [18-
23]. 
BCR/ABL chimeric abnormal tyrosine kinase enhances survival of leukemia cells 
through modulation of pro-apoptotic and anti-apoptotic molecules in chronic 
myelogenous leukemia. BCR/ABL is involved in Ras signaling, JAK/STAT kinase 
pathways, PI3K/AKT kinase pathway, just to mention the most important ones [24-27]. 
BCR/ABL was found responsible of decreased expression of pro-apoptotic protein Bim, a 
Bcl-2 mediator [28-30]. BCR/ABL acts on PI3K/AKT pathway [31] that modulates 
activation of Bad and BCR/ABL prevents the translocation of Bad and Bax to the 
mitochondria [32-35]. 
 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. Actions of CK2 depending on its localization. 
Cytoplasmic CK2 acts on major cellular pathways stimulating cellular survival and 
rescuing cells from apoptosis and nuclear CK2 regulates cell cycle and nuclear proteins. 
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Therefore BCR/ABL involvement in intricate mechanisms of cellular signaling is 
responsible for its oncogenic action. Interestingly, CK2α was found to be a substrate for 
the ABL domain of BCR/ABL [36] and to form a specific complex with the BCR domain 
of BCR/ABL [37]. It was hypothesized that CK2α impedes sterically the binding of the 
ABL SH2 domain to BCR [37]. This results in proliferation abnormalities in Ph+ cells. 
Therefore CK2α was shown to be a possible regulator of BCR/ABL function [36, 37]. 
These studies sustain the idea that CK2α is an attractive cancer treatment target 
even though it is a pleiotropic kinase. Other proteins like PI3K, AKT, PKA, PKC, 
Topoisomerase II are targeted for cancer therapy, even though they are ubiquitous and 
pleiotropic. A general kinase inhibitor (also a CK2 inhibitor), heparin is used as a drug 
for thrombosis. Therefore, CK2 inhibitors can be exploited in order to develop new 
cancer drugs and also as an adjuvant of actual cancer therapies. 
1.1.2 Casein kinase 2 inhibitors 
CK2α protein kinase quite specific inhibitors have been developed. Such CK2α 
inhibitors belong to the classes of tetra-bromo-benzimidazole/triazole derivatives, 
indoloquinazolines and condensed polyphenolic compounds, see table I [38, 39]. TBB 
and DMAT inhibitors (ATP site directed) are cell permeable and are available for 
purchase at Calbiochem, USA. A hydrophobic pocket next to the ATP/GTP binding site 
(which in the CK2 case is smaller than on most of the other kinases, due to the aminoacid 
residues side-chains that are less bulky) gives them the high selectivity [38, 39]. TBB and 
DMAT are from the most selective (as screened from a panel of 38 kinases) and potent 
inhibitors of CK2α [40-42], see table I. DMAT has one of the lowest Ki value (40 nM) of 
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all the CK2α available chemically synthesized inhibitors and is one of the most specific 
inhibitors with respect to CK2, up to date. DMAT is ineffective on casein kinase 1 (CK1) 
up to 200 µM [40-42]. .The use of such inhibitors in various cancer cell lines in vitro 
produced apoptosis and proliferation arrest [1, 2, 6, 7, 10, 36, 43]. CK2 inhibitors use in 
human rhabdomyosarcoma cells increased the effects of tumor necrosis factor-related 
apoptosis-inducing ligand (TRAIL –Apo2L-) [20]. 
1.1.3. Cancer cells and apoptosis. 
Cancer cells are characterized by increased proliferation and loss of the normal 
phenotype and function. Cancer is caused by defects in signaling pathways including 
deregulation of apoptosis process with the consequent imbalance in cell growth. 
Apoptosis is a genetically programmed and evolutionary conserved mechanism 
through which normal development and tissue homeostasis are maintained [44-46]. 
Necrosis is cell death associated with an inflammatory process as a response to tissue 
damage. The programmed cell death, apoptosis, shows specific morphological features 
(figure 1.2) such as: cell shrinkage, DNA fragmentation and nuclear breakdown, cell 
blebbing, phosphatidylserine redistribution at the cell surface [44, 46, 47]. These 
morphological features are different from the ones found in the necrotic process, i.e., loss 
of membrane integrity, swelling and rupture of the cells [48]. It is important to 
differentiate cell death originating through apoptosis or cell death originating through 
necrosis. It has been shown [49, 50] that malfunctioning of the apoptotic event, triggers 
autoimmunitary disorders, immunodeficiency, cancer, viral infections, neurodegenerative 
and hematological diseases. 
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CK2 INHIBITOR Ki (µM) 
Emodin (from the cactus Aloe vera) – related coumarinic 
compound 8-hydroxy-4-methyl-9-nitrobenzo[g]chromen-2-
one (NBC) 
0.22 
Ellagic acid (from raspberry seeds) 0.02 
Tetra-bromo-cinnamic acid (from cinnamon) 0.11 
5,6-dichloro-1-ß-o-ribofuranosyl benzimidazole (DRB) 2 
4,5,6,7-Tetrabromobenzotriazole (TBB) 0.56 
2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole 
(DMAT) 
0.04 
Indoloquinazoline derivative – 5-oxo-5,6-
dihydroindolo(1,2a)quinazolin-7-yl acetic acid (IQA) 
0.17 
Heparin 0.14 
 
Table I. Most common CK2 inhibitors efficiency (Ki) 
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1.1.4. The apoptotic pathways 
Proliferation inducing oncoproteins malignantly transform cells in cooperation 
with anti-apoptotic processes [51]. For example studies of colon specimens harvested at 
diverse points along the adenoma-carcinoma conversion show that apoptosis is high in 
normal colonic epithelium, intermediate in adenomas and low in carcinomas [52].  
Death signals, from inside and outside of the cell, activate signaling networks, and form 
the apoptosis mechanism, see figure 1.3. The most important pathways that lead to 
apoptosis are categorized as the extrinsic apoptosis pathway and the intrinsic apoptosis 
pathway. Once an apoptotic signal is received, the apoptotic process is carried out by the 
caspases cascade, and mitochondria pathways [50, 53, 54]. The caspases cascade includes 
the activation of caspase-3, 6 and 7 by caspase-8. Regarding the extrinsic apoptosis 
pathway cells were classified as type 1, from FAS death receptor (CD95/Apo-1) leading 
to an efficient formation of death inducing signaling complex DISC, and type 2, from 
FAS death receptor (CD95/Apo-1) with slow DISC formation. In type 1 cells the 
caspases cascade is sufficient to induce cell death, whereas type 2 cells require an 
amplification of the death signal through the mitochondria pathway. 
 8 
 
 
 
 
 
 
 
 
Figure 1.2. Apoptotic versus necrotic phenotypes. 
The phenotype of apoptotic cell (blebbing, nuclear shrinkage and condensation, nuclear 
fragmentation) is different from the necrotic cell phenotype (cellular swelling and cellular 
rupturing) [55] 
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The mitochondria pathway requires the proteolytic activation of the BH3-only protein 
Bid by caspase-8 to a truncated form tBid (a C-terminal fragment) [56, 57] tBid 
translocates to the mitochondria and releases cytochrome c and other pro-apoptotic 
factors (SMAC/Diablo, AIF, ENDO-G, HtrA2/OMI) from mitochondrion. Release of the 
cytochrome c contributes to the formation of the apoptosome, i.e., cytochrome c, Apaf-1 
and dATP. The apoptosome activates caspase-9, which in turn contributes to the caspase 
cascade by activating caspase-3 [48, 56, 58-63]. Bid was found to be involved in the 
intrinsic pathway too, in anoikis (Bmf activation through subcellular relocalization) and 
by being a p53 target. Bid is the most obvious connection between the extrinsic and 
intrinsic pathway [60, 64, 65]. Even more evidence shows that both type 1 and type 2 
cells (FAS/CD95) activate mitochondria, releasing cytochrome c with different kinetics. 
The cytochrome c release is slower for the type 1 cells. and the cascade is regulated and 
directed by the amount of caspase-8 [56]. Bid is also involved in the metabolic cycle of 
cardiolipin. Cardiolipin is the major component of the mitochondria membrane [22]. 
Patients with anti-cardiolipin antibodies have recurrent thrombotic events, like patients 
suffering from myeloproliferative disorders [66]. Bid and tBid were found to 
permeabilize the mithocondrial membrane and to oligomerize and interact with other 
proteins involved in apoptosis (anti and pro apoptotic Bcl-2 family) [19, 21-23, 50, 62, 
67-69]. Therefore, Bid acts as a control in any event that results in loss of mithocondrial 
membrane potential and cytochrome c release and it may be said that is a very important 
link between the apoptotic pathways.  
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1.1.5. Apoptosis and casein kinase 2   
CK2 protects prostate cancer cells from tumor necrosis factor-related ligand 
(TRAIL/Apo2-L) mediated apoptosis, through prevention of caspase activation and 
blockage of mithocondrial apoptosis induced by TRAIL. TBB specific inhibition of CK2 
in PC-3 cells enhances TRAIL induced apoptosis after 24 hours of treatment [70]. DRB, 
another CK2 specific inhibitor, enhances TRAIL induced apoptosis in 
rhabdomyosarcoma and human colon carcinoma cells, by enhancing activity of DISC and 
caspase-8 mediated cleavage of Bid [13, 20]. Inhibition of CK2 will prevent 
phosphorylation of Bid, and thus caspase-8 will cleave Bid to tBid (its truncated form) 
which is Bid’s active form (pro-apoptotic). 
1.1.6. Bid apoptotic protein and casein kinase 2 
It was found out that Bid is a phosphoprotein and the phosphorylated protein is 
less sensitive to cleavage by caspase-8 and caspase-3 [18, 57]. Murine Bid is 
phosphorylated by casein kinases CK1 and CK2 (CK1ε isoform and CK2α in vitro and in 
vivo). Inhibition with heparin, a specific CK2 inhibitor (it does not inhibit CK1) 
increased significantly the cleavage by caspase-8 [18]. CK2 alone phosphorylates murine 
recombinant Bid and murine Bid isolated from mouse kidney cytosol. By means of this 
phosphorylation, the rate of cleavage of Bid, by caspase-8, is significantly reduced [57]. 
In murine Bid the CK2 proposed phosphorylation site was Thr58. For CK1 the proposed 
phosphorylation sites where Ser61 and Ser64. Other phosphorylation sites of murine Bid, 
by CK2 were found [18]. A human Bid decapeptide phosphorylation in vitro at Thr59 (a 
CK2 phosphorylation site) makes it less sensitive to cleavage by caspase-8 and caspase-3 
[57].  
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Figure 1.3. Main apoptotic and common pathways for CK2 and BCR/ABL proteins. 
Extrinsic apoptotic pathway starts from the outside of the cell from death receptors and it can go 
through the mitochondria or through the caspases cascade. The intrinsic apoptotic pathway 
gathers signaling from the inside of the cell and goes through the mitochondria. BCR/ABL 
chimeric oncoprotein as well as CK2 kinase are involved in important pathways like the Ras 
signaling, JAK/STAT kinase pathway, PI3K/AKT pathway and apoptotic pathways. [48, 56, 61] 
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Thr59 is more critical in human when compared with Ser61, Ser65 relative to the 
corresponding murine Thr58, Ser61 and Ser64 (in mouse, Ser61 and Ser64 count for the 
highest level of phosphorylation) [18, 57]. Therefore phosphorylation sites and their 
importance in the context, differ between species. This data suggests that for human Bid, 
CK2 is the most important phosphorylating enzyme. Given this information we can 
conclude that CK2 is an important enzyme in the apoptotic cascade. 
1.1.7. Philadelphia chromosome positive disorders 
The reciprocal chromosomal translocation (9; 22), known as the Philadelphia 
positive chromosome (Ph+) [71] is associated with chronic myelogenous leukemia 
(CML) [72], acute lymphocytic leukemia (ALL) [73, 74] and can appear in acute 
myelogenous leukemia (AML) [75]. This genetic abnormality results in a chimeric 
oncoprotein BCR/ABL tyrosine kinase, which is thought to be the main cause of the 
abnormal survival and over-proliferation of hematopoietic stem cells and their progeny 
[76, 77]. In CML, the BCR/ABL tyrosine kinase is constitutively activated.  Different 
intracellular pathways are transformed by the oncoprotein BCR/ABL, resulting in 
uncontrolled hematopoietic proliferation. The late phase of CML, named blast crisis (or 
blastic phase), is characterized by extreme overproliferation of stem cells in the bone 
marrow and their progeny. During blast crisis, the major complication is thrombosis due 
to high platelet counts [77]. Platelets (thrombocytes) are vital for maintaining normal 
hemostasis and for the response of the human body to trauma. Thrombosis is lethal 
because it leads to organ damage (stroke, hearth attack). In myeloproliferative disorders, 
like CML, the platelet count and function are abnormal due to malignant 
megakaryoblasts overproliferation, as well as impaired maturation of blastic cells.  
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1.1.8. Chronic myelogenous leukemia: actual treatments and problems 
The treatment of choice for CML is Imatinib Mesylate (4-[(4-Methyl-1-
piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-yrimidinyl]amino]-phenyl]-
benzamide - methanesulfonate), a BCR/ABL tyrosine kinase inhibitor (Gleevec) formerly 
named STI571 [77]. Treatments with STI571 show good hematologic and cytogenetic 
remission in patients with early stage CML. However, patients in blast crisis are little or 
no responsive to the inhibitor. These patients also present additional and more aggressive 
adverse effects. The main cause of this problem is the development of STI571 resistance 
[72, 77-79]. Point mutations, ATP phosphate-binding loop mutations [78], gene 
amplification and protein over-expression of BCR/ABL tyrosine kinase are the main 
cause of this resistance, besides other defects in intracellular signaling pathways [79, 80]. 
Other BCR/ABL tyrosine kinase inhibitors (Dasatinib and AMN107) show a better 
response than Imatinib in phase II trials, but acquired resistance still remains the major 
problem [79]. A point mutation in the BCR/ABL kinase (Thr315→Ile) was associated 
with resistance to all BCR/ABL pharmaceutical inhibitors. This specific mutation causes 
resistance, because of a hydrogen bond that impedes inhibitor binding and which does not 
affect the protein BCR/ABL carcinogenic function [81]. Altogether, the data 
demonstrated that the acquired mutations in BCR/ABL oncoprotein together with other 
molecular changes induce BCR/ABL tyrosine kinase inhibitors resistance. Activation of 
other kinases may contribute to the onset of the disease and also to the gained resistance. 
Targeting such kinases with protein kinase inhibitors may offer a clinical benefit by 
providing drugs that could overcome the resistance to BCR/ABL tyrosine kinase 
inhibitors. 
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1.1.9. BCR-ABL oncoprotein and apoptosis 
BCR/ABL tyrosine kinase enhances survival of leukemic cells through modulation 
of pro-apoptotic and anti-apoptotic molecules in chronic myelogenous leukemia. 
BCR/ABL is involved in Ras signaling, JAK/STAT kinase pathways, PI3K/AKT kinase 
pathway, just to mention the most important ones [24-27]. BCR/ABL was found 
responsible of decreased expression of pro-apoptotic protein Bim, a Bcl-2 mediator [28-
30]. BCR/ABL acts on PI3K/AKT pathway [31] that modulates activation of Bad and 
BCR/ABL prevents the translocation of Bad and Bax to the mitochondria [32-35]. 
Therefore BCR/ABL involvement in intricate mechanisms of cellular signaling is 
responsible for its oncogenic action. CK2 is an interacting partner and regulator of 
BCR/ABL [2, 4-6, 13, 36, 82-86]. 
1.1.10. Casein kinase 2 and BCR/ABL 
The up-regulation and hyperactivity of CK2 has an anti-apoptotic effect in 
leukemia and results in abnormal platelet counts [12]. Interestingly, CK2α was found to 
be a substrate for the ABL domain of BCR/ABL [36] and to form a specific complex 
with the BCR domain of BCR/ABL [37]. It was hypothesized that CK2α impedes 
sterically the binding of the ABL SH2 domain to BCR [37]. This results in proliferation 
abnormalities in Ph+ cells. Therefore CK2α was shown to be a possible regulator of 
BCR/ABL function [36, 37]. Other functions of CK2α downstream of the BCR/ABL 
interaction may provide an overall cancer promoting response in Ph+ positive cells. 
1.1.11. Megakaryocytopoiesis and thrombocytopoiesis processes 
Megakaryocytes are polyploid cells, originating from hematopoietic stem cells in 
the bone marrow. All hematopoietic progenitor cells express surface antigens CD34 and 
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CD41 and characteristic to the megakaryocytic lineage is the expression of CD61 and 
increased expression of CD41 [87]. CD61 antigen recognizes a 110-kDalton protein, also 
known as GpIIIa, the common β subunit (integrin β3-chain) of the GpIIb/IIIa complex 
(αIIbβ3) and the vitronectin receptor – αVβ3– [88]. The GpIIb/IIIa complex and αVβ3 are 
glycoproteins from the class of integrins. Integrins are α/β- heterodimeric glycoprotein 
complexes that are involved in cell adhesion. The CD41 antigen corresponds to the GpIIb 
(αIIb) protein. The GpIIb/IIIa (αIIbβ3) complex is formed from the GpIIIa (antigen CD61) 
and GpIIb (antigen CD41) proteins. This GpIIb/IIIa (αIIbβ3) complex acts as a receptor for 
fibrinogen, von Willebrand factor (vWf), fibronectin and vitronectin on activated 
platelets. With the αVβ3, α-chain or αv (CD51 antigen), the GpIIIa (CD61 antigen) forms 
αVβ3. αVβ3 mediates activation-independent cell adhesion to vitronectin, vWf, fibrinogen, 
and thrombospondin. The CD61 and CD41 antigens are found on all normal resting and 
activated platelets. The CD61 antigen is found on endothelial cells, megakaryocytes, and 
on some myeloid, erythroid, and T-lymphoid leukemic cell lines. CD41/CD61 complex is 
expressed on platelets, megakaryocytes, and early hematopoietic progenitors [89-93]. 
Megakaryocytes produce and release platelets into the circulation, through a 
complex process, normally regulated by cytokines (thrombopoietin –TPO– and 
interleukins –IL–). TPO and interleukins, which are modulating all the steps of 
megakaryocytic development (megakaryocytopoiesis) were proven not to be essential in 
the final stages of platelets production (pro-platelets formation and platelets release) [94]. 
More interesting, TPO was found to inhibit platelets formation in vitro [87, 95]. 
Megakaryocyte progenitors are usually identified the bone marrow by 
immunoperoxidase and AChE labeling. Megakaryoblasts undergo endomitosis (usually 
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to attain a DNA content of 16N, but higher DNA contents were noticed) and cytoplasmic 
maturation to the stage of megakaryocytes prior to platelets release, through a process 
called megakaryocytopoiesis (see figure 1.4). The first precursor in the megakaryocytic 
linage is the promegakaryoblast (2N ploidy level). The megakaryoblast comes from the 
promegakaryoblast and has two sets of chromosomes (4N) and is 10 to 50 µm diameter. 
In Romanovski stain is intensely basophilic (this is an indication of high quantities of 
ribosomes). The platelet specific granules are not found in megakaryoblasts. 
Promegakaryocyte stage is the last one before megakaryocyte stage is achieved. 
Promegakaryocytes are bigger in diameter (20-80 µm) with the cytoplasm less basophilic 
and are positive for alpha granules. After the process of endomitosis is finished, 
megakaryocytes undergo cytoplasmic maturation. During this process, the cytoplasm fills 
with platelets-specific proteins, organelles and membrane systems (demarcation 
membrane system or “platelets maps”, the dense tubular system) and secretory granules. 
Mature megakaryocytes reach the pro-platelets bearing stage as final level of this 
differentiation process. Proplatelets bearing megakaryocyte fragments give rise to the 
anucleated cells, platelets, through the process of thrombocytopoiesis, see figure 1.5 [87, 
94, 96-106]. 
1.1.12. Apoptosis and platelets production 
The thrombocytopoiesis process (platelets production from megakaryocytes) is not 
fully understood but is linked with constitutive apoptosis of megakaryocytic cells [99, 
101-113]. It has been shown that pro-platelets bearing megakaryocytes contain nuclei 
with typical apoptotic chromosomal condensation and DNA fragmentation. The whole 
process of platelet formation from megakarycoytes consists of cytoskeletal 
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reorganization, membrane condensation, ruffling and specific apoptotic nuclear changes 
[87]. Megakaryocytes with proplatelet extensions were stained positive for active 
caspases [99]. Caspase activation in megakaryocytes is connected with platelet 
production. Caspase 3 and 9 are active in mature megakaryocytes and their inhibition 
stops proplatelets formation [108]. Caspase 3 is overexpressed and caspase 9 is not 
present in platelets. Caspase 12 found in megakaryocytes is absent in platelets [87]. 
Apoptosis inducing cytokines like TNFα and INFα trigger the release of platelets [99, 
109]. Megakaryoblasts from individuals with CML are capable of differentiating in vitro 
in response to Phorbol 12-myristate 13-acetate (PMA) [96, 114], nitric oxide (NO) [109], 
aphidicolin and nocodazole (which are apoptosis inducers, by inhibiting DNA synthesis) 
[106, 111]. Megakaryocytopoiesis results in platelet formation as a consequence of 
mitochondrial cytochrome c release, either by intrinsic apoptotic pathway or by type 2 
extrinsic apoptotic pathway [99, 108, 113]. Apoptosis inhibitory proteins such as Bcl-2 
and Bcl-XL are expressed in early megakaryocytes but are not found in mature 
megakaryocytes and platelets [104, 112]. Nitric oxide is also expressed in mature 
megakaryocytes and has a pro-apoptotic function [109]. Transforming growth factor-β1 
and SMAD induce apoptosis in megakaryocytes (pro-apoptotic) [115].  
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Figure 1.4. Hematopoietic stem cell differentiation. 
The megakaryocytopoiesis process starts with hematopoietic progenitor cells named 
pluripotent hematopoietic stem cells. Such cells become uncommitted stem cells. Further, 
due to specific stimuli (like cytokines) uncommitted stem cells will become committed 
stem cells. Myeloid stem cells are such committed stem cells, which can develop into 
megakaryocytic lineage. Committed myeloid stem cells will differentiate into 
megakaryoblasts, again due to specific stimuli. Megakaryoblasts will undergo a process 
of differentiation, going through the intermediary stage named pro-megakaryocyte to 
reach the final stage of megakaryocyte. [105] 
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Figure 1.5. The platelets production (thrombocytopoiesis) process. 
After the megakaryocytopoiesis process is accomplished, megakaryocytes A, increase 
their size and undergo nuclear endomitosis and cytoplasmic maturation B, microtubules 
move to the cell cortex and the cell starts to form pseudopods C, the megakaryocyte 
reaches the pro-platelets bearing stage D, proplatelets are released and finally platelets 
will rupture out and the megakaryocyte nucleus is extruded. [116] 
 22 
 
 
Pro-apoptotic and pro-survival proteins are regulated towards apoptosis during 
megakaryocytopoiesis and thrombocytopoiesis [99, 103, 105, 107, 108, 112]. In 
megakaryoblasts, apoptosis inducers produce proliferation arrest, followed by maturation 
to megakaryocytes towards the pro-platelets bearing stage. Next, blebbing and 
compartmentalized fragmentation of megakaryocytes concludes with platelets shedding 
through an apoptotic process. 
1.1.13. Cell cycle and endoreplication in megakaryocytic cells 
DNA synthesis occurs independently of mitosis for endoreplication and for this to 
happen, several cell cycle checkpoints must be overcome (figure 1.6). The checkpoints 
that a cell needs to overcome to undergo endomitosis, are located in late S-phase (S/M, 
telophase, centrosome duplication checkpoints), in G2-phase (G2/M checkpoint), and in 
M-phase (spindle and post-spindle checkpoints) [117-124]. In the endoreplication cycle, 
many of these checkpoints are naturally absent or are naturally overcome. Human 
megakaryocytes with 8N-128N giant nuclei express cyclin B1 correlated with H1 histone 
kinase activity. Endomitosis in megakaryocytes occurs because of abortion of mitosis in 
late anaphase and collapse of cytokinesis. Consequent reinitiation of G1 and S phases 
results in polyploidy [125-127]. 8N-ploidy represents a general limit, above which cells 
cannot execute mitosis. 16N-32N cells and cells of higher ploidy are usually unable to 
divide by mitosis, and they abrogate cytokinesis. Megakaryocytes belong to the so-called 
hyperploid class of polyploids [120, 121, 124, 127, 128].  
The megakaryocytic progenitor cells start the cell cycle, undergoing the G1 phase, 
continues with the S phase for DNA synthesis and then the G2 phase (short) is continued 
with the beginning of the mitotic cycle. However, megakaryocytic cells go from prophase 
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to anaphase A, but do not enter anaphase B, neither telophase and therefore they do not 
undergo cytokinesis. After reaching anaphase A, megakaryocytes nuclear envelope 
breaks down and a specific spherical mitotic spindle forms. The spindle poles do not 
move apart and newly formed sister chromatides remain together. A new nuclear 
envelope emerges forming a lobed and big nucleus [129, 130]. 
As it can be seen in figure 1.6, G2 arrested cells can go directly from the G2/M 
damage checkpoint into the endocycle (the case of endomitotic cancer cells) or go on to 
undergo apoptosis (normal cells). If the G2/M checkpoint is adapted, cells can also enter 
into mitosis, and from there, they may arrest in the metaphase. In turn, M-arrest has three 
alternative exits: to return to the mitotic cycle, to undergo apoptosis  (normal cells) or, 
through restitution, to enter the endocycle (cancer cells). Normally, mitosis restitution is 
unstable and can be aborted, therefore inducing apoptosis, however malignant cells 
cannot do this. Endocycling cells often rash apoptosis, but can also return through 
somatic reduction to the mitotic cycle. The checkpoint(s) for this last process are 
unknown [124, 131, 132].  
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Figure 1.6. Cell cycle diagrams. 
On the left of the figure is the cell cycle description. On the right of the diagram are the 
cell cycle checkpoints and connection with apoptosis and endoreplication. Left: G1 phase 
– synthesis of RNA and proteins, preparation for S phase, S phase – replication of DNA, 
G2 phase – preparation for M (mitosis), M phase – mitosis (prophase - chromosome 
condensation, nuclear envelope breakdown, mitotic spindle assembly; metaphase – 
kinetochore assembly at each centromere and association with microtubules, anaphase – 
separation of sister chromatids, telophase – mitotic spindle disassembly, chromosome 
decondensation); Right: The diagram shows the available switch-points from the mitotic 
pathway to the endocycle (endomitosis) in cancer cells and stimulation of this switch by 
DNA damage. [124] 
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1.1.14 Casein kinase 2 and cell cycle 
A variety of signals regulate the endomitosis process. However Cdc2 and cyclin B 
form a protein complex named mitosis promoting factor (MPF) which seems to control 
the the entrance of cells into mitosis. MPF has a kinase activity and either inhibition of 
cdc2 or of cyclin B will result in endomitosis. However other signals play independent 
functions in the control of the mitosis process. Absence or inhibition of Aurora-B/AIM-1 
and survivin are causing endomitosis [133, 134]. 
CK2 has been found to phosphorylate cell cycle proteins and by this to modulate 
their activity. The use of DRB (a CK2 inhibitor) as well as antisense depletion of CK2 
resulted in an inhibition of MPF activation (cdc2/cyclin B) in response to nocodazole in 
epithelial cells. Interestingly, when the cell cycle characteristics of nocodazole treated 
cells were examined, it was found that depletion or inhibition of the catalytic subunit of 
CK2, in the presence of microtubule inhibitors, resulted in a compromise of the G2 arrest 
(spindle checkpoint). It was also found that CK2 increases survivin expression via 
enhanced beta-catenin-T cell factor/lymphoid enhancer binding factor-dependent 
transcription. Other cell cycle proteins that are regulated by CK2 are cdc25 and 
topoisomerase II [43, 135-138].  
CK2 was found to regulate both apoptosis and cell cycle following DNA damage 
induced by 6-thioguanine (apoptosis inducer), by controlling caspase and cdc2 proteins 
activity. CK2α relocalize from nucleus to the endoplasmic reticulum after 6-thioguanine 
treatment. CK2 is essential for apoptosis inhibition due to 6-thioguanine [139]. Ionizing 
radiation induces CK2 to inhibit apoptosis and CK2α to move to perinuclear structures. 
CK2α reduction affects cell cycle progression independent of ionizing radiation in the 
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transformed HeLa cells. CK2 negatively regulates caspase activity following ionizing 
radiation exposure of HeLa cells [140]. CK2 has a deregulated expression in tumors. 
CK2 signaling activity related to cell growth is focused on sites like nuclear matrix and 
chromatin. A nuclear localization of CK2 is associated with the neoplastic 
transformation. Therefore a higher intracellular nuclear localization is observed in tumor 
cells compared with normal cells, where the cytosolic localization is dominant [3-5, 7, 
141]. All these information related to nuclear localization of CK2 in malignant processes 
suggest that CK2 action on cell cycle progression protects cells from apoptosis first of all 
and induces abnormal proliferation.  
BCR/ABL inhibits apoptosis and cause anchorage independent growth. BCR/ABL 
signaling acts on down-regulation of cyclin-dependent kinase activity and cell cycle 
arrest in serum and growth factor deprived cells, thus inhibiting both apoptosis and 
altering cellular proliferation [142]. As it was proposed [36, 37], CK2 maybe an arbitrator 
of the BCR/ABL function and a possible interacting protein. Therefore CK2 may play a 
very important role in the cell cycle regulation and cellular proliferation of the 
transformed CML cells. 
Altogether, CK2 inhibition may provide a very useful tool in the study of 
megakaryocytic endomitosis and it points out again that CK2 deregulation endows cells 
with oncogenic properties. 
1.1.15 Platelets 
Platelets are very small blood cells, 2 to 5 µm and have a thickness of 0.5 µm and 
a mean cell volume of 10 femtoliters. The lifespan of platelets is 7 to 10 days. Platelets 
are also known as thrombocytes. Thrombocytes are anucleated cells and are characterized 
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by a very complex physiology [87]. They are capable to undergo shape-change in 
response to agonists and to release α-granules, various molecules (like coagulation 
factors), expose P-Selectin and phosphaditylserine and to aggregate and form the fibrin 
clot. In vivo animal studies with adenosine diphosphate (ADP), a platelet agonist, showed 
a link between platelets aggregate formation and myocardial infarction [143]. Platelet 
phospholipids present a very high content of arachidonic acid and have a transcellular 
eicosanoid metabolism between them, leukocytes and endothelial cells [144]. The blood 
coagulation cascade occurs on the lipid membrane of platelets [145]. This cascade 
culminates with the formation of fibrin from fibrinogen, which will “glue” the platelets, 
to form a “stable” clot. The platelets plug however presents the feature of “clot 
retraction” [146]. This is due to fibrin lysis as well as due to the large amounts of 
contractile proteins like actin and myosin, which are muscle proteins, present in platelets, 
which make platelets extremely mobile [87]. Surface platelets receptors like GpIIbIIIa or 
αIIbβ3 (integrin complex) are at the molecular basis of Glanzmann thromboasthenia. 
GpIIbIIIa acts as a receptor for fibrinogen. Integrins are involved in cell adhesion and 
aggregation [147]. Defects in platelets integrins cause various disorders, like Bernard-
Soulier syndrome [92]. Defects in platelets clot formation causes bleeding disorders like 
haemophilia (“A” due to factor VIII deficiency and “B” due to factor IX deficiency) and 
increased clotting like thrombosis (mainly due to factor V defects). Platelet counts are 
very important, low platelet counts (thrombocytopenia) causing bleeding and high 
platelet counts (thrombocytosis) causing thrombosis, ischemia, organ failure, stroke, 
myocardial infarction [87, 148].   
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Studies have shown that platelets can interact directly with tumors, and some 
tumors may induce or enhance platelet aggregation. Low platelets counts have been 
correlated with decreased tumor formation and inhibition of metastasis. Platelets are rich 
in vascular endothelial growth factor (VEGF) which is released when platelets are 
activating, makes platelets an important player in the tumor increased angiogenesis. 
Platelets have been involved in the pathogenesis of psychiatric disorders (like anxiety 
disorders), Alzheimer, schizophrenia [87]. 
Therefore platelets are very important in maintaining normal hemostasis and play 
a vital function in the body. 
1.1.16 Casein kinase 2 and platelets 
CK2 was found to be constitutively active in platelets and appears to be a major 
messenger-independent protein. CK2 function in platelets is regulated by protein 
phosphatases or by accessibility of substrates [149]. Platelets CK2 phosphorylates 
coagulation factors [148]. CK2 also acts on adherence and blood coagulation pathways 
[82, 148, 150-152]. Therefore in hematological malignancies like CML, CK2 high 
concentration and hyperactivity not only affects the hematopoietic stem cells but also 
platelet number and activation. This leads to thrombosis, due to both platelet counts and 
platelet abnormal function. 
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1.2 GENERAL METHODS INTRODUCTION 
1.2.1 Principles of flow cytometry  
Flow cytometry is a method that uses an instrument called flow cytometer (or 
cytofluorometer) to collect multi-parametric data from particles and cells (as small as 0.5 
µm up to 200 µm).  
Principles of light scattering, light excitation and emission of fluorochrome 
molecules.  
Cells are hydro-dynamically focused in sheath fluid (PBS) and intercepted with a 
focused light source, a laser, see figure 1.7. The nozzle of the instrument suctions cells at 
variable speeds creating a single-cell flow. In this way the laser hits each cell separately 
and the scatter from each cell is collected, see figure 1.8. Each cell has its own scatter 
(“auto-fluorescence”), but when labeled with fluorochromes they are scattered at a higher 
energy state and the fluorochrome emission signal can be identified. For commonly used 
fluorochromes emission and excitation spectra (table II). The most unique feature of flow 
cytometry is that measures fluorescence per cell or particle [153]. Sophisticated analysis 
(statistics) and collection software provides high quality data that is used in advanced 
diagnosis (in clinical laboratory), providing accurate blood counts, and identifying 
diseases like hematological malignancies, as well as a powerful tool in medical research, 
molecular biology, marine biology.  
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Table II. Emission and excitation spectra for most common fluorochromes (dyes) 
used in flow cytometry. 
 
 FL1, FL2, FL3, FL4 correspond to each channel (laser). The wavelength is measured in 
nm. [153] 
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Figure 1.7. Flow chamber and laser beam assembly of a flow cytometer. 
Hydro-dynamic focusing of the cell suspension occurs in the flow chamber due to the 
sheath fluid. Single-cell suspension is hit by the laser light and the scattered light is 
collected. [153] 
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Figure 1.8. Optics of a flow cytometer. 
SS = side scatter, FS = forward side scatter, BP = band pass, BK = blocking filter, DL = 
dichroic long pass [153] 
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Flow cytometry applications. 
Parameters that can be measured with flow cytometry are: volume and 
morphological complexity of cells, cell pigments such as chlorophyll or phycoerythrin, 
DNA (cell cycle analysis, cell kinetics, proliferation etc.), RNA, chromosome analysis 
and sorting (library construction, chromosome paint), protein expression and localization, 
transgenic products in vivo, particularly the green fluorescent protein or related 
fluorescent proteins, cell surface antigens (Cluster of differentiation (CD) markers), 
intracellular antigens (various cytokines, secondary mediators etc.), nuclear antigens, 
enzymatic activity, pH, intracellular ionized calcium, magnesium, membrane potential, 
membrane fluidity, apoptosis (quantification, measurement of DNA degradation, 
mitochondrial membrane potential, permeability changes, caspase activity), cell viability, 
monitoring electro-permeabilization of cells, oxidative burst, characterising multidrug 
resistance (MDR) in cancer cells, glutathione, various combinations (DNA/surface 
antigens etc.) [153].  
Basic flow cytometry operations.  
Gating. Through the operation of gating we have to possibility to focus on a 
population of cells that is of interest. Gating is done through the software, is not a 
physical thing, but it allows the possibility to focus on what is important and some 
physical changes can be applied to the collection mode, like adjusting the best 
compensation for this specific population.  
Compensation. Due to spectral overlap between the emission and excitation 
spectra of each dye (color), the optics of the instrument (see figure 1.8.), need the 
software, besides their factory setup in order to eliminate the “spillover”, and this process 
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is called compensation. Most software’s also allow the user to do compensation during 
analysis. Data is represented as histograms, dot plots isometric displays, contour plots, 
chromatic plots, 3D projections [153].  
General compensation protocol for three dyes in tandem 
To perform this work a FACS Calibur flow cytometers was used, which is an older 
generation instrument. Such instruments require compensation done by user, using 
specific flow cytometry software. 
A mixture of approximately equal parts of unstained cells, green-only cells and 
orange-only cells (U/G/O mix) was used. The same mixtures were made for orange and 
red cells (U/O/R mix). Six samples were prepared for three-color compensation as 
follows: (1) unstained (no dyes) to remove background noise, (2) green-only that 
correspond to the FL1 channel (FL1-H), (3) orange-only that correspond to the FL2 
channel (FL2-H) and (4) red-only that correspond to the FL3 channel (FL3-H), (5) the 
U/G/O mix (equal parts of unstained, green and orange) and (6) the U/O/R mix (equal 
parts of unstained, orange, red). The samples are run on the instrument, in order. Sample 
(1) was run with unstained cells to establish proper settings such as PMT and voltage. 
This procedure enabled to visualize correctly the cells on the FSC-H, SSC-H dot plot. 
Sample (2) was run with green cells and FL1-H was adjusted to get a good signal. In the 
same manner each of the following sample was run in order to adjust FL2H (orange) and 
FL3H (red), respectively. After all the settings were done, sample (5) with U/G/O mix  
was run on the cytometer. FSC/SSC settings have to be adjusted more, in order to bring 
cells on scale, and then gating around the population of interest is required. Dot plots will 
be constructed for the pair FL2 (y) versus FL1 (x) and then for the pair FL3 (y) versus 
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FL2 (x). The plots are going to be set to display only events in the above gate. The FL1, 
FL2 and FL3 amplifiers will be set to logarithmic mode. Now adjustment of the voltage 
on the FL1 detector to position the negative cell population at about FL1=100 will be 
performed, keeping the bright FL1 population on scale. The same procedure will be 
applied to FL2 channel. Sample (6) with the U/O/R mix has to be run next on the 
cytometer. FL3 versus FL2 plot will be referred. The voltage on the FL3 detector will be 
adjusted to position the negative cell population at about FL3=100, but keeping the bright 
FL3 population on scale. Now, FL3-%FL2 compensation control is next adjusted, in 
order to bring the orange-only cell population downwards until the FL3 median of this 
population is approximately the same as the FL3 median of the negative cells. In the 
similar fashion, adjustment of the FL2-%FL3 compensation control to bring the red-only 
cell population leftwards until the FL2 median of this population is approximately the 
same as the FL2 median of the negative cells. Sample (6) the U/G/O mix is run on the 
cytometer. FL2 versus FL1 plot is referred. We need to adjust now the FL2-%FL1 
compensation control in order to bring the green-only cell population downwards until 
the FL2 median of this population is approximately the same as the FL2 median of the 
negative cells. In the same way, we need to adjust the FL1-%FL2 compensation control 
to bring the orange-only cell population leftwards until the FL1 median of this population 
is approximately the same as the FL1 median of the negative cells. Some cytometers have 
an extra pair of compensation controls for FL1 and FL3. A dotplot of FL3 versus FL1 
will be created and FL3-%FL1 and FL1-%FL3 adjusted, at this point. For most purposes 
it is adequate to set compensation "by eye" as in the two color example. If accuracy is 
required, then regions around the 3 cell populations will be draw, statistics will be 
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displayed and fine adjustments to the compensation controls will be made, in order to 
equalize the median fluorescence values. Compensation will be now set correctly. Newer 
generations of instruments have auto-compensation capabilities. 
1.2.2. Scanning Electron Microscopy (SEM) 
Principles of SEM 
The Scanning Electron Microscope (SEM) provides an image of surfaces and is 
capable of both high magnification and good depth of field, so that even at low 
magnifications it is often more useful than an optical light microscope. SEM uses 
electrons instead of white light to view the specimen, see figure 1.9. The scanning 
electron microscope (SEM) provides a three-dimensional high-resolution image of cells 
and tissues. In SEM the surface of the tissue is studied. The electrons are generated from 
a thin tungsten wire in the "gun" of the SEM. Electricity is passed through the wire and 
then focused by magnets onto the sample. When the electrons from the gun strike the 
surface coating of gold, electrons are reflected back off the specimen to a detector, this is 
transmitted to a television screen where the image is viewed and photographed. 
Sample Preparation 
Tissues prepared for SEM are usually chemically fixed using glutaraldehyde 
buffer and then dehydrated in ethanol before being dried. Drying at critical point has 
become the preferred method. The tissue is introduced into liquid carbon dioxide which is 
then brought to its critical point. The critical point is the combination of pressure and 
temperature at which the fluid and gaseous phases exist together without an interface or 
meniscus. Thus there is no surface tension. The presence of surface tension during drying 
is disruptive to a tissue and causes visible distortions.  
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Figure 1.9. Scanning Electron Microscope (SEM).  
An SEM consists of an electron source (the electron gun), condenser lens, objective, 
scanning coil and sample chamber [154]. 
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After drying, the surface of the tissue is sputter coated in a vacuum with an electrically 
conductive layer of gold. [109, 154, 155]. The coated dry sample is placed in a vacuum 
so that the electron beam can move without interference. SEM has a variety of 
applications including material surface studies (chemistry) and observation of detailed 
surface cell morphology. 
1.2.3. Transmission electron microscopy (TEM) 
Principles of TEM. 
The TEM can resolve objects 0.001 µm apart. A TEM consists of a tall, evacuated 
column which has a heated filament that emits electrons at its top. The electrons are 
moved at uniform high velocity down the column by a high voltage (around 100kV) and 
pass through the slice of specimen at about half-way down. Because the density of the 
specimen varies, the “shadow” of the beam falls on a fluorescent screen near the bottom 
of the column and forms an image. A camera mounted beneath the screen records the 
image. The electron beam is controlled by magnetic fields produced by electric coils, 
called electron lenses. One electron lens, called the condenser, controls the beam size and 
brightness before it strikes the specimen. Another electron lens, called the objective, 
focuses the beam on the specimen and magnifies the image about 50 times. Other 
electron lenses below the specimen then further magnify the image. [100, 109, 110, 154, 
155] 
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Figure 1.10. Transmission electron microscope (TEM).  
A TEM consists in an electron source, electron beam focusing on the sample, 
electromagentic lense and data collector device (camera) [154]. 
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Sample Preparation 
Uses of TEM are various like study of the internal structure of the cells as well as  
study molecular interactions, like protein complex formation. 
Cells are fixed in 2.5% glutaraldehyde buffer When the sample is ready for TEM, 
the sample will be washed with PBS three to five times. Then cells are refixed in 1-4% 
osmium tetroxide buffer and then dehydrated in ethanol steps. Next samples are 
infiltrated with one part resin-epon/two parts solvent (overnight) and two parts resin-
epon/one part solvent (overnight) and finally with 100% resin-epon- (one hour). The cells 
in 100% resin are placed in a suitable container (embedding). Polymerization is done at 
60-700C overnight. Sections are cut through thin sectioning and then samples are 
analyzed using a Phillips CM12 TEM microscope. 
TEM is a powerful imaging technique providing accurate intracellular details at 
very high magnifications making possible observation of intracellular ultrastructures like 
organelles. 
1.2.4. Confocal microscopy 
Confocal microscopy [155] is an optical imaging technique used to increase 
micrograph contrast. Confocal microscopy use includes reconstruction of three-
dimensional images by using a spatial pinhole to eliminate out-of-focus light in 
specimens that are thicker than the focal plane, see figure 1.11. In a conventional 
fluorescence microscope, the entire specimen is flooded in light from a light source. Due 
to the conservation of light intensity transportation, all parts of the specimen throughout 
the optical path will be excited and the fluorescence detected by a photodetector or a 
camera.  
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Figure 1.11. Confocal microscope. 
A confocal microscope consists of a laser excitation source, dichromatic mirror which 
focuses the excitation light rays through the objective on the sample and the detector 
pinhole which eliminates out of focus light rays from the samples and the detector [155]. 
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In contrast, a confocal microscope uses point illumination and a pinhole in an 
optically conjugate plane in front of the detector to eliminate out-of-focus information. 
Only the light within the focal plane can be detected, so the image quality is much better 
than that of wide-field images. As only one point is illuminated at a time in confocal 
microscopy, 2D or 3D imaging requires scanning over a regular raster, which is a 
rectangular pattern of parallel scanning lines, in the specimen. The thickness of the focal 
plane is defined mostly by the square of thenumerical aperture of the objective lens, and 
also by the optical properties of the specimen and the ambient index of refraction. 
Sample preparation for confocal microscopy. 
Basically the protocol is the same as for the preparation of cells for regular 
fluorescence micrsocopy. Shortly cells are washed, then fixed (2% paraformaldehyde in 
PBS), then permeabilized if necessary with Triton X-100, 0.1% solution in PBS. After 
permeabilization and fixation, cells are washed and stained with specific fluorochrome 
conjugated monoclonal antibody or protein (like phalloidin). After staining and washing 
to remove unbound stain, cells are mounted and then analyzed using the confocal 
microscope.  
Confocal microscopy provides a wonderful imaging technique when various 
proteins from cells can be stained to observe their localization (nuclear or cytoplasmic), 
cellular membrane can be stained with „dyes” like Bodipy, Dil (Invitrogen, NY, USA), 
nucleus with DAPI. GFP expressing cells can also be observed in detail using this 
technique, like for example for imaging of embrionar stages in insects. 
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CHAPTER II 
TREATMENT OF MEGAKARYOBLASTIC LEUKEMIA CELLS 
WITH CASEIN KINASE 2 INHIBITORS 
2.1. ABSTRACT 
Megakaryoblasts are hematopoietic progenitor stem cells that differentiate to the 
stage of megakaryocytes. Mature megakaryocytes form pro-platelets and give rise to 
platelets. We studied the effect of inhibition of casein kinase 2 alpha subunit (CK2α) with 
specific inhibitors in a megakaryoblastic cell line (MEG-01) from a chronic myelogenous 
leukemia patient in blast crisis. We found that these inhibitors induce proliferation arrest 
while maintaining a steady cell number for a period of one week. Treated cells grew at a 
significantly lower rate than non-treated cells. Apoptosis was induced by CK2 inhibitors 
in MEG-01 cells, and this phenomenon was dose and time dependent. Necrosis was 
minimal in the presence of the inhibitors, suggesting that such compounds may not be 
cytotoxic. In the presence of CK2 inhibitors megakaryocytes matured to the pro-platelets 
bearing stage. Platelets were subsequently released through rupture, following 
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cytoplasmic fragmentation and nuclear extrusion. Thrombocytopoiesis due to the use of 
CK2 inhibitors occurred both in suspension as well as with MEG-01 cells grown on a 
fibronectin matrix. The platelets release process has apoptotic features (blebbing, specific 
DNA fragmentation). Platelets obtained following these treatments are functional. These 
platelets get activated in response to various agonists and form a fibrin clot. Such 
platelets adhere to collagen and fibronectin coated surfaces. The structure of such 
platelets was found to be comparable to normal blood platelets. These findings suggest 
that CK2 may be involved in MEG-01 cells differentiation and platelet production. Thus, 
the use of CK2 inhibitors as a tool for platelet generation in culture, provides the 
opportunity to study platelets production and to engineer MEG-01 cells to produce 
platelets that will express desired proteins. 
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2.2. INTRODUCTION 
Normal cells are characterized by the capability to reproduce themselves exactly 
and their proliferation rate corresponds to each type of cell (function and tissue) so the 
body functions properly. Normal cells will self-destruct when they are damaged, or when 
is necessary (through the apoptosis process) and they will become specialized or 
“mature”. Normal cells signal with the surrounding cells and execute their specialized 
function accordingly. Cancer cells, on the other hand, are characterized by abnormal 
proliferation (never-ending reproducing with apparition and propagation of defects due to 
mutations) and loss of the normal phenotype and function. Such cancerous cells become 
unspecialized and can grow anywhere and manifest the feature of anchorage 
independence. Cancer cells do not signal with the neighboring cells and do not stick 
together. Such cells do not mature and can move to other parts of the body (the metastasis 
process) and due to their increased proliferation they form tumors. Cancer is caused by 
defects in signaling pathways including deregulation of the apoptosis process.  
Megakaryocytes are highly specialized hematopoietic precursor cells that release 
into circulation the platelets. Megakaryocytes are polyploid cells, originating from 
hematopoietic stem cells in the bone marrow. Megakaryoblasts undergo endomitosis 
(DNA replication without cell division) and maturation to the stage of megakaryocytes, 
through a process called megakaryocytopoiesis [1]. After the endomitosis is completed, 
megakaryocytes undergo a cytoplasmic expansion characterized by the formation of the 
demarcation membrane system (DMS). High quantities of proteins are expressed in 
mature megakaryocytes and platelets specific proteins and granules are accumulating in 
the cytoplasm. The demarcation membrane system reorganizes into beaded cytoplasmic 
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extensions called pro-platelets. Proplatelets bearing megakaryocytes fragment to give rise 
to platelets, through the process of thrombocytopoiesis [2]. Thrombocytopoiesis is the 
development of anucleated cells, platelets, from megakaryocytes [3].  
Platelets (or thrombocytes) are vital for maintaining normal hemostasis and for the 
response of the body to trauma. The process of platelet formation is complex and not well 
understood [4]. The thrombocytopoiesis process was linked to the constitutive apoptosis 
of megakaryocytes. Caspase activation in megakaryocytes was connected with platelets 
production. Pro-apoptotic and pro-survival balance is shifted towards apoptosis during 
megakaryocytopoiesis and thrombocytopoiesis [3, 5-10].  
The reciprocal chromosomal translocation t(9;22), known as the Philadelphia 
positive chromosome (Ph+) [11] is associated with chronic myelogenous leukemia 
(CML). This genetic abnormality results in the chimeric oncoprotein BCR/ABL tyrosine 
kinase, which is thought to be the main cause of the abnormal survival and over-
proliferation of hematopoietic stem cells and their progeny [12-14]. In chronic 
myelogenous leukemia, the BCR/ABL tyrosine kinase is constitutively activated. 
Different intracellular pathways are transformed by the oncoprotein BCR/ABL, resulting 
in uncontrolled hematopoietic proliferation. The late phase of chronic myelogenous 
leukemia, named blast crisis (or blastic phase), is characterized by extreme 
overproliferation of stem cells and their progeny in bone marrow. In myeloproliferative 
disorders, like chronic myelogenous leukemia, the platelet counts and function are 
abnormal due to malignant megakaryoblasts overproliferation [13, 15].  
MEG-01 cell line. A megakaryoblastic leukemia cell line named MEG-01 was 
established in 1983. MEG-01 was isolated from a bone marrow aspirate of a patient with 
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chronic myelogenous leukemia in megakaryocytic blast crisis [16]. MEG-01 
megakaryoblasts were found to release platelets that are morphologically 
indistinguishable from normal blood platelets, viable and functional, when treated with 
apoptosis inducers. These cells are of interest for our proposal because they are cytokine 
independent [17-19], and therefore do not respond to cytokine treatments (interferons and 
thrombopoietin), and can be induced to release platelets [6, 16, 20-23]. Cytokine 
independence imposes a problem when using the cytokine treatment for the advanced 
stage of CML (the blastic phase). MEG-01 cells were characterized as being 
megakaryoblasts in the early stage of differentiation on the megakaryocytic lineage, and 
they are committed progenitors towards platelet production. These cells have 
Philadelphia positive chromosome, expressing BCR/ABL oncoprotein [16, 21, 22]. 
MEG-01 cells do not express c-mpl (the thrombopoietin receptor) and have a non-
functional p53 (due to a major deletion) [24, 25]. Due to the fact that c-mpl-/- knockdown 
mice survive and have functional megakaryocytes and platelets, even though they present 
a reduction in the number of megakaryocytes and do not present severe bleeding 
abnormalities and because it was shown that the thrombocytopoiesis process does not 
depend on thrombopoietin (TPO) only, it has been suggested that actually TPO is not 
required for the final stages of platelets release. Therefore other factors are responsible 
for megakaryocytic differentiation and platelets release [2, 26]. So such a cell line, like 
MEG-01 (cytokine independent) can be used to study what other factors may contribute 
to the thrombocytopoiesis process. 
The up regulation and hyperactivity of CK2 has an anti-apoptotic effect which is 
associated with abnormal platelet counts and function in leukemias [27]. Interestingly, 
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CK2α was found to be a substrate for the ABL domain of BCR/ABL [28] and to form a 
specific complex with the BCR domain of BCR/ABL [29]. It was hypothesized that 
CK2α impedes sterically the binding of the ABL SH2 domain to BCR [29]. This results 
in proliferation abnormalities in Philadelphia positive cells. Therefore CK2α was shown 
to be a possible arbitrator of BCR/ABL function [28, 29]. Other functions of CK2α 
downstream of the BCR/ABL interaction give an overall oncogenic response in 
Philadelphia positive cells.  
CK2α protein kinase inhibitors have been developed and studied, like emodin, 5, 6-
dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB), 4,5,6,7-Tetrabromobenzotriazole 
(TBB), 2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole (DMAT), ellagic acid 
[30-36]. Inhibition of CK2 in various cancer cell lines produced apoptosis and 
proliferation arrest [30-32, 37-47].  
Given these facts, it will be interesting to assess the effects of CK2 inhibitors on the 
MEG-01 cell line which has an increased proliferation and survival rate. 
2.3. EXPERIMENTAL PROCEDURES 
2.3.1. Cell Culture  
Materials 
Cell Dissociation Buffer Solution (CDBS) - Gibco BRL (Gaithersburg, MD, USA)  
DMEM F12 1X - Central Cell Services, Media Lab, Lerner Research Institute, 
Cleveland Clinic (Cleveland, USA) 
Endothelial Cell Growth Factor Supplement (ECGS) – BD Biosciences (Bedford, 
MA, USA) 
Fetal Bovine Serum (FBS) - Invitrogen (Carlsbad, CA, USA) 
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Fibronectin - BD Biosciences (Bedford, MA, USA) 
L-Glutamine - Central Cell Services, Media Lab, Lerner Research Institute, 
Cleveland Clinic (Cleveland, USA) 
Hank’s Balanced Salt Solution (HBBS) – Gibco BRL (Gaithersburg, MD, USA) 
HEPES Buffer - Invitrogen, (Carlsbad, CA, USA) 
Heparin Sodium Salt- Calbiochem (San Diego, CA, USA) 
Penicillin/Streptomycin - Invitrogen (Carlsbad, CA, USA) 
Phosphate Saline Buffer (PBS) - Central Cell Services, Media Lab, Lerner 
Research Institute, Cleveland Clinic (Cleveland, USA) 
RPMI 1640 1X - Central Cell Services, Media Lab, Lerner Research Institute, 
Cleveland Clinic (Cleveland, USA) 
Sodium Pyruvate Solution - Invitrogen (Carlsbad, CA, USA) 
Trypsin/EDTA Solution – Sigma Chemical Co (St. Louis, MO, USA) 
Trypsin Neutralization Solution (TNS) – ScienCell (Carlsbad, CA, USA) 
MEG-01 cells culture 
MEG-01 megakaryoblastic cell line [16], was a generous gift from Dr. P. B. Tracy, 
(Department of Biochemistry, University of Vermont, College of Medicine, Burlington, 
VT, USA). MEG-01 cells were also purchased from American Tissue Culture Collection 
(Manassas, VA). Cells were maintained in an incubator, with humidified atmosphere of 
CO2 5%, and at 37 0C. Cell culture media was RPMI 1640 1X with L-Glutamine (2mM), 
was adjusted to contain 10 mM HEPES, and 1.0 mM Sodium Pyruvate and 10-20 % heat-
inactivated fetal bovine serum (FBS) and 5U Penicillin/Streptomycin. Cells were seeded 
at 2 X 105 cells/ml, media was renewed and cell number was adjusted two times per 
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week. 20% of FBS was observed to improve the growth and endurance of MEG-01 cells. 
Cells were washed by centrifugation (150 g for 5-10 minutes) and the washing buffer was 
PBS. The mature MEG-01 cells become adherent to the culture flask wall and therefore 
in order to provide a better surface area for them, flaks can kept on the side, this will also 
help with the platelets production. For some experiments, MEG-01 cells were grown on 
fibronectin coated plates ( 1 µg/cm2). 
HUVEC cells culture 
Human umbilical vascular endothelial cells (HUVEC) were purchased from Dr. P. 
DiCorletto (LRI, Cleveland Clinic, Cleveland, OH, USA) by Dr. Byzova TV (LRI, 
Cleveland Clinic, Cleveland, OH, USA). HUVEC cells were grown in DMEM F-12 cell 
culture media supplemented with 15 % heat-inactivated fetal bovine serum (FBS) and 
endothelial growth factor supplement (ECGS) 150 µg/ml, heparin sodium salt (90 µg/ml) 
and 5U Penicillin/Streptomycin. HUVEC cells were grown on fibronectin coated 
surfaces. Fibronectin was used at a concentration of 1 µg/cm2 in PBS buffer. Fibronectin 
was incubated in PBS with the surface for at least 45 minutes at 370 C, in CO2 cell culture 
incubator or overnight at 4 0C and after this coating procedure, the coated surface was 
washed twice with PBS buffer or HBBS buffer. The cell number was adjusted when 
confluence reached 70%, by splitting the cells. When cells needed to be detached, they 
were either detached with Trypsin/EDTA solution or with cell dissociation buffer (EDTA 
based, enzyme free) depending on application. When trypsin was used to detach cells, 
cells were immediately treated after trypsinization with trypsin neutralization solution 
(TNS). Cells were washed by centrifugation (300 g for 5 minutes) and the washing buffer 
was either PBS or HBBS with 2 % FBS. 
 75 
 
 
2.3.2. Cell Treatments  
Materials 
2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole (DMAT) - Calbiochem 
(San Diego, CA, USA) 
Dimethylsulfoxide (DMSO) - Calbiochem (San Diego, CA, USA)  
Phorbol 12-myristate 13-acetate (PMA) - Calbiochem (San Diego, CA, USA) 
4,5,6,7-Tetrabromobenzotriazole (TBB) - Calbiochem (San Diego, CA, USA) 
Method 
Cells were treated with the CK2α inhibitors, TBB and DMAT [31, 32]. The vehicle 
for DMAT and TBB was DMSO. As a differentiation control, besides the untreated 
control (DMSO only), PMA was used [48]. Apoptosis and viability assays were 
performed with various inhibitors concentrations and time lengths of treatments in order 
to choose the non-cytotoxic concentrations of TBB and DMAT that have a significant 
effect (titration assays). At the beginning of each treatment cells were counted with a 
Neubauer hemacytometer (using Trypan blue dye at half-dilution) and were split to 
~2X105 cells/ml. To assess the effect of CK2 inhibitors, the treatments length went up to 
four days without splitting. Other treatments went up to one month with the required 
splitting and re-treatments. 
2.3.3. Platelets isolation from culture.  
Platelets were separated from the megakaryocytic cells, by differential 
centrifugation [9] and analyzed separately. Suspension cells (MEG-01 culture) were 
centrifuged first at 400 g for 15 minutes, MEG-01 pellet was discharged. The platelets 
rich supernatant was kept and centrifuged again at 2000 g for 15 minutes. The platelet 
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pellet was resuspended in the appropriate buffer (Tyrode’s buffer with CaCl2, pH 7.4), for 
analysis. For impeding artefactual aggregation of platelets in the control sample, EDTA 
and RGD or RGDS were added in the cell suspension from the beginning of the 
centrifugations, and with each centrifugation step. 1 mg/ml RGD or RGDS and 10 mM 
EDTA final concentrations, were used for negative control (inactivated) or resting 
platelets. Platelets were activated with different agonists: 100 nM PMA, 1 µg/ml TRAP 
and 0.5 U/ml human α-thrombin [49]. For most of assays TRAP 1 µg/ml was used. For 
scanning electron microscopy experiment (formation of the fibrin clot) we used human α-
thrombin. For both sample sets, activated (with TRAP) and inactivated (EDTA, RGD or 
RGDS), we used platelets collected from MEG-01 cultures incubated with 10 µM DMAT 
for 4 days.  
2.3.4. Platelets isolation from whole blood (human) 
Platelets isolation from whole blood was adapted as previously described [49-51].  
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Figure 2.1. Schematics of platelets isolation from whole blood. 
Whole blood treated with ACD and PGE-1 is centrifuged at 100 g, then the supernatant 
named platelets rich plasma is centrifuged again at 2400 g. After the second 
centrifugation step, platelets pellet is resuspended in plasma (1/3 volume) and the run 
over a column with Sepharose CL2B with Tyrode’s buffer 1X. Gel filtered platelets are 
collected from the void volume of the column (aproximative 4 ml for a 50 ml column). 
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Materials 
Bovine Serum Albumine (BSA) – Sigma Chemical Co (St. Louis, MO, USA) 
Sodium Chloride, NaCl - Sigma Chemical Co (St. Louis, MO, USA) 
Sodium BiCarbonate, NaHCO3 - Sigma Chemical Co (St. Louis, MO, USA) 
Potassium Chloride, KCl - Sigma Chemical Co (St. Louis, MO, USA) 
Magnesium Chloride (hexahydrate), MgCl2*6H2O - Sigma Chemical Co (St. Louis, 
MO, USA) 
Calcium Chloride CaCl2 - Sigma Chemical Co (St. Louis, MO, USA) 
Dextrose, HOCH2CH(CHOH)4O - Sigma Chemical Co (St. Louis, MO, USA) 
Sodium Citrate (DiHydrate), C6H5Na3O7*2H2O - Sigma Chemical Co (St. Louis, 
MO, USA) 
Citric Acid (Monohydrate), C6H8O7*H2O - Sigma Chemical Co (St. Louis, MO, 
USA) 
Prostaglandin, PGE-1 - Sigma Chemical Co (St. Louis, MO, USA) 
Sepharose CL-2B - Pharmacia, A.K.A. Amersham Biosciences (Uppsala, Sweden) 
Net for column – Pharmacia A.K.A. Amersham Biosciences (Uppsala, Sweden) 
Chelex 100 – BioRad (Hercules, CA, USA) 
Instruments 
Centrifuge: Beckmann Allegra 6, tabletop (rotor diameter is 39 cm) 
Reagents  
Tyrode’s stock buffer 10X (1.368 M Na Cl, 0.1199 M NaHCO3, 0.0255 M KCl 
0.0206 M MgCl2*6H2O, MgCl2 is optional as well as 500 mM CaCl2)  
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Tyrode’s buffer 1X (diluted from 10X stock buffer 1:10 with miliq H2O), added 0.1 
% BSA (A7638) and Dextrose 0.1 %, the final pH of the buffer is 7.2  
ACD –anticoagulant– (84.8 mM C6H5Na3O7*2H2O, 64.8 mM C6H8O7*H2O, 111 
mM Dextrose HOCH2CH(CHOH)4O) 
Sepharose CL-2B (code 17-0140-01, 45-165 µm particle size) 
Sepharose CL-2B column (40 to 50 ml bed volume, equilibrated with 1X 
TYRODE’S buffer containing BSA and Dextrose at a pH of 7.2) 
Net for column (code 19-0659-01, 45 µm, PTFE) 
Chelex 100 (code 142-2832, biotechnology grade, 100 g, Na+, 100-200 dry mesh, 
150-300 µm wet bead).  
Observations: Plastic materials need to be used during all the procedure. Isolation 
of platelets requires room temperature.  
Isolation of human platelets from whole blood using adapted Sepharose CL-2B 
procedure, see figure 2.1.  
Whole blood from healthy volunteers was collected (60-70 ml) and patients must 
be checked for aspirin usage. To the whole blood during collection was added an 1:6 ratio 
ACD plus PGE-1 at 0.86 µM (final concentration, where molecular weight of PGE-1 is 
354.5 g/mol. PGE-1 (Prostaglandin) has anticoagulant effects. Each blood tube was 
divided in half using new tubes. Samples were spun at 800 rpm (rotor 39 cm, 280 x g), 
without brake. Platelet rich plasma (PRP) was removed carefully with a plastic transfer 
pipet. Red cell pellet should not be touched. PRP may sit at RT (room temperature) for 
several hours before isolation of platelet. PRP was next spun at 2300 rpm (rotor 39 cm, is 
2306 x g) for 15 minutes at room temperature, (Chronolog recommends 2400 g for 20 
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min at RT). Plasma was removed and platelet pellet was gently resuspended in 1 ml 1X 
Tyrode’s buffer with 0.1% BSA and with 0.1% Dextrose, pH 7.2. Platelet suspension was 
applied to the Sepharose Column. Washed platelets were recovered in void volume in a 
final volume of about 4 ml. Platelets were counted using a Coulter counter or by 
hemocytometer. At this point, the platelets isolated from human blood are ready to be 
used in any experiment. Normal human platelets were used as normal control, when 
appropiate. 
2.3.5. Flow cytometric analysis 
Cells were analyzed using a FACSCalibur flow cytometer (Becton-Dickinson), 
with CellQuestPro ver.3.3 software. The data was further analyzed with FlowJo ver. 6.2, 
and WinMDI 2.8 softwares. 
2.3.6 MEG-01 samples gating of specific cell populations 
Proper gating was performed to characterize each cell population (MEG-01 cells 
and platelets). The population of cells high on forward side scatter (FSC-H) and side-
scatter (SSC-H), identified as large, non-granulated particles, corresponds to MEG-01 
cells (figure 2.2). 
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Figure 2.2. Gating of the cells populations from MEG-01 culture.  
Proper gating was performed to characterize each cell population (MEG-01 cells and 
platelets). The population of cells high on forward side scatter (FSC-H) and side-scatter 
(SSC-H), identified as large, non-granulated particles, corresponds to MEG-01 cells (gate 
R1). Platelets are localized between 101-102 of the logarithmic scale (low on FSC-H and 
SSC-H (gate R2). A highly granulated and small population may consist in granules or 
debris (gate R3).  
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This population is involved in proplatelet formation. The population that 
corresponds to platelets (small, granulated particles), is PI negative because thrombocytes 
are anucleated cells (only the viable cells were considered). Platelets from MEG-01 cells 
were distinguished by their capacity to get activated, undergoing shape change in 
response to agonist and to show phosphaditylserine (PS) exposure when activated [6]. 
Platelets were further separated from the megakaryocytic cells, by differential 
centrifugation [9], considering the size difference between these cells populations (1-5 
µm for platelets and 35-150 µm for megakaryocytic cell line MEG-01) and analyzed 
separately. Voltage and channels settings were adjusted accordingly. Analyzed values 
were obtained with WinMDI ver.2.8 or Flow Jo ver.6.2.  
2.3.5.2. Flow Cytometric Apoptosis Assays with AnnexinV-FITC and 
propidium iodide (PI).  
Materials 
AnnexinV protein conjugated with Fluorescein Isothiocyanate (AnnexinV-FITC) is 
a part of the kit AnnexinV-FITC and PI Apoptosis Kit I - BD Biosciences, (Bedford, MA, 
USA) 
AnnexinV-binding buffer 10X, is a part of the kit AnnexinV-FITC and PI 
Apoptosis Kit I - BD Biosciences, (Bedford, MA, USA) 
Propidium Iodide (PI) is a part of the kit AnnexinV-FITC and PI Apoptosis Kit I - 
BD Biosciences, (Bedford, MA, USA) 
Staurosporine - Sigma Chemical Co (St. Louis, MO, USA) 
Tumor Necrosis Factor alpha (TNF α) – GenScript (Pistacaway, NJ, USA) 
Ethanol, HPLC grade - Sigma Chemical Co (St. Louis, MO, USA) 
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Method 
Apoptosis Assay Controls 
For induction of typical apoptosis, cells were grown in the presence of 1µM 
staurosporine for 6 hours or for 24 hours with TNFα in the case of HUVEC cells (tumor 
necrosis factor is cytotoxic to HUVEC cells). The staurosporine treated cells were stained 
as follows: a control with PI, a control with AnnexinV-FITC and a control with both PI 
and AnnexinV-FITC in order to have the brightest controls for compensation and proper 
collection of the flow cytometry data. Cell necrosis was induced by heat shock (650C for 
30 minutes) or ethanol treatment. Controls for necrosis were stained in the same way as 
for the Staurosporine treated cells. The unstained control signal was subtracted by gating 
from the stained control and the rest of stained samples, to get only the positive cells 
signal (stained). The stained control (PI and AnnexinV-FITC labeled), was then used as 
the reference in establishing the level of apoptosis induced by the treatments. Data was 
collected on logarithmic modes, two-colors. AnnexinV-FITC corresponds to FL1H 
channel, and PI to FL3H or FL2H channels. Proper compensation was established 
considering median values. 
AnnexinV-FITC and PI apoptosis assay staining protocol  
Freshly isolated from culture, 105 – 106 cells were stained with 50 µg/ml PI and 
with 0.5 µg/ml FITC-labeled Annexin V using the staining protocol provided by the 
supplier.  
Briefly, cells were counted using a Neubauer hemacytometer, then washed (by 
centrifugation with PBS buffer at 150 g for 5 minutes for MEG-01 cells and 300 g for 5 
minutes with PBS buffer with 2 % FBS, for HUVEC cells). After washing, cells were 
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resuspended in the appropriate amount of AnnexinV-binding buffer 1X (provided in the 
kit), in order to have 106 cells in 100µl. Then PI and AnnexinV-FITC solutions were 
added to the cells. Incubation was performed for 15 minutes in the dark at room 
temperature. Cells were washed after incubation once as described previously, but with 
Annexin V binding buffer 1X. Fresh samples were then analyzed immediately by flow 
cytometry. HUVEC cells when trypsinized need to be treated with trypsin neutralization 
solution, and the use of cell dissociation buffer is not recommended, because the high 
content of EDTA from this solution will inhibit AnnexinV binding to phosphaditylserine 
exposed on the cell membrane due to apoptosis (this binding is calcium dependent). 
Treatment of cells for apoptosis assay. MEG-01 and HUVEC cells were treated 
with DMAT (10 and 20 µM) and TBB (25 and 50 µM) inhibitors for 24 h, 48 h, 72 h and 
96 h (without splitting). Next cells were stained and analyzed as described above. 
2.3.5.3. Flow cytometric DNA content assessment assay using PI/RNAse A.  
Materials 
2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole (DMAT) - Calbiochem 
(San Diego, CA, USA) 
Dextrose - Sigma Chemical Co (St. Louis, MO, USA) 
Ethanol, HPLC grade - Sigma Chemical Co (St. Louis, MO, USA) 
Mesh 50 µm – BD Biosciences (Bedford, MA, USA) 
PI – BD Biosciences (Bedford, MA, USA) 
RNAse A I – Qiagen (Valencia, CA, USA) 
Sodium Citrate – Sigma Chemical Co (St. Louis, MO, USA) 
Sodium Chloride - Sigma Chemical Co (St. Louis, MO, USA) 
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Method 
Cells were serum starved in order to synchronize them in the G0 phase of the cell 
cycle. Cells were fixed in 80% cold Ethanol/PBS added drop-wise and kept in the 
ethanol/PBS solution for at least 24 hours at 4 0C, until further processing. Before PI 
staining cells were washed with sterile, RNAse, DNAse free, PBS buffer. Fixed cells 
were incubated with 50 µg/ml PI and 100 µg/ml RNAse A-I in hypotonic citrate buffer 
(0.37 g sodium citrate/L, 0.15 g sodium chloride/L, and 0.63 g dextrose/L, 0.1% Triton 
X-100, pH adjusted to 6.2) for 30 minutes in dark, at room temperature. Cells were 
passed through a 50 µm mesh (Falcon type) in order to eliminate clumps and further 
analyzed by flow cytometry (logarithmic mode - because of the ploidy characteristic of 
the cells -, one-color channel FL3H). All the protocol steps were performed at 4 0C. 
Treatment of MEG-01 cells for DNA content assessment. Treatment with 
DMAT 10 µM for a period of 4 days was performed and then cells were collected for 
further processing. Control cells were also kept in culture like the DMAT treated without 
splitting. 
2.3.5.4. RPE-CD41a immunophenotyping of MEG-01 cells.  
Materials 
CD41a (anti human αIIbβ3 monoclonal antibody) conjugated with R-Phycoerythrin 
(R-PE) - BD Biosciences (Bedford, MA, USA) 
Sodium Azide (NaN3) – Sigma Chemical Co (St. Louis, MO, USA) 
0.22 µm Filter – Millipore (Billerica, MA, USA) 
Method 
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CD41a is the antigen for αIIbβ3 complex and it is found on platelets and platelet 
precursors, including MEG-01 cell line [9, 16]. αIIbβ3 complex is a marker of 
differentiation for megakaryocytes. The staining protocol provided by BD Biosciences 
was used. Briefly, cells were washed (by centrifugation at 150 g) and resuspended in 1 X 
PBS (with 0.1% FBS, 0.01% NaN3) 0.22 µm filtered buffer. Cells were counted and 
adjusted to 106 cells/ml and 20 µl of RPE-CD41a was used for 180 µl cell suspension. 
Cells were incubated with RPE-CD41a for 30 minutes, then washed with PBS buffer. 
Usually cells were analyzed fresh, but they can also be fixed (2% paraformaldehyde in 
PBS, overnight), when fixed, staining was done after washing thoroughly fixed samples. 
RPE-CD41a stained cells were collected on FL2H channel and gating was performed on 
FSC and SSC logarithmic modes. The unstained control signal was subtracted from the 
stained cell signal, in order to measure the staining of the cells without background noise.  
2.3.5.5. Labeling of Fibrinogen with Alexa Fluor 488. 
Human fibrinogen was conjugated with Alexa Fluor 488 fluorochrome (F-13191) 
following the recommended Molecular Probes procedure, using the Alexa Fluor 488 
labeling kit. This labeling procedure was modified, in the way that the column step, was 
replaced with a dialysis step (performed overnight), and the bicarbonate buffer (from the 
kit) was used at 1 M concentration. Before labeling, fibrinogen was also dialyzed in PBS 
buffer (overnight) to remove any unwanted amines. Final concentration of fibrinogen 
conjugated to Alexa Fluor 488 was determined using a spectrophotometer. 
2.3.5.6. Fibrinogen-Alexa Fluor 488 staining of MEG-01 cells and analysis by 
flow cytometry 
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The same protocol as for CD41a-FITC staining of MEG-01 cells was followed for 
labeling cells with Fibrinogen-Alexa Fluor 488, see point 2.3.5.4. Samples stained in this 
way were run on the flow cytometer and analyzed using WinMDI and GraphPad Prism 
software. 
2.3.6. Platelets functional assays 
Materials used in platelets functional assays  
Human Fibrinogen - Sigma Chemical Co, (St Louis, MO, USA) 
RGD peptide - Sigma Chemical Co, (St Louis, MO, USA) 
RGDS peptide - Sigma Chemical Co, (St Louis, MO, USA) 
TRAP peptide – Sigma Chemical Co, (St Louis, MO, USA) 
CD62P (anti human P-Selectin monoclonal antibody) conjugated with FITC - BD 
Biosciences (Bedford, MA, USA) 
MicroDialysis Apparatus - Pierce Chemical Co (Rockford, IL, USA) 
PAC-1 monoclonal antibody conjugated with FITC - BD Biosciences (Bedford, 
MA, USA).  
Human thrombin IIa (α)- Haematologic Technologies Inc (Essex Junction, VT, 
USA)  
Phalloidin conjugated with Alexa Fluor 488 - Molecular Probes (Eugene, OR, 
USA) 
Alexa-Fluor 488 protein labeling kit - Molecular Probes (Eugene, OR, USA). 
Horm collagen -  Hormon-Chemie (Munchen, Germany) 
Material details.  
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Human Thrombin IIa (alpha) has a molecular weight of 36700 g/mol = 36700 Da. 
Thrombin Unit (NIH) is defined as that amount of enzyme required to cleave 1 mg 
of a test protein. Haematologic Technologies states that 3800 NIH Units of 
Thrombin/mg and Thrombin extinction coefficient is E1%1cm, 280 nM = 18.3 for 
human alpha-thrombin.  
TRAP peptide is an agonist, a platelet activator. 
RGD and RGDS peptides are inhibitors of platelets activation. 
Phalloidin is a toxin from the death cap (Amanita phalloides) and it binds actin (a 
cytoskeletal protein), preventing its depolymerization. 
Alexa Fluor 488 is a fluorochrome commonly used in fluorescent staining of cells 
for microscopy or flow cytometry. 
CD62P is a monoclonal antibody that recognizes a specific epitope on P-Selectin 
which is a protein exposed by platelets only when they are activated. 
PAC-1 is a monoclonal antibody that recognizes an epitope specific only to an 
activated form of the protein αIIbβ3. 
Fibrinogen is a zymogen, a soluble plasma glycoprotein that is synthesized in the 
body, by the liver. Fibrinogen is very important in the coagulation cascade, because it 
makes the fibrin mesh (by polymerization when activated by thrombin) which forms 
together with platelets the hemostatic clot. 
2.3.6.1. PAC-1-FITC binding due to platelet activation flow cytometric assay 
The monoclonal antibody PAC-1 recognizes an epitope on the glycoprotein αIIbβ3 
of activated platelets. PAC-1 binds only to the activated platelets. PAC-1 will not bind 
EDTA and RGD or RGDS peptides treated platelets [50, 52, 53], therefore platelets 
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suspensions treated with any of these inhibitors were used as a negative control. Platelets 
were collected from MEG-01 cells suspension, using two centrifugation steps. After 
collection, platelets were activated with TRAP and then incubated with PAC-1-FITC 
Activation of platelets with 1 µg/ml TRAP peptide was performed for 10 minutes. 20µl 
PAC-1-FITC was used for 5 µl fresh platelets suspension, in Tyrode’s buffer with CaCl2. 
The protocol provided by BD Biosciences for PAC-1-FITC staining was followed. PAC-
1-FITC antibody was incubated with the platelets for 30 minutes, in dark. After the 
incubation platelets were washed once by centrifugation. Samples prepared this way were 
run on the flow cytometer. 
2.3.6.2. CD62P-FITC exposure due to platelet activation flow cytometric assay 
Platelets were collected from MEG-01 cells suspension, using two centrifugation 
steps. After collection, platelets were activated with TRAP and then incubated with 
CD62P-FITC. Activation of platelets with 1 µg/ml TRAP was performed for 10 minutes. 
20µl CD62P-FITC were used for 5 µl fresh platelets suspension, in Tyrode’s buffer with 
CaCl2. Incubation was performed in dark, at room temperature, for 30 minutes, as 
recommended by BD Biosciences and then samples were washed by centrifugation with 
Tyrode’s buffer. After washing platelets were analyzed by flow cytometry.  
2.3.6.3. Fibrinogen-Alexa Fluor 488 binding to platelets flow cytometric assay 
Platelets were collected from MEG-01 cells suspension, using two centrifugation 
steps. After collection, platelets were activated with TRAP and then incubated with 
Fibrinogen-Alexa Fluor 488. Activation of platelets with 1 µg/ml TRAP was performed 
for 10 minutes. After activation, 300 nM (final concentration) labeled fibrinogen was 
incubated with platelets suspension for 30 minutes, in dark, at room temperature. Further 
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platelets were washed at 2000 g, 15 minutes at room temperature then analyzed by flow 
cytometry. 
2.3.6.4. AnnexinV-FITC for phosphatidylserine (PS) exposure on platelets  
Platelets were collected from MEG-01 cells suspension, using two centrifugation 
steps. After collection, platelets were activated with TRAP and then incubated with 
Annexin V-FITC. For this assay, AnnexinV-FITC (BD Biosciences) was used, as 
recommended by the manufacturer. Following activation for 10 minutes with agonist (1 
µg/ml TRAP), incubation of the platelets with Annexin V – FITC was performed in the 
dark, at room temperature, for 30 minutes. Tyrode’s buffer with CaCl2 was used in all the 
steps. 
2.3.7. Viability (proliferation) assay of MEG-01 cells, Trypan blue exclusion  
Cells were counted using a Neubauer hemacytometer. Trypan blue dye was used 
according to the manufacturer (Sigma-Aldrich). DMSO, which is the vehicle for TBB, 
DMAT and PMA, was used as a mock control, considering the highest amount that was 
used as a vehicle for TBB and DMAT.  
2.3.8. Anchorage independence in “soft agar” assay for MEG-01 cells.  
Agarose (Promega) was mixed with MEG-01 growth media RPMI1640 1X with 
10% FBS. Cells were grown in 12 wells dishes at 37 0C, 5% CO2, 90% humidity in a 
VWR incubator. Colonies formation was observed and micrograph images were taken 
using an Olympus CK80 microscope. Cells were observed after one week. We compared 
the control (DMSO) samples with the samples grown in the presence of 25 µM DMAT. 
Media was renewed on the top of the agar every 4 days and DMAT treatment was 
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performed every time. 85 colonies from 30 images were analyzed.  Measurements of the 
colonies areas were performed using the NIH Image software ver.1.63 for MacOS 9.  
2.3.9. Light microscopy (phase contrast) and DAPI fluorescence microscopy  
Cells were daily observed using phase-contrast inverted microscopes.  
High quality pictures and live imaging were obtained at Cleveland Clinic Imaging 
Core (Cleveland, OH). DAPI staining of cultured MEG-01 cells was performed with 
fresh cells. For live imaging (observing a single cell for a 24 hour period of time) of the 
thrombocytopoiesis process, MEG-01 suspension cells were made adherent by using 
Fibronectin (FN) coated culture dishes and cells were kept in a special imaging chamber 
which reproduced the mammalian cell culture incubator conditions (CO2 5%, humidity 
90%). FN was used, at 5 µg/cm2 and incubated at 37 0C for 1 h, as recommended by the 
supplier (BD Biosciences, Bedford, MA, USA) [54].  
2.3.10. Scanning electron microscopy (SEM)  
Cells treatments and prep before SEM 
Cell preparation and pictures were performed at the Imaging Core Facility 
(Cleveland Clinic). Cells were grown for four days in the presence of 10 µM DMAT and 
then collected by differential centrifugation. Cells were washed twice in phosphate buffer 
(PBS) buffer by centrifugation. Further, cells were fixed in glutaraldehyde buffer 
(provided by the Imaging Core). The clot was prepared with platelets collected from 
MEG-01 cultures treated with 10 µM DMAT. Human thrombin 0.5 U/ml for 15 minutes 
was used to activate them.  
SEM sample preparation protocol 
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The fixation buffer for SEM is 2.5% glutaraldehyde in 0.1M phosphate buffer 
(PBS), pH 7.2 -7.4. Fixation needs to be performed for at least 24-48 hours. Tissue was 
washed with 0.1M phosphate buffer four times for 15 minutes. Tissue was next rinsed 
with distilled water three times for 5 minutes. Tissue was dehydrated with ethanol. Times 
for dehydration are dependant on specimen size and density. There is a succesion of 
dehydration steps: 50% ethanol 20 minutes, 70% ethanol 20 minutes. At this moment the 
tissue can be stored in 70% ethanol. When the final processing of the sample is required, 
then more dehydration steps are done: 80% ethanol 20 minutes, 90% ethanol 20 minutes, 
95% ethanol 20 minutes and 100% ethanol three times for 20 minutes. At this point, 
samples were ready for critical point drying. After critical point drying samples were 
sputter-coated with gold. Finally, prepared samples were analyzed using a JEOL SEM 
microscope [23, 55]. 
2.3.11. Transmission Electron Microscopy (TEM) 
Cells treatments and prep before TEM 
Cell preparation and pictures were performed at the Microscopy Core Facility 
(Cleveland Clinic). Cells were grown for 4 days in the presence of 10 µM DMAT and 
then collected by differential centrifugation. Cells were washed twice in phosphate buffer 
(PBS) buffer by centrifugation. Further, cells were fixed in glutaraldehyde buffer and 
then further processed at the Core. The clot was prepared with platelets collected from 
MEG-01 cultures treated with 10 µM DMAT. Human thrombin 0.5 U/ml for 15 minutes 
was used to activate them.  
TEM sample preparation protocol 
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Cell were washed through centrifugation with PBS buffer two times. Next cells 
were fixed in 2.5% glutaraldehyde buffer (glutaraldehyde in PBS, pH 7.2-7.4). Fixation is 
for at least 2 hours at (40C) or rapid in microwave. The best fixation time is overnight. 
Fixed cells can be kept for longer periods of time. When the sample was ready for TEM, 
the sample was washed with PBS three to five times. Then cells were refixed in 1-4% 
osmium tetroxide buffer and then dehydrated in ethanol steps. Dehydration steps: 25% 
ethanol, 50% ethanol, 70-75% ethanol, 90-95% ethanol and 100% ethanol. Next 
infiltration steps are required: 1 part resin-epon-/2 parts solvent (overnight) and 2 parts 
resin-epon-/1 part solvent (overnight) and 100% resin-epon- (one hour). The cells in 
100% resin were placed in a suitable container (embedding). Polymerization was done at 
60-700C overnight. Sections were cut through thin sectioning and then samples were 
analyzed using a Phillips CM12 TEM microscope [23, 55-57]. 
2.3.12. Confocal microscopy 
Cells treatments and prep before confocal microscopy 
Cell pictures were taken at the Microscopy Core Facility (Cleveland Clinic). MEG-
01 cells were grown for 4 days in the presence of 10 µM DMAT on fibronectin coated 
glass slides. Cells were washed twice in phosphate buffer (PBS) buffer. Platelets were 
isolated from the MEG-01 cell culture through differential centrifugation and whole-
blood platelets were isolated through gel-filtration. Platelets were incubated at 370C with 
glass slides coated with collagen or fibronectin. Platelets adhesion to collagen was 
performed as previously described by [49]. Coverslips were coated with 20 µg/mL Horm 
collagen (Hormon-Chemie, Munchen, Germany) and platelets were added in the absence 
of calcium and in the presence of 2 U/mL apyrase. Attached platelets stained with Alexa 
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Fluor 488 - Phalloidin were  viewed using a fluorescence microscope. Human thrombin 
0.5 U/ml for 15 minutes was used to activate platelets samples that were already on the 
collagen coated slides. Platelets were washed and incubated in Tyrode’s 1X buffer. 
Further, all cells were fixed in 2% paraformaldehyde buffer.  
Sample preparation for confocal microscopy (for Phalloidin-Alexa Fluor 488 
staining) 
Paraformaldehyde 2% buffer was prepared freshly from a 10% stock solution 
(prepared by heating paraformaldehyde powder in PBS buffer at 600C, plus one drop of 
NaOH 1M, sterile filtered at 0.2 µm). Paraformaldehyde 2% buffer is the fixation 
solution. Cells were fixed in 2% paraformaldehyde buffer for 15 minutes at room 
temperature. After fixation samples were permeabilized in 0.1% Triton-X100 in PBS for 
one minute. Cells were incubated in Phalloidin-Alexa Fluor or Rhdomanine-Phalloidin 
(Molecular Probes) solution, diluted 1:100 in PBS, for 15 minutes. Washing three times 
with PBS buffer was required in order to remove unbound Phalloidin-Alexa Fluor 488 
from the sample. Cells on the glass slide were mounted for microscopy analysis using 
DAPI-Vecta Shield mounting medium. Regular transparent nail polish was used on the 
sides of the glass slide so the slide will not fall. Samples prepared in this way were 
analyzed using a laser scanning confocal microscope. [58] 
2.3.13. Statistical Analysis 
Error bars are standard deviations (SD). Experiments were performed at least in 
triplicates. Statistical analysis and graphing were performed using GraphPad, Prism 
software ver.2.01. One-Way ANOVA Test-Repeated Measures followed by Dunnett’s 
Multiple Comparison Test (which compares all treatment columns vs. the control 
 95 
 
 
column) or student t-test were also performed. p < 0.05 (*) was considered significant, p 
< 0.01 (**) very significant and p < 0.001 (***) extremely significant.  
Briefly, for each sets of samples that need to be compared, the sample distribution 
was plotted and the normality assumption was tested (to check whether or not we have 
Gaussian distribution). If the normality was tested positive, then t test (one-sided two 
sample) or One-Way Anova test (parametric) were performed. If the normality was not 
tested, then non-parametric tests were performed, usually the Mann-Whitney-Wilcoxon 
test. 
 
2.4. RESULTS  
2.4.1. The effects of CK2 inhibitors on MEG-01 cells, as cancer cells 
The goal of this study was to determine the effects of CK2α inhibition with CK2 
inhibitors on malignant megakaryoblasts. To accomplish our goal we selected the MEG-
01 cell line, which is characterized as early stage megakaryoblasts with Philadelphia 
positive chromosome. The cells were initially isolated from a patient with CML, in blast 
crisis [16]. These cells are extremely malignant with an increased proliferation rate.  
MEG-01 cell proliferation arrest.  
We first tested the effect of CK2α inhibitors (TBB and DMAT) on the proliferation 
rate of MEG-01 cells using Trypan blue proliferation assay (see figure 2.3). Because 
DMAT and TBB were solubilized in DMSO, initial control experiments were undertaken 
to establish the effect of DMSO on cell growth. The data demonstrate that DMSO has no 
effect on MEG-01 cells proliferation rate and apoptosis (figure 2.3). In the absence of 
inhibitor there is a 6-fold increase in cell number (figure 2.3, open squares). In the 
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presence of 5 nM PMA, which is known to induce proliferation arrest and differentiation 
in MEG-01 cells, a decrease in proliferation was observed (figure 2.3, open diamonds) 
and the level of decrease was similar to that obtained in the presence of 25 µM DMAT 
(figure 2.3, open circles) suggesting that DMAT may also induce differentiation. High 
concentrations of CK2 inhibitors, (50 µM DMAT or 100 µM TBB) maintained a steady 
number of cells for the 4 days of treatment and induced significant reduction in the 
proliferation rate of MEG-01 cells (figure 2.3, filled triangles and filled circles). These 
data suggest that the inhibitors are capable of reducing the increased proliferation rate of 
MEG-01 cells due to apoptosis, without inducing necrosis.  
DMAT inhibits anchorage independence of MEG-01 cells. 
We next tested the effect of DMAT on the malignant potential of MEG-01 cells, 
using anchorage independence assay in soft agar (figure 2.4, panels A and B). Anchorage 
independence of growth in soft agar assay is strongly connected with tumorogenicity and 
invasiveness. It has been well established that malignant cells form colonies when grown 
on soft agar, while non-transformed cells do not grow under similar experimental 
conditions. Our data show that the area and the number of the colonies formed by 
untreated MEG-01 cells are extensive (figure 2.4, panel A), whereas the DMAT-treated 
MEG-01 cells do not form colonies (figure 2.4, panel B). The results in figure 2.5 
summarize colony area determined from 30 representative images, 80 colonies. 
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Figure 2.3. MEG-01 cells proliferation assays results.  
Cell proliferation (viability) assay, with Trypan Blue exclusion. Five days of treatment of 
MEG-01 cells. Open squares represent the control (DMSO), open triangles 50 µM TBB, 
filled triangles 100 µM TBB, open circles 25 µM DMAT, filled circles 50 µM DMAT 
and open diamonds PMA 5 nM. Each day quadruplicate measurements were taken and 
triplicate sets of experiments were considered for the plot and analysis. 
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Figure 2.4. Anchorage independence assay in soft agar of MEG-01 cells.  
A. Control (DMSO) colony formation in soft agar by MEG-01 cells, magnification X20, 
phase-contrast micrograph. B. DMAT treated (25 µM) colony formation in soft agar by 
MEG-01 cells, magnification X20, phase-contrast micrograph. 
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Figure 2.5. Anchorage independence assay in soft agar of MEG-01 cells. 
Comparison of colonies areas (pixels) between control (DMSO) and DMAT treated 
MEG-01 cells. Data was collected from 30 representative images (80 colonies total). 
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These data suggests that inhibition of CK2α by DMAT eliminates the anchorage 
independence characteristic of MEG-01 cells. 
Maturation of MEG-01 megakaryoblasts due to CK2 inhibitors (DMAT and 
TBB) 
Thrombocytopoiesis follows the maturation and differentiation of megakaryoblasts. 
In order to assess the maturation process of MEG-01 cells in the presence of CK2 
inhibitors, we used flow cytometric immunophenotyping method. The αIIbβ3 integrin 
complex is a megakaryocytic maturation marker (maturation correlates with increased 
levels of αIIbβ3). Following incubation with the inhibitor, the levels of expression of 
αIIbβ3 increase. This increase is correlated with differentiation of megakaryoblasts, see 
figure 2.6, panels A and B. figure 2.6. Panel A shows that 10 µM DMAT is sufficient to 
obtain significant maturation levels compared to the control untreated cells. A further 
increase in the concentration of DMAT (up to 20 µM) induces a slight increase in the 
maturation level of MEG-01 cells. In figure 2.6, panel B, we show that 20 µM DMAT 
induced similar maturation level as 1 nM PMA and 25 µM TBB. This was assessed based 
on immunophenotyping for CD41 (αIIb). Increase in the fibrinogen binding to MEG-01 
cells shows increased expression of αIIbβ3 complex (figure 2.7). This increase is due to 
maturation of the cells. Black line represents the Control (DMSO) collected after 4 days 
of culture, blue line represents DMAT 10 µM treatment (4 days) and gray line represents 
DMAT 20 µM treatment (4 days) see figure 2.7. Finally, DNA content assay 
demonstrates that MEG-01 cells become polyploid (ploidy higher than 2N) in the 
presence of 10 µM DMAT (figure 2.8.) The increase in DNA content demonstrates that 
MEG-01 undergo maturation in the presence of CK2α inhibitors treatments.  
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Figure 2.6. Maturation (differentiation) of MEG-01 cells due to DMAT. 
A. RPECD41a (αIIbβ3 integrin expression) flow cytometric immunophenotyping for 
DMAT, TBB and PMA treatments versus control (DMSO). Histogram shows results 
from one set of treatments (total relative fluorescence). Control (DMSO) unstained – red 
line, control (DMSO) stained –black line, 10 µM DMAT – green line, 25 µM TBB – blue 
line, 1nM PMA – purple line. B. Graph represents total relative fluorescence percentages 
for RPE-CD41a immunophenotyping, conform analysis of data in WinMDI ver 2.8, from 
triplicate experiments. 
 102 
 
 
 
 
 
 
 
 
 
 
Figure 2.7. Fibrinogen binding to MEG-01 cells.  
Increase in the fibrinogen binding to MEG-01 cells shows increased expression of αIIbβ3 
complex. This increase is due to maturation of the cells. Control (DMSO),4 days – black 
line, DMAT 10 µM treatment (4 days) –blue line and gray line represents DMAT 20 µM 
treatment (4 days) 
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Figure 2.8. DNA content analysis of MEG-01 cells treated with DMAT. 
MEG-01 cells were treated with 10 µM DMAT for 4 days, as assessed by PI and RNAase 
A, flow cytometric assay. Gray filled line represents the Control (DMSO) and Black line 
is DMAT 10 µM treatment. 
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Figure 2.9. Apoptotic assays. 
Total apoptotic cells percentages were plotted for each treatment set daily. A. Quadrant 
gating of a control untreated MEG-01 cells after 24 hours (AnnexinV-FITC and PI flow 
cytometric assay). B. Quadrant gating of cells treated with 20 µM DMAT following 24 
hours. C. The effect of TBB and DMAT treatment on MEG-01 cells apoptosis after 24 
hours. D. The effect of TBB and DMAT treatment on MEG-01 cells apoptosis after 48 
hours E. The effect of TBB and DMAT treatments on MEG-01 cells apoptosis after 72 
hours. F. The effect of TBB and DMAT treatments on MEG-01 cells apoptosis after 96 
hours. The results provided in C, D, E, F represent the average found in three 
independent experiments.  
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If we compare the Control (DMSO) sample, represented by the gray filled line 
(ploidy level achived 16 N) versus the DMAT 10 µM treated sample, black line (ploidy 
level achieved 64N) it is obvious that DMAT induces an increase in ploidy level which 
correlates with an increase in differentiation level. Collectively the data demonstrate that 
inhibition of CK2 in MEG-01 cells results in proliferation arrest followed by maturation 
of the cells. 
Apoptosis of MEG-01 cells is induced by DMAT and TBB  
In order to understand the effect of the inhibitors on MEG-01 cells and verify if the 
treatment is not cytotoxic, we assessed both apoptosis and necrotic levels, using an assay 
employing Annexin V and PI. Percentages of total apoptotic cells are the sum of (FL1H+, 
FL3H-) lower right quadrant, corresponding to early apoptotic cells gate, with (FL1H+, 
FL3H+) upper right quadrant, corresponding to late apoptotic cells. Necrotic cells 
correspond to the upper left quadrant gate (FL1H-, FL3H-). figure 2.9, panel A 
demonstrates that following 24 hours incubation in the absence of CK2 inhibitors 8.7% of 
the control untreated cells are apoptotic while 0.87% are necrotic. Following 24 hours 
treatment with 20 µM DMAT the level of apoptotic cells has significantly increased 
(19%) while the level of necrotic cells remained low (figure 2.9, panel B). A comparative 
summary of the results obtained following 24 hours incubation with either TBB or 
DMAT is provided in figure 2.9, panel C. The data shown in 2.9, panel D (48 hours of 
treatment). The effect is dose dependent and reaches a maximum after four days, see 
figure 2.9, panel E (72 hours of treatment) and figure 2.9, panel F (96 hours of treatment). 
Following 96 hours incubation the results obtained with 10 µM DMAT are similar to the 
results obtained with 20 µM inhibitor. A direct comparison between control cells and 
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DMAT-treated cells establish that treatment with DMAT induces significant apoptosis in 
MEG-01. 
Our findings also show that CK2 inhibitors may not be cytotoxic, due to necrotic 
cells percentages which are not different between the DMSO treated sample versus 
DMAT, TBB treated samples. 
It has been well established that physiologically, platelets derive from 
megakaryoblast following an apoptotic process [3, 5-10, 21, 22, 57]. 
Since DMAT and TBB induce apoptosis in MEG-01 cells, we next verified if 
CK2α inhibitors could also be thrombocytopoiesis inducers. The data shown in figures 
2.10 and 2.11 demonstrate that CK2α inhibition result in thrombocytopoiesis.  As early 
as from the second day DMAT induced MEG-01 cells to form proplatelet extensions. 
This process was dramatically enhanced following four days of treatment. 
Thrombocytopoiesis phenotype. 
CK2α inhibition with DMAT was found to result in thrombocytopoiesis. This is 
shown in figure 2.10 and figure 2.11. As early as from the second day DMAT induced 
MEG-01 cells to form proplatelet extensions. This process was dramatically enhanced 
following four days of treatment (figure 2.10 panels A-E and figure 2.11). The 
megakaryocytes were found to undergo thrombocytopoiesis and showed apoptotic 
features, DNA condensation and fragmentation. Comparing figure 2.10 A versus figure 
2.10 B we notice bigger cells, blebbing, pro-platelets formation and particle release. 
Phenotype change is induced in MEG-01 cells by DMAT treatment as seen in figure 2.10 
D shows a scanning electron micrograph of a DMAT MEG-01 stimulated cell (blebbing 
and pro-platelets in incipient phase) correlating with the previous results. MEG-01 cell 
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(on fibronectin matrix) treated with DMAT 10 µM extended long beaded filaments. 
These filaments will rupture releasing the platelets and in the mean time the same cell 
also undergoes extensive cytoplasmic fragmentation (figure 2.10 F left panel). In figure 
2.10 E right panel we show the nucleus with DAPI stain of the MEG-01 cell from figure 
2.10 F left panel. It is noticeable that the pro-platelets forming cell has specific nuclear 
apoptotic fragmentation. MEG-01 cell in suspension that undergo thrombocytopoiesis, 
following DMAT treatment, confirmed that platelets release from MEG-01 cells is not 
due to stimulation from the fibronectin matrix (see figure 2.10 C). The proplatelets and 
platelets do not stain positive with DAPI (figure 2.10, panel G, white arrow), showing 
that the beaded ends indeed will become anucleated cells.  
Thrombocytopoiesis cellular structural insights 
Cells were grown in suspension and incubated with DMAT 10 µM for 4 days. 
Structural insights using transmission electron microscopy into this platelets 
production effect of DMAT on MEG-01 cells are shown in figure 2.11. In figure 2.11, 
panel A resting MEG-01 cells are shown where demarcation membrane system and 
nucleus can be observed. Progression of the thrombocytopoiesis process (figure 2.11 B) 
is characterized by extensive cytoplasmic fragmentation on the demarcation membrane 
system. The peripheral pro-platelets formation is shown in figure 2.11 panels C,D. The 
long filaments with bulbous ends (pro-platelets) are shown in figure 2.11 E. The 
proplatelets characteristic cytoskeleton can be observed in figure 2.11 G (a confocal laser 
scanning microscopy micrograph  using 63 X magnification). Phalloidin-Alexa Fluor 488 
is used for staining MEG-01 cells actin. Confocal microscopy shows specific nucleus that 
mature megakaryocytes have, big and lobulated.  
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Figure 2.10. Phenotype change in MEG-01 cells treated with 10 µM DMAT.  
A. Control (DMSO) MEG-01 cells phase-contrast micrograph after 96 hours, 
magnification X 20, B. MEG-01 cells treated with 10 µM DMAT phase-contrast 
micrograph, following 96 hours of treatment X 20. C. Proplatelets formation, in 
suspension, phase-contrast micrograph, following DMAT treatment (10 µM) between 72 
and 96 hours, magnification X 40. D. Scanning electron microscopy micrograph of 
MEG-01 cells, magnification X 7500, voltage 15 kV E. Proplatelets formation on 
fibronectin coat, phase-contrast micrograph, following DMAT treatment (10 µM) 
between 72 and 96 hours of treatment, magnification X 40. F. DAPI staining micrograph 
of proplatelets bearing MEG-01 megakaryocyte following DMAT treatment (10 µM) 
between 72 and 96 hours of treatment, magnification X 40. G. Platelets-like particles 
identified as anucleated cells with DAPI staining, magnification X 40 following DMAT 
(10 µM treatment) at 72 to 96 hours. Panels E and F represent the same cell. 
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Figure 2.11. Ultrastructural features of MEG-01 cells treated with DMAT. 
Black arrows show nucleus, blue arrows show demarcation membrane system and red 
arrows show pro-platelets. A. MEG-01 cell in resting state (control), magnification 
5600X B. MEG-01 cell that undergoes thrombocytopoiesis process (treated with DMAT 
10 µM, 4 days), notice demarcation system formation, magnification 6300X, C. MEG-01 
cell that undergoes thrombocytopoiesis process (treated with DMAT 10 µM, 4 days), 
notice pro-platelets formation, magnification 2000X, D. MEG-01 cell that undergoes 
thrombocytopoiesis process (treated with DMAT 10 µM, 4 days), notice pro-platelets 
formation, magnification 5600X, E. Pro-platelets with characteristic bulbous end 
formation in MEG-01 cells treated with DMAT 10 µM, 2000X and 4000X magnification, 
F. Confocal scanning electron micrograph of MEG-01 cells undergoing 
thrombocytopoiesis due to DMAT treatment, notice characteristic bulbous end formation 
at the tip of pro-platelets, 63X magnification. 
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The staining for cytoskeleton shows pro-platelet and pseudopodia formation and this can 
be better observed in the magnified image (figure 2.11. G right panel), 4X digital zoom, 
over 63X physical zoom. Together the data demonstrate that CK2α inhibition induces 
apoptosis of MEG-01 cells, which in turn result in the release of platelet-like particles, 
following a maturation process (see figures 2.8-11). 
DMAT induces functional platelets release from MEG-01 cells, in vitro  
The next step was to verify if the platelet-like particles released following treatment 
with DMAT in culture, are indeed platelets and are functional. Several functional studies 
were performed and the results are reported in figure 2.12 panel A-D. The platelets are 
capable of undergoing shape change in response to agonists (human thrombin, TRAP, 
ADP, and PMA). Activated platelets stain positive for PAC-1 (an antibody that 
recognizes a specific epitope on αIIbβ3 integrin, exposed only when platelets are 
activated) (figure 2.12, panel A). Following activation the platelets were found to expose 
P-Selectin (figure 2.12, panel B), phosphatidylserine (figure 2.12, panel C) and bind 
fibrinogen (figure 2.12, panel D). Finally, following activation with 0.5 U/ml of human 
α-thrombin (IIa) the platelets form a visible clot. SEM of this clot demonstrates that this 
platelets develop spiked lamelapodia appearance, aggregation and formation of a fibrin 
net (figure 2.13, panels A-C). Platelets were harvested from MEG-01 cells grown in the 
presence of DMAT (10 (M, 72 hours). Human thrombin 0.5 U/ml (15 minutes exposure) 
was used as agonist. A detail of the  MEG-01 platelets, fibrin clot formation 
magnification X 5,000, voltage 20 kV is depicted in figure 2.13 A. The platelets detail at 
a X 7,500 magnification, voltage 20 kV is shown in figure 2.13 B.  
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Figure 2.12. Platelets from MEG-01 cells obtained after DMAT treatment  
MEG-01-derived platelets following treatment with DMAT (10 µM for 72) were 
collected and used. Platelets were activated with TRAP peptide. Controls were treated 
with EDTA and RGDS to prevent any artefactual activation. A. P-Selectin exposure 
(CD62P – FITC) by activated platelets. B. PAC-1 binding (PAC-1-FITC) by activated 
platelets. C. Fibrinogen-Alexa Fluor 488 binding to activated platelets. D. Annexin V-
FITC binding to activated platelets (phosphatidylserine exposure). In all panels, the 
control platelets are represented by the red line, while the results obtained with activated 
platelets are represented by the green line. E. Resting MEG-01 derived platelets gate, F. 
Activated platelets gate. 
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Figure 2.13. Platelets from MEG-01 cells (in culture) after DMAT treatment. 
Platelets were harvested from MEG-01 cells grown in the presence of DMAT (10 (M, 72 
hours). Human thrombin 0.5 U/ml was used as agonist . A. Detail of the fibrin clot 
magnification X 5,000, voltage 20 kV. B. Platelets and fibrin net detail, magnification X 
7,500, voltage 20 kV, C. fibrin net detail from the clot, magnification X 20,000 voltage 
20 kV. 
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Figure 2.14. Confocal microscopy analysis of platelets derived from MEG-01 cells.  
A. resting platelets from MEG-01 cells resulted during treatment with DMAT 10 µM for 
4 days incubated with coverslips coated with 20 µg/ml collagen and for 15 minutes at 
room temperature. B. activated platelets with α-thrombin (IIa) 0.5 U/ml from MEG-01 
cells incubated with coverslips coated with collagen, 63X zoom, C. activated platelets 
with α-thrombin (IIa) 0.5 U/ml from MEG-01 cells incubated with coverslips coated with 
collagen, 63X zoom, 8X digital zoom, D. activated platelets with α-thrombin (IIa) 0.5 
U/ml from MEG-01 cells incubated with coverslips coated with collagen, 63X zoom, 4X 
digital zoom 
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Figure 2.15. Ultrastructure of MEG-01 derived platelets (TEM). 
A. Resting MEG-01 derived platelet (with characteristic granules and lack of nucleus), 
magnification 10000 X, 60 kV B. Activated MEG-01 derived platelet (which releases its 
contents, undergoes shape change and still has some granules), 20000 X magnification, 
60 kV. “g” represents the platelets specific granules. 
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Finally the fibrin net detail from the clot at X 20,000 magnification and a voltage of 20 
kV is shown in figure 2.13 C. Confocal microscopy experiments revealed specific platelet 
cytoskeleton and lack of DAPI staining (anucleated cells) for MEG-01 derived platelets 
adhered to collagen, see figure 2.14. MEG-01 derived platelets resting were found to 
adhere to collagen coated slides (figure 2.14 panel A). These MEG-01 derived platelets 
were found to become activated with α-thrombin (IIa) 0.5 U/ml (figure 2.14 panel B). 
The cytoskeleton organization, see figure 2.14, panels C,D, is characteristic to platelets. 
Such platelets extended cytoskeleton filaments when 0.5 U/ml human α-thrombin (IIa) 
was added to the adhered platelets on collagen slides, see figure 2.14, panels B-D. The 
ultrastructures of MEG-01 derived platelets due to DMAT 10 µM treatment (transmission 
electron microscopy) is depicted in figure 2.15. MEG-01 cells were treated with DMAT 
for 4 days and then platelets were collected through differential centrifugation. Resting 
MEG-01 platelet is depicted in figure 2.15, panel A using a X 10,000 magnification and a 
voltage of 60kV. The activated MEG-01 platelets (0.5U/ml thrombin vortexed until they 
formed a platelet clot) are shown in figure 2.15, panel B using a X 20,000 magnification 
and a voltage of 60kV. These activated platelets show release of their contents. The lack 
of nucleus and α-granules can be observed, as well as the open canalicular systems 
(figure 2.15). 
HUVEC cells apoptosis versus MEG-01 cells apoptosis. 
HUVEC apoptosis versus MEG-01 cells apoptosis show that after 24 hours the 
effect of DMAT is more pronounced in MEG-01 cells (malignant) versus primary 
(normal) cells (see figure 2.16). 
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Representative data from apoptosis assay (Annexin V and PI) for MEG-01 cells 
after 24 hours, treated with DMAT 20 µM are shown in the histogram shown in figure 
2.16 A. Representative of apoptosis assay for HUVEC cells treated with DMAT 20 µM 
are shown in the histogram in figure 2.16 B. Lower right (FL1H+, FL3H-) quadrant 
which corresponds to early apoptotic cells has 13.7 % cells for MEG-01 sample versus 
8.4 % cells for HUVEC sample. Late apoptotic cells quadrant (FL1H+, FL3H+), upper 
right, are 6.9 % for MEG-01 cells versus 4.9 % for HUVEC cells. Dead or necrotic cells 
quadrant (FL1H-, FL3H+), upper left, has 0.5% for MEG-01 cells versus 1.9 % HUVEC 
cells, which is not a significant difference for a flow cytometry experiment (error can be 
up to 2%). The positive control for induced apoptosis of HUVEC cells is shown in figure 
2.16 C. For this, tumor necrosis factor (TNFα) which is very cytotoxic for HUVEC cells, 
was used. In figure 2.16 C, TNFα induces 34% total apoptosis (and most cells are dying 
already as noticed from the high percentage located in the late apoptotic gate). Three 
experiments data (as total apoptotic cell percentage: including late, early and dead cells 
gates) are represented in figure 2.16 D. In conclusion, it is suggested that apoptosis is 
induced different in malignant versus normal cells (figure 2.16). Mechanisms are 
unknown, but it may have something to do with the expression, localization and activity 
of CK2 that are different in MEG-01 cells versus normal primary cells. MEG-01 cells 
have various aberrations, deregulations, including the presence of BCR/ABL abnormal 
kinase, thus this result may not be as surprising as it seems at a first view. 
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Figure 2.16. HUVEC apoptosis versus MEG-01 cells apoptosis. 
After 24 hours the effect of DMAT is more pronounced in MEG-01 cells (malignant) 
versus primary (normal) cells. A. HUVEC cells apoptosis, B. MEG-01 cells apoptosis, C. 
HUVEC cells apoptosis induced by treatment with TNFα, D. Comparation of averaged 
percentages of apoptotic cells after 24 h (HUVEC vs. MEG-01). 
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2.5. DISCUSSION 
Our data demonstrate for the first time that CK2α inhibition induces malignant 
MEG-01 megakaryoblasts maturation and enhances functional platelet progeny release. 
Interestingly, we found that CK2α inhibition with DMAT and TBB, induces proliferation 
arrest and apoptosis, without being cytotoxic. Proliferation arrest as well as apoptosis was 
correlated with length and amount of treatment. DMAT, which is a better inhibitor than 
TBB, had effect at concentrations as little as 5 and 10 µM. Due to the importance of 
protein kinases in malignant processes, this study can be considered to have 
consequences for future therapeutic interest as previously described [27, 29, 37-39, 47, 
59-63] 
A striking observation that results from our studies is that CK2α inhibition with 
DMAT and TBB induces thrombocytopoiesis. The megakaryocytes undergoing 
thrombocytopoiesis showed apoptotic features, as DNA condensation and fragmentation, 
blebbing and phosphatidylserine exposure. Mature megakaryocytes start to bleb and form 
pseudopodia. Following explosive fragmentation, long filaments with beaded ends 
(proplatelets) are formed. The proplatelets do not stain positive in DAPI, demonstrating 
that the beaded ends indeed will become platelets. Platelets are expelled out from the 
proplatelets, and the fragmented nucleus slowly is extruded. Thrombocytopoiesis process 
occurred in cells bound to fibronectin matrix as well on cells in suspension. 
The thrombocytopoiesis process observed in the present study follows the 
maturation and differentiation process of MEG-01 megakaryoblasts. This differentiation 
is similar to the effect observed with phorbol ester (PMA), however, CK2α inhibitors are 
not cytotoxic, whereas PMA is a potent tumorigenic substance as well as a powerful 
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platelet activator [48, 64-66]. We speculate that maturation of MEG-01 cells is a result of 
proliferation arrest that makes incomplete repeated cell cycle to enter into endomitosis, 
probably due to the action of CK2 on the cell cycle. This hypothesis is strongly supported 
by the preponderant nuclear localization of CK2α in malignant cells as compared to its 
localization in normal cells [38, 40, 62, 67-69]. We assessed this maturation process 
using flow cytometry, by measuring the expression of αIIbβ3 integrin increase (which was 
shown to correlated with increase in size and differentiation of megakaryoblasts). 
Increase in DNA content and cell size following incubation of the cells with the 
inhibitors; also adds further evidence that MEG-01 cells mature due to CK2α inhibition. 
Anchorage independence assays in soft agar, is an experiment that identifies 
malignant cells versus normal cells due to their unique capability to be immature and 
“live by themselves”. Cancerous cells grow in any conditions without a support or 
signaling with the neighboring cells. We found that MEG-01 cells treated with DMAT do 
not form colonies in soft agar and this maybe due to the fact that MEG-01 cells mature, 
regain their function to produce platelets and decrease their proliferation rate. Also, these 
results obtained from the soft agar experiments suggest that the adherence pathways 
controlled by CK2α maybe involved in the process of developing anchorage 
independence. BCR/ABL was found to be involved in the malignant transformation of 
Ph+ cells, but its inhibition is not sufficient to suppress anchorage independence of such 
cells, suggesting involvement of other molecular mechanisms [70]. Our results connect 
CK2 inhibition with apoptosis and the mechanism of thrombocytopoiesis that follow 
megakaryocytopoiesis. It has been previously shown that platelet shedding results from a 
constitutive form of apoptosis of megakaryocytes [3, 5-10, 21-23, 57]. Our study also 
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shows for the first time that CK2 inhibition induces release of functional platelets from 
malignant megakaryoblasts. In megakaryoblasts, CK2 inhibition first produces 
proliferation arrest, followed by differentiation to megakaryocytes that culminate with 
proplatelets formation, blebbing, and compartmentalized fragmentation of 
megakaryocytes, finalized by thrombocytes release. Platelets obtained in culture, 
following CK2α inhibition are functional. These platelets form a clot visible with the eye 
when exposed to agonists. This clot was analyzed with SEM and fibrin net formation and 
characteristic platelet phenotype were observed.  
After 24 hours of treatment, the effect of DMAT is more pronounced in MEG-01 
cells (malignant) versus primary (normal) cells. Overall, our data clearly demonstrate that 
treatment of MEG-01 cells with casein kinase 2 inhibitors results in proliferation arrest, 
maturation and release of functional platelets. 
In conclusion, CK2α inhibition studies with TBB and DMAT, suggests a key role 
of CK2 in oncogenic development as well as in the megakaryocytopoiesis and 
thrombocytopoiesis processes and at least provides wonderful applicability of such 
compounds.  
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CHAPTER III 
TREATMENT OF MEGAKARYOBLASTIC LEUKEMIA MURINE 
XENOGRAFTS WITH DMAT 
3.1. ABSTRACT 
Megakaryoblasts are hematopoietic progenitor stem cells that differentiate to the 
stage of megakaryocytes. MEG-01 cells are malignant megakaryoblasts isolated from a 
patient with chronic myelogenous leukemia in blast crisis. MEG-01 cells are presenting a 
malignant phenotype showing increased proliferation and capacity to produce solid 
tumors in vivo. MEG-01 cell line may provide a useful model for testing the in vivo 
efficacy of anti-tumor agents and immunotoxins, and for studying the pathophysiological 
mechanisms of human megakaryoblastic leukemia. Our findings following treatment of 
MEG-01 murine xenografts with the CK2 inhibitor DMAT were striking. The MEG-01 
tumors infiltrated the spleen, and leukemic megakaryoblastic cells seem to appear in the 
blood of mice with MEG-01 tumors (as high abnormal cell counts). All MEG-01 tumor 
bearing mice had splenomegaly (treated and untreated). The tumors released platelets in 
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vivo and this phenomenon was increased due to casein kinase 2 inhibitor treatment 
(DMAT). DMAT treatment induced significant proliferation arrest of tumors and 
necrosis and apoptosis in tumor tissue. Angiogenesis was reduced in tumor tissue due to 
DMAT treatment. Liver, brain, kidney, muscle tissue seem to be normal in DMAT 
treated mice. 
3.2. INTRODUCTION 
Megakaryoblasts are hematopoietic progenitor stem cells that differentiate to the 
stage of megakaryocytes.  MEG-01 cells are malignant megakaryoblasts isolated from a 
patient with chronic myelogenous leukemia in blast crisis [1]. MEG-01 megakaryoblasts 
were found to release platelets that are morphologically indistinguishable from normal 
blood platelets, viable and functional, when treated with apoptosis inducers. These cells 
are of interest for cancer research because they are cytokine independent [2-4], and 
therefore do not respond to cytokine treatments (interferons and thrombopoietin), and can 
be induced to release platelets [1, 5-9] and are very proliferative. Cytokine independence 
imposes a problem when using the cytokine treatment for the advanced stage of CML 
(the blastic phase). MEG-01 cells were characterized as being megakaryoblasts in the 
early stage of differentiation on the megakaryocytic lineage, and they are committed 
progenitors towards platelet production. These cells have Philadelphia positive 
chromosome, expressing BCR/ABL oncoprotein [1, 6, 7]. 
MEG-01 cells are presenting a malignant phenotype showing increased 
proliferation and capacity to produce solid tumors in vivo [10, 11]. MEG-01 cell line may 
provide a useful model for testing the in vivo efficacy of anti-tumor agents and 
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immunotoxins, and for studying the pathophysiological mechanisms of human 
megakaryoblastic leukemia.  
Inhibition of CK2 in various cancer cell lines produced apoptosis and proliferation 
arrest [12-25]. 
Antisense nucleotides against CK2α were studied in mouse human prostate cancer 
xenografts, in vivo [14]. A very interesting observation was that antisense nucleotides 
treatments against CK2α in prostate cancer mouse xenografts, were affecting the tumors 
(by inducing apoptosis and tumor ablation), but not the normal surrounding tissue. This 
was explained as being caused by different localizations of the alpha subunit of casein 
kinase 2 in normal versus malignant tissue. This conclusion was based on histological 
analysis of normal and neck squamos carcinoma tissues [14, 26-28]. These studies sustain 
the idea that CK2α is an attractive cancer treatment target even though is a pleiotropic 
kinase.  
Our preliminary results suggest that apoptosis and proliferation arrest, followed 
by megakaryocytopoiesis and thrombocytopoiesis were induced by DMAT in CML Ph+ 
cell line MEG-01. MEG-01 platelets obtained after DMAT treatments were found to be 
functional. 
The last step before assessing the DMAT effects into a murine model of CML 
Ph+ (that mimics the disease) is to create first a murine xenografts model with MEG-01 
tumors. In this murine model we can analyze the platelets levels and function following 
DMAT treatments.  
The formulation of the drug is very important considering the solubility of DMAT 
(it is not in a polar solvent soluble form). DMAT is soluble in DMSO. 
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This model will also provide the means to design a targeted drug delivery of 
DMAT as an ultimate goal, in order to avoid as much as possible any side effects that 
may occur due to the localization of CK2 in both malignant and normal tissue.  
 
3.3. EXPERIMENTAL PROCEDURES  
3.3.1. Cell Culture  
Materials, see Chapter II (Cell Culture protocol) 
Method 
MEG-01 megakaryoblastic cell line [1], was a generous gift from Dr. P. B. Tracy, 
(Department of Biochemistry, University of Vermont, College of Medicine, Burlington, 
VT, USA). MEG-01 cells were also purchased from American Tissue Culture Collection 
(Manassas, VA). Cells were maintained in an incubator, with humidified atmosphere of 
CO2 5%, and at 37 0C. Cell culture media, RPMI 1640 1X with L-Glutamine (2mM), 
was adjusted to contain 10 mM HEPES, 1.0 mM Sodium Pyruvate and 10-20 % heat-
inactivated fetal bovine serum (FBS) and 5U Penicillin/Streptomycin. Cells were seeded 
at 2 X 105 cells/ml, media was renewed and cell number was adjusted two times per 
week. 20% of FBS was observed to improve the growth and endurance of MEG-01 cells. 
More mature MEG-01 cells become adherent to the culture flask wall and therefore in 
order to provide a better surface area for them, flaks were kept on the side. 
3.3.2. Creation of MEG-01 xenografts 
Animals.  
Immunodeficient male athymic nude nu/nu mice were used. These animals were 
provided and housed by Dr. Lindner, DJ from Taussig Cancer Center, Cleveland Clinic 
and Case Western Reserve University. Mice were checked every day. Mice were housed 
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in filtered air flow cabinets with autoclaved bedding at a density of 5 mice/cage. They 
were fed autoclaved Purina Lab Rodent Chow 5010 and HCl-acidified distilled water ad 
libitum and were placed in rooms with controlled temperature, humidity and 12-hr light-
dark cycles. Procedures involving animals and their care were conducted in conformity 
with the institutional guidelines that are in compliance with national and international 
laws and policies (EEC Council Directive 86/609, OJL 358, December 1, 1987, and the 
National Institutes of Health Guide for the Care and Use of Laboratory), Animals, NIH 
Publication 85-23, 1985).  
The average weight of the mice used in these sets of experiments was 30-35 g. 
Animals were observed for distress or dehydration and their weight was measured 
every two days. 
Engraftment of MEG-01 cells in nude mice 
For engraftment, washed cells, resuspended in cell culture media were injected. 
MEG-01 myeloid blast crisis cells (10×106 cells/100 µl in cell culture media (RPMI 1640 
1X, 10 % FBS) were injected subcutaneously into the lower flanks of mice (left and 
right) using 0.5 ml tuberculin syringes with 25G needles. Cells were counted with a 
Neubauer hemacytometer using Trypan blue, before innoculation. Only live cells were 
counted. 
After about ten days all the animals developed tumors big enough to start the 
treatment. Tumors were visible after 6-7 days from inoculation. Treatment with DMAT 
was started when tumors were at least 100-200 mm3 volumes (prolate spheroid).  
Tumor volumes were calculated as prolate spheroid using the formula described 
bellow: 
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V=(4/3)*π*(a)2*(b) 
Were „a” is half the minor axis and „b” is half the major axis of the prolate spheroid. 
“2a” and “2b” were measured with a caliper (mm).  
Animals were treated with DMAT for approximately two weeks (when tumor 
volumes reached an unacceptable size with the IACUC protocols, animals were sacrificed 
in a CO2 euthanasia chamber). Tumors were collected following necropsy for further 
histological analysis.  
3.3.3. In vivo therapy of MEG-01 xenografts with DMAT 
Therapy with DMAT was done in two trials. DMAT in DMSO, as well as just 
DMSO as a control, were administered by injection subcutaneous in the fat pad tissue of 
the neck (exogenous from the tumor). Tumor measurements were used to assess the 
effects of DMAT on MEG-01 xenografts. Tumor diameters were measured using a 
caliper and tumor volume was calculated using the prolate-spheroid formula. 
Treatment of MEG-01 murine xenografts with DMAT 
First trial with n = 4 (2 tumors on left and right flanks) was started when tumor 
volumes were quite big (500-650 mm3). DMAT in DMSO was administered daily at 2 
mg/ml per animal (an average of 61.5 mg/kg DMAT considering a male mouse weight 
between 30-35 g). DMAT injection was performed subcutaneous, into the neck (in the 
neck fat pad), exogenous from the tumors. Injection volume was 50 µl (DMAT 2 
mg/animal per day). The trial length was two weeks. Tail-bleeding and blood collection 
were performed on these animals before sacrifice, under anesthesia. 
Second trial with n = 6 (2 tumors on left and right flanks) was started when tumor 
volumes were smaller, at 100-200 mm3. DMAT in DMSO was administered daily as 3 
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mg/animal per day (an average of 92.3 mg/kg DMAT considering a male mouse weight 
between 30-35 g). DMAT injection was performed subcutaneous, into the neck (in the 
neck fat pad), exogenous from the tumors Injection volume was 50 µl. The trial length 
was two weeks. 
At the end of the trial, tail-bleeding times assay was performed and blood was 
collected for blood counts from live and anesthetized mice. After these experiments were 
completed mice were sacrificed and tumors and organs were collected. Samples were 
fixed (at least overnight at room temperature) in formalin fixative for further processing. 
Two batches of control mice (with MEG-01 tumors), n = 4 and respectively n = 6, 
were treated with 50 µl DMSO, which is the vehicle for DMAT. The control batch was 
analyzed and compared with the DMAT treated mice (as tumor volumes, tissue histology, 
tail-bleeding and blood counts). 
3.3.4. Pilot study for in vivo toxicity of DMAT 
A male nude mouse (without tumors) was treated with DMAT to determine a 
toxicity level. A saturated solution of DMAT in DMSO was inoculated daily in the neck, 
subcutaneous (100 µl of 100 mg/ml DMAT in DMSO). Therefore this animal received 10 
mg DMAT per day (308 mg/kg/day). After two weeks this animal was sacrificed and 
organs were collected for further analysis. 
3.3.5. Hematoxylin & Eosin (H&E) staining of tumor tissue and organs 
After euthanasia with CO2, mice were suposed to necropsy. Tumors were collected 
from under the skin from both flanks and were measured for the last time and then fixed 
in formalin fixative. Spleen, liver, kidney, brain, lungs and legs were collected and fixed. 
Spleens were also measured (as lenght, mm). Fresh tissue was immersed immediatly into 
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liquid nitrogen and kept frozen at -800C. Fixed tissue was embedded in parafin and next 
processed for H&E (the basic dye hematoxylin, and the alcohol-based synthetic material, 
eosin) by the Cleveland Clinic Histology Core facility. Sections (4-µm thick) were 
stained with hematoxylin and eosin and evaluated for pathologic changes in a blinded 
fashion. H&E staining gives morphological information (vascularization, normal 
proliferating tissue, necrosis and apoptosis of the tissue). 
Hematoxylin & Eosin Staining Protocol 
Materials 
Hematoxylin – Richard-Allan Scientific (Kalamazoo, MI, USA) 
Eosin - Richard-Allan Scientific (Kalamazoo, MI, USA) 
Ethanol – Sigma Chemical Co. (Carlsbad, CA, USA) 
Paraformaldehyde - Sigma Chemical Co. (Carlsbad, CA, USA) 
Xylene - Sigma Chemical Co. (Carlsbad, CA, USA) 
Permount solution – Vector Laboratories (Burlingame, CA, USA)
Microscope glass slides – Fisher Scientific (Pittsburgh, PA, USA) 
Method 
Paraformaldehyde fixed tissue was washed thouroughly with running water (1-2 
h). Then tissue was washed for 2 minutes with 100% ethanol. After alcohol washing, 
staining was performed with hematoxylin (8 minutes), then washed with running tap 
water for 30 minutes, then tissue was incubated with eosin for 3 minutes. After eosin 
staining, tissue underwent a series of alcohol incubation steps. First alcohol step was 
done overnight with 70% ethanol, next two times (15 minutes) with 80% ethanol, then 
three times (30 minutes) with 95% ethanol and finally three times (45 minutes) with 
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100% ethanol. An incubation with xylene, three times (10 minutes) on shaker was 
performed. This processed tissue was embeded in parafin and then thin sliced. The slices 
were mounted with Permount solution on microscope glass slides and visualized with an 
Olympus CK40 inverted microscope and pictures were taken for each slide, usually at 10 
X and 20 X magnification. 
3.3.6. Mice blood collection and blood counts 
Materials, see Chapter II (human platelets isolation protocol). 
Method 
Blood counts are dependent upon the method and time of blood collection [29]. 
Whole blood was collected from the retro-orbital sinus (under the eye) of anesthesiated 
mice (both DMSO treated and DMAT treated batch). EDTA – citrate buffer (ACD) and 
prostaglandin E1 (PGE1) were used at collection to prevent clotting during blood 
collection. 500 µl mouse whole blood with 100 µl anticoagulant (EDTA 25 mM, as a 1:5 
dilution) was used for counting.  
A hematological analyzer (a clinical flow cytometer located at Cleveland Clinic 
Stem Cell Research Department) was used for getting whole blood counts from the mice 
blood. Samples were compared (gated) with normal mice (C57BL strain). 
3.3.7. Tail-bleeding assay 
Materials 
Ketamine – Fort Dodge Animal Health (Fort Dodge, IA, USA) 
Xylasine – Vedco (St. Joseph, MO, USA) 
Saline solution – Baxter Healthcare (Deerfield, IL, USA) 
Scalpel - Roboz Surgical Instrument Co. (Gaithersburg, MD, USA) 
Method 
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Tail-bleeding times are important to investigate whether the platelets could 
establish hemostasis in vivo. Platelet aggregation and clot retraction in response to 
physiologic agonists adenosine diphosphate (ADP), epinephrine, and thrombin will affect 
tail-bleeding times. Normal tail-bleeding times are between 1.5-3 minutes in C57BL 
mouse strain [30]. 
We used pre-warmed tubes of saline solution at 37ºC and these tubes were 
maintained at this temperature during the measurements. Inhalation of isoflurane vapors 
or, alternatively, intraperitoneal injection of (ketamine, xylasine and saline buffer 
cocktail) was used to induce general anesthesia. Using a sharp new razor or a scalpel 
blade, tails were cut exactly 0.5 cm of the distal tip of the tail of the adult mouse and 
immediately inserted into the pre-warmed tube of saline. A stopclock was started at this 
time. The tail was hold gently, near its base, to avoid a "torniquet effect." Venous blood 
flowing into the tube can be observed. In this way it can be easily detected when the 
bleeding stops. The stopclock provides an accurate bleeding time. 
3.3.8. Data Analysis  
To assess the statistical significance of the difference between pairs of means of 
tumor volumes, student’s two-tailed t test was usually used. p < 0.05 (*) was considered 
significant, very signficant, p < 0.01 (**),extremly significant, p < 0.001 (***) , for each 
set of data, daily. Data was ploted in order to establish whether or not the population 
follows a normal distribution and then depending on the type of data, parametric or non-
parametric tests were performed, to establish a proper „p” value. When was necesary due 
to the data type, unpaired student t-test was used to examine statistical differrences. 
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Data was plotted as average tumor volume (mm3) from all tumors (n = 8 for trial 1 
and n = 12 for trial 2) or averaged blood counts, spleen sizes, necrotic areas, respectively 
vascularized areas.  
 
3.4. RESULTS 
Our in vitro studies of MEG-01 cells treated with the casein kinase 2 inhibitor, 
DMAT, revealed that DMAT has anti-cancerous activity (see Chapter II). MEG-01 cells 
are malignant megakaryoblasts with high proliferation rate. DMAT inhibited malignant 
proliferation and induced apoptosis dose and time dependent, in vitro, in MEG-01 cells. 
And more interesting is that the primary cell line (normal) HUVEC is not so sensitive to 
DMAT as MEG-01 cells are, as observed from apoptosis assays. 
 MEG-01 xenografts were treated with DMAT for a period of two weeks. Thus, based on 
these results, it is necessary to test DMAT in vivo in order to be able to acknowledge 
DMAT as a possible anti-cancer drug candidate. The in vivo model chosen for these 
preliminary pre-clinical studies was the MEG-01 murine xenograft. 
Two experimental sets for these in vivo studies were considered. First set consisted of 
animals with bigger tumors (n = 4, with tumors on both flanks left and right) were 
studied, see figure 3.1. This trial was started when tumor volumes were quite big (500-
650 mm3). DMAT in DMSO was administered daily as 2 mg/animal, subcutaneous, into 
the neck (in the neck fat pad), exogenous from the tumors. Tumors were measured daily 
and tumor volume was calculated for each tumor using the prolate-spheroid formula 
(mm3). Control mice received a 50 µl DMSO injection daily. The treatment length was 
two weeks. From the 7th day of treatment with DMAT, tumors start to stop their 
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development maintaining a constant size, slightly decreasing until the end of the 
treatment. From the 7th day of treatment the difference between treated (filled triangles) 
and untreated tumors (filled squares) becomes statistically significant different, as seen 
on figure 3.1.  
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Figure 3.1. MEG-01 xenograft treated with 2 mg DMAT/animal/day for 2 weeks. 
 
Black filled squares represent an average of tumor volumes of  8 tumors for Control 
batch (DMSO only) represented versus tumor volumes from DMAT treated batch (8 
tumors) represented with filled triangles. * represent p < 0.01 as assessed daily with 
student t-test. 
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Figure 3.2. shows the results from a MEG-01 xenograft treatment with DMAT second 
trial. This second trial (n = 6, 12 tumors on both flanks left and right) was started when 
tumors were smaller (100-200 mm3), see figure 3.2. DMAT in DMSO was administered 
daily at 3 mg/animal exogenous from the tumors. Tumors were measured daily and tumor 
volume was calculated for each tumor using the prolate-spheroid formula (mm3). Control 
mice received a 50 µl DMSO injection daily. The treatment length was two weeks. 
Because of a dose increase in the DMAT treatment and smaller starting tumor size, the 
effect of DMAT was more pronounced, see figure 3.2 versus figure 3.1. Significant effect 
was observed earlier than with the first trial, starting from the 4th day (3 days earlier). 
From this day up to the end of the trial, tumor development inhibition and tumor ablation 
(filled triangles) were observed. In contrast, the control tumors (just DMSO, filled 
squares) were growing exponentially for both experimental sets. 
Thus we can conclude that the treatment of MEG-01 xenografts induces 
proliferation arrest in vivo. This tumor proliferation arrest is due to apoptosis-necrosis of 
tumor tissue and reduced angiogenesis, as observed from the histological analysis of the 
tumor tissue (H&E staining), see figure 3.3. Figure 3.3, panel A and B shows the 
hematoxylin-eosin staining of MEG-01 tumors (Control-DMSO versus Treated with 
DMAT). Figure 3.3, panel C shows a plot of necrotic area, apoptotic area versus normal 
areas (pixels) from hematoxylin and eosin images from all the MEG-01 tumors. Figure 
3.3, panel D shows a plot of angiogenesis area in untreated (DMSO) MEG-01 tumors 
(pixels) versus angiogenesis areas in DMAT treated MEG-01 tumors.  
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Figure 3.2. MEG-01 xenograft treated with 3 mg DMAT/animal/day for 2 weeks. 
 
Black filled squares represent an average of tumor volumes of 12 tumors for Control 
batch (DMSO only) represented versus tumor volumes from DMAT treated batch (12 
tumors) represented with filled triangles. * represent p < 0.01 
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Figure 3.3. Hematoxylin-eosin staining of MEG-01 tumor tissues. 
 
A. Control – DMSO MEG-01 tumor, magnification X10 B. Treated with DMAT tumor, 
magnification X10, C. MEG-01 H&E apoptotic-necrotic areas, D. MEG-01 H&E 
angiogenesis areas 
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Based on our in vitro observations that MEG-01 cells treated with DMAT produce 
platelets, we tested whether or not this phenomena occurs in vivo also. Thus platelets 
counting (figure 3.4 and figure 3.5) and tail-bleeding experiments (figure 3.6) were 
performed. Figure 3.4. shows the processed results of blood counts for the second set (n = 
6) of MEG-01 xenograft. Figure 3.4, panel A shows platelets counts from MEG-01 
xenograft mice (Control, DMAT treated) versus normal murine platelet counts (cells/µl).  
Figure 3.4, panel B shows abnormal cell counts from MEG-01 xenograft mice 
(Control, DMAT treated) versus normal murine abnormal cell counts (cells/µl). It is 
interesting to observe that the mice bearing MEG-01 tumors have increased platelets 
counts, as well as high abnormal cell counts. Details of such blood counting experiment 
can be observed in the figure 3.5. Figure 3.5 shows a MEG-01 Control (whole blood) 
sample versus a MEG-01 treated sample, when analyzed with the hematological analyzer 
to determine blood counts. Figure 3.5. panel A, is a representative of a Control-MEG-01 
xenograft (DMSO only), with very high abnormal cells percentage. In contrast, in figure 
3.5, panel B, is a representative DMAT treated sample from MEG-01 xenograft with very 
high platelets counts, but low abnormal cell counts. These results are very interesting 
because it seems that MEG-01 tumors in mice will produce circulating blast cells or that 
this tumors may produce stimulating factors that will induce the release of such abnormal 
cells from mice bone marrow. Mice treated with DMAT had higher platelets counts than 
the ones treated just with the vehicle DMSO, showing that DMAT induces platelets 
release in vivo from MEG-01 tumors.  
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Figure 3.4. Whole blood counts for MEG-01 xenograft trial. 
 
A. Platelet counts (counts*106 cells/µl) for Control-DMSO MEG-01 xenograft, DMAT-
treated MEG-01 xenograft versus Normal mice blood counts (no tumor), B. Abnormal 
cell percentages for Control-DMSO MEG-01 xenograft, DMAT-treated MEG-01 
xenograft versus Normal mice blood counts (no tumor). Unpaired student t-test was used 
to see statistical differrences (* significant, p<0.05, ** very signficant, p<0.01, *** 
extremly significant, p<0.001)  
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A     B 
 
Figure 3.5. Whole-blood cell counts histogram results. 
 
A. Control-MEG-01 xenograft DMSO only, with high abnormal cells percentage, B. 
DMAT treated MEG-01 xenograft with very high platelets counts. 
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The mice treated with DMAT had lower abnormal cell counts which may be 
correlated with the maturation process from blast to megakaryocytes induced by DMAT 
in MEG-01 cells, thus less blasts are available to be release in the blood stream. It can 
also be speculated that, because DMAT decreases tumor size, smaller tumors will 
produce less stimulating factors and thus we will have less abnormal cells.  
However, the examination of spleen tissue sections (H&E, figure 3.6) revealed 
megakaryocytic cell infiltration in spleen of both treated and non-treated MEG-01 tumor 
bearing mice (cells with huge nucleus are highlighted with white squares). Figure 3.6 
shows comparatively, the hematoxylin-eosin staining of spleens from MEG-01 tumor 
bearing mice (Control-DMSO, figure 3.6 panel A versus DMAT treated, figure 3.6 panel 
B) versus normal spleen from normal healthy mice (figure 3.6 panel C –horizontal 
section- and figure 3.6 panel D – transversal section).  
Next we measured spleeen sizes for all sets of mice, as it can be observed in figure 
3.7 (length, cm). Normal mice, MEG-01 xenograft Control (DMSO) and MEG-01 
xenograft treated with DMAT (2 and 3 mg/animal/day) averaged spleen lengths were 
compared with normal spleens sizes from normal mice. This analysis showed very 
significant statistical differences between the normal mice and MEG-01 tumor bearing 
mice. The tumor bearing mice treated with DMAT had smaller spleens than the non-
treated mice with tumors. Thus, we can conclude that the observed abnormal cell counts 
are due to MEG-01 blasts released into circulation from MEG-01 tumor bearing mice. 
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Figure 3.6. Hematoxylin-eosin staining of MEG-01 spleen.  
 
A. Control –DMSO MEG-01 xenograft spleen, B. Treated with DMAT xenograft spleen, 
C. Control no tumors, no treatment, horizontal section (normal), D. Control no tumors, 
no treatment, transversal section (normal). Magnification X10 
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Figure 3.7. MEG-01 xenografts spleen sizes. 
 
Spleens were measured (length, cm). Student unpaired t-test was used to analyse data, 
MEG-01 Control (DMSO only) spleen sizes were compared with MEG-01 DMAT 
treated (2 and 3 mg/animal/day) DMAT, (*, p<0.05) and compared each of them through 
student unpaired t-test with Normal spleen sizes (***, p<0.001) showed very significant 
statistical differences. 
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Because MEG-01 mice had high platelets counts, it was interesting to examine if 
this thrombocytosis induces any diferrence versus normal and DMAT treated tail-
bleeding times. Figure 3.8. shows the results of tail-bleeding times from both MEG-01 
trials versus normal tail-bleeding times for both sets of mice (higher tumors at the 
beginning of treatment and 2 mg/animal/day DMAT dose and smaller tumor at the 
beginning of treatment and 3 mg/animal/day). This data show that there is no statistically 
significant diference between the tail-bleeding times of this set of mice, for the second set 
(3 mg/ml) there is some effect. It seems that MEG-01 mice have a slightly decreased tail-
bleeding time than the normal untreated mice, whereas the DMAT treated mice had a 
slightly increased tail-bleeding time versus the the MEG-01 tumor bearing mice left 
untreated.  
However for this type of experiments like tail-bleeding, a much bigger number of 
samples (an averge optimal n = 100) should be considered, in order to be able to draw 
any conclusions. Thus considering these results we can speculate that DMAT may have a 
mild platelet aggregation inhibitory effect, like heparin, which is also a CK2 inhibitor. 
These DMAT treated mice seem to be fine (they do not present symptoms of blood 
clotting problems like severe bleeding or thrombosis) which sustains these tail-bleeding 
results. 
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Figure 3.8. Tail-bleeding times for MEG-01 xenograft. 
 
Squares represent tail-bleeding times (minutes) for MEG-01 Control (DMSO) mice, 
triangles represent tail-bleeding times (minutes) for MEG-01 Treated (2 mg/animal/day 
DMAT) and circles represent normal values. A. Tail-bleeding times for trial 1 (2 mg/ml), 
B. Tail-bleeding times for trial 2 (3 mg/ml) 
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Figure 3.9. Hematoxylin-eosin staining of MEG-01 liver. 
 
A. Control MEG-01 – liver from MEG-01 xenograft mouse (DMSO treated) B. Liver 
from a MEG-01 mouse xenograft treated with DMAT, C. Normal liver from a healthy 
normal mouse (horizontal section), D. Normal liver from a healthy normal mouse 
(transversal section). Magnification X10. 
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In order to see if there is any cytotoxic effect of DMAT on MEG-01 xenografts, 
liver sections stained with H&E were examined (figure 3.9). MEG-01 tumor bearing 
mice show some abnormal liver features, like increased spaces (liver fibrosis) see figure 
3.9, panel A. The liver from MEG-01 tumor bearing mouse treated with DMAT (figure 
3.9 panel B) looks normal like a healthy liver from C57BL (figure 3.9, panel C and D). 
This data suggests first of all that DMAT is not toxic and that the MEG-01 tumors may 
induce stress on the liver. 
A toxicity pilot study was performed. A normal healthy nu/nu male mouse was 
treated with a high quantity of DMAT (10 mg/animal/day, which is 308 mg/kg/day) in 
the same way as the other treatments were executed. The animal was observed for three 
weeks. The comportament of the animal was relatively normal, he ate, slept, drinked 
water. The animal presented increased soreness and swollen tissue at the injection site. 
After two weeks, blood was collected from this animal and then he was euthanized and 
tissues were collected for histology. Tissues from various parts of the body were 
collected and stained with H&E. Results are summarized in figure 3.10 (H&E of brain, 
liver, kidney, spleen, injection site and muscle). If we compare these histological results 
with normal healthy mouse tissues (from a C57BL animal), see figure 3.11 and figure 
3.12, we can definetly say that the organs of the DMAT treated mouse are normal. Figure 
3.11 shows H&E staining of tissues (horizontal sections) from organs isolated from a 
healthy normal C57BL mouse (panel A brain, B. Liver, C hearth, D kidney, E lung, F 
aorta). Figure 3.12 shows shows H&E staining of tissues (transversal sections) from 
organs from a C57BL mouse that was normal and healthy. 
 162 
 
 
From this pilot toxicity study we can withdraw the conclusion that DMAT is not 
toxic to the animal even at this high dose. But it may also be possible that DMAT was 
wasted and not metabolized because it is not soluble. DMAT deposits were observed like 
calcifications in the tissue were the injections were performed. 
Blood from this toxicity study mouse was also collected and runned on the flow 
cytometer whithout any staining just to observe wether or not the blood presents normal 
cell populations, see figure 3.13 (panel A logarithmic scale, FSCH-SSCH histogram, 
panel B linear scale, FSCH-SSCH histogram). From this figure we can tell that there 
were no changes in the whole blood cells populations due to DMAT treatment. Cell 
percentages for gated populations are in normal ranges, see figure 3.13, panel B. Gate R1 
(monocytes) is 2%, gate R2 (lymphocytes) is between 20-40%, gate R3 (granulocytes) is 
about 6 % and platelets gate R4 is about 40%. These values are normal [31, 32]. 
DMAT induced tumor proliferation arrest and ablation. Tumors from mice treated 
with DMAT had high necrotic and apoptotic areas. Vascularization areas of such tumors 
were significantly reduced versus the non-treated tumors, suggesting a possible anti-
angiogenic effect. DMAT enhanced platelets release from MEG-01 cells in vivo. Mice 
bearing MEG-01 tumors had high abnormal cell counts and highly polyploid cells 
infiltrates the spleens of such mice. MEG-01 xenografts also had splenomegaly and 
DMAT treated mice had smaller spleens and lower abnormal cell counts. DMAT 
administered at high concentration did not have toxic effects. Thus we can propose 
DMAT as a candidate for developing new therapies for chronic myelogenous leukemia. 
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Figure 3.10. DMAT toxicity level (10 mg/day/animal) treated male nude mice (2 
weeks of treatment). 
 
A. brain H&E, B. Liver H&E, C. Kidney H&E, D. Spleen H&E, E. Injection site, F. 
Muscle from leg 
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Figure 3.11. Normal healthy C57BL mouse (horizontal sections) H&E staining of 
organs 
 
A. brain H&E, B. Liver H&E, C. Hearth H&E, D Kidney H&E, E. Spleen H&E, F. 
Lung, H&E F. Aorta H&E 
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Figure 3.12. Normal healthy C57BL mouse (transversal sections) H&E staining of 
organs 
 
A. brain H&E, B. Liver H&E, C. Hearth H&E, D Kidney H&E, E. Spleen H&E, F. 
Lung, H&E F. Aorta H&E 
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Figure 3.13. Toxicity mouse whole-blood non-lysed flow cytometry 
 
A. logarithmic scale (FSCH and SSCH histogram), gate R1 – RBC cells, gate R2 – 
platelets, gate R3 - debris B. Linear scale (FSCH and SSCH histogram), gate R1 – 
monocytes (2%), gate R2 – lymphocytes (25%), gate R3 – granulocytes (6%), gate R4 – 
platelets (40%). 
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3.5. DISCUSSION 
MEG-01 cells are malignant megakaryoblasts isolated from a patient with chronic 
myelogenous leukemia in blast crisis [1]. MEG-01 cells are presenting a malignant 
phenotype showing increased proliferation and capacity to produce solid tumors in vivo. 
MEG-01 cell line may provide a useful model for testing the in vivo efficacy of anti-
tumor agents and immunotoxins, and for studying the pathophysiological mechanisms of 
human megakaryoblastic leukemia [11]. Thus we created MEG-01 murine xenografts to 
study the effects of DMAT in vivo. 
First thing that we noticed with these studies is that DMAT induces tumor 
proliferation arrest in vivo, in MEG-01 xenografts. DMAT has a better effect on smaller 
tumors, which is normal. Also if the concentration of DMAT is increased, the response is 
better. This proliferation arrest of the tumors is due to apoptosis and necrosis induced. 
These effects were expected based on the fact that DMAT induces apoptosis and 
proliferation arrest of MEG-01 cells, as observed from in vitro experiments previously 
described in Chapter II. DMAT through its action on CK2 may modulate the AKT kinase 
[33, 34] and therefore this could be a possible explanation of reduced angiogenesis in 
treated tumor tissue versus non-treated, see figure 3.3 panel D and this reduction in 
angiogenesis may result in tumor growth arrest. Tumors are highly vascularized because 
they need a lot of nutriments to sustain their accelerated growth, which are brought to 
them by blood. 
The MEG-01 tumors released platelets in vivo due to casein kinase 2 inhibitor 
treatment (DMAT). We observed very high platelets counts for both MEG-01 treated and 
untreated xenografts. Tail-bleeding times for MEG-01 xenograft mice were close to 
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normal (slightly decreased for Control-DMSO untreated and slightly increased for MEG-
01 DMAT treated mice). Based on the functional platelets assays performed in vitro with 
MEG-01 platelets, we know that these MEG-01 platelets (released due to DMAT 
treatment) are functional and can aggregate. These tail-bleeding results maybe due to 
several possibilites: first thing, murine platelets respond to a different thrombin (IIa is not 
evolutionary conserved). IIa in humans activates PAR-1 and PAR-4 receptors on human 
platelets whereas on murine platelets PAR-3 and PAR-4 receptors are involved [35]. IIa 
in human has a Na+ binding site, whereas due to a mutation (Asp 222 to Lys) in murine 
IIa, this Na+ binding site does not exist [36]. Thus considering these facts, it is possible 
that murine platelets may respond to human thrombin, but the reverse is less likely, 
because the mechanism of platelet activation by IIa is more complex in human than in 
mouse. Therefore if MEG-01 tumors produce platelets in vivo due to DMAT action, these 
human platelets will not be able to form the stable clot, because murine thrombin will not 
act properly on them, so the only stable clots will occur with mouse’s own platelets. 
Another possibility is that DMAT being a CK2 inhibitor, like heparin and as any other 
kinase inhibitors is not 100% specific to CK2, therefore it may inhibit other required 
phosphorylations so it will induce a short delay in the in vivo clotting. Anyway the 
differences versus normal tail-bleeding times are not as big to create a problem in the 
survival of these animals. More tail-bleeding experiments (n = 100) are required in order 
to be able to indeed have enough data points to be certain of a specific effect. 
It is certain though that the MEG-01 tumors may infiltrate the spleen of MEG-01 
xenografts, see figure 3.6 (both control and treated) and leukemic megakaryoblastic cells 
appeared in the blood of mice with MEG-01 tumors (as high abnormal cell counts) see 
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figure 3.4, and figure 3.5. MEG-01 mice had all splenomegaly (treated and untreated), 
see figure 3.7. This splenomegaly is correlated directly with high abnormal cell counts 
(found in both treated and non-treated mice), see figure 3.4. Control mice with bigger 
tumors, have bigger spleen sizes and also have higher percentages of abnormal cell 
counts, which maybe correlated with release of MEG-01 undifferrentiated blasts in the 
blood stream. Also, high platelets counts maybe responsible for increased spleen sizes. 
Now what it is interesting is that chronic myelogenous leukemia is characterized by 
circulating blasts (high abnormal cell number) and high platelets counts [37-39]. Various 
models of murine chronic myelogenous leukemia were created, like murine CML models 
made by transferring human stem cells that express BCR-ABL from retroviral vectors 
[40, 41]. An alternative approach to developing an in vivo model of CML was developed 
based on the fact that normal human haemopoietic cells will engraft relatively efficiently 
in immunodeficient mice. Transplantation of cell suspensions from patients with chronic 
phase CML into irradiated SCID or NOD/SCID mice has required the use of relatively 
large cell doses in order to detect cells with engrafting potential. Similarly, although 
some Ph+ cells can be produced in the immunodeficient murine hosts, a greater 
engraftment of the mice with normal (Ph−) cells is typically seen [40, 42]. Thus MEG-01 
engrafted mice makes an inexpensive, easy to maintain and produce model of chronic 
myelogenous leukemia which manifests itself by releasing circulating blasts and 
thrombocytosis, which are characteristic symptoms of CML. 
Thus having a murine model and the potential drug candidate DMAT which works 
in vivo in the same manner as in vitro (see Chapter II), we wanted to see if DMAT has 
toxic effects. Livers from DMAT treated mice were stained with H&E and examined. 
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Liver tissues from MEG-01 mice treated with DMAT had a normal histology. This data 
suggests first of all that DMAT is not toxic. In order to see if indeed DMAT is not toxic, 
then a pilot toxicity study was done. A nude healthy mouse was injected daily with high 
amounts of DMAT (10 mg/animal). Liver, brain, kidney, muscle tissue seem to be 
normal in DMAT toxicity level treated mice, when H&E sections from this animal were 
examined and compared with normal tissues from C57BL healthy mice. The injection 
site shows necrosis. This is due to insoluble DMAT deposits and DMSO (the vehicle for 
DMAT). The lack of toxicity at a such high concentration of DMAT maybe also due to 
the insolubility in body buffers of the CK2 inhibitor. Accumulation at the injection site 
was observed in all the treated mice (even with very low concentrations), but with such a 
high concentration, crystal-like solid deposits formed. A novel formulation of the 
substance maybe required if it presents interest as a drug. 
Overall this data shows that DMAT may behave as a megakaryocytic maturation 
inducer in vivo and this is correlated with in vitro studies. DMAT also has potent anti-
cancerous activity and does not seem to be toxic. This may have very important clinical 
value. 
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CHAPTER IV 
TREATMENT OF VARIOUS CANCER CELL LINES WITH DMAT 
4.1. ABSTRACT 
Casein kinase 2 was found to be up-regulated and over-expressed in tumor tissue 
and maybe responsible for the cancer apparition and sustainability. Studies with various 
CK2 inhibitors (antisense nucleotides) and ATP site inhibitors in malignant cell lines as 
well as in murine xenografts revealed that such inhibitors maybe considered as possible 
tools in developing new cancer therapies. Such inhibitors induced apoptosis and 
proliferation arrest in vitro and in vivo in different cancer cell lines. MCF-7 cells are 
breast cancer cells, estrogen dependent, with a highly abnormal proliferation rate. SW-
480 are malignant colon cells (ephitelial cancer cells). WM-164 are very agressive 
melanoma cells. Such cells are all resistant to apoptosis and manifest anchorage 
independence by growing colonies in soft agar (a sign of malignicity). All these cell lines 
were not tested before us in vitro and in vivo for effects due to the CK2 inhibitor DMAT. 
Based on our preliminary results with MEG-01 megakaryoblastic leukemia cell line, and 
based on literature data, we decided to test this inhibitor in a few very differrent cancer 
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cell lines to see if it can be a general cancer drug. Results were as expected. DMAT 
induced proliferation arrest in vitro, due to apoptosis and inhibited growth in soft agar. In 
vivo results were very good for the MCF-7 xenografts (at very low concentrations of 
DMAT). This may suggest involvement of CK2 in the female hormone metabolism. 
MCF-7 showed proliferation arrest in tumors, even small tumor ablation due to DMAT 
treatment. Similar results were obtained for colon cancer and skin cancer (but at much 
higher concentrations of inhibitor). Tumors treated showed necrosis, apoptosis and 
reduced angiogenesis versus untreated (DMSO only) tumors. All these data together 
suggest a common mechanism were CK2 acts that exists in all the cancer cells. 
 
4.2. INTRODUCTION 
Casein kinase 2 (CK2), was found to be constitutively activated, over-expressed 
and to serve as an oncoprotein in various cancers [1-7]. In cancer cells, CK2 localization 
is nuclear and also CK2 is deregulated, being elevated 3- to 7- folds. The up-regulation 
and hyperactivity of CK2 has an anti-apoptotic effect and is correlated with aggressive 
tumor behavior in different cancer types examined and results in abnormal platelet counts 
in leukemia [8].  Antisense nucleotides treatments against CK2α mRNA were studied in 
mouse human prostate cancer xenografts. A very interesting observation following these 
studies showed that CK2 inhibition affects the tumors (by inducing apoptosis and tumor 
ablation), but does not affect the normal surrounding tissue [3, 7]. This was explained as 
being caused by different localizations of the alpha subunit of casein kinase 2 in normal 
(preponderant cytoplasmic) versus malignant tissue (preponderant in the nuclear matrix). 
CK2 elevation in nuclear matrix in cancerous cells is related to cell growth, survival and 
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resistance to apoptosis mainly due to cell cycle control [5, 7, 9]. The disparity effect of 
CK2 inhibition in malignant versus normal cells (as well as tissues) was observed on 
histological analysis of normal and neck squamos carcinoma tissues [3, 10]. Also 
differential response to CK2 inhibition (with antisense nucleotides against CK2α mRNA, 
as well as with specific CK2 inhibitor, DRB) in different normal and benign cell lines 
was observed [6, 11]. Therefore it seems that normal and benign cells are less sensitive to 
the CK2 inhibition. Mechanisms in which CK2 plays a role are very complex and occur 
both in the nuclear matrix as well as in the cytoplasm. What succession of events occurs 
first (the cytoplasmic or nuclear) was not determined, thus to speculate that it can be 
either one it would not be realistic. 
MCF-7 breast cancer cell line. 
MCF-7 is a breast cancer cell line established from the mammary gland of a 69 
years old woman, it is an adenocarcinoma derived from pleural effusion (metastatic site) 
[12]. MCF-7 are differentiated mammary epithelium cells that express estrogen receptor. 
MCF-7 cells express oncogenes (WNT7B and Tx-4) and are sensitive to TNF alpha, 
which inhibits their growth [13]. MCF-7 growth in vivo is hormone dependent (estradiol) 
[14]. MCF-7 produce insulin-like growth factor binding proteins (IGFBP). IGFBP 
secretion from MCF-7 can be modulated by treatment with anti-estrogens [15].  
Clinical studies have shown that therapeutic agents preventing the synthesis and 
actions of estrogens are highly successful in the treatment of breast cancer. The 
mechanisms by which estrogens stimulate cell proliferation, however, are still not clear. 
The epithelial breast cancer derived MCF-7 cell line is one of the most frequently used 
model systems. Casein kinase 2 was found to promote aberrant activation of nuclear 
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factor- B, transformed phenotype, and survival of breast cancer cells [16]. The Her-2/neu 
oncogene is a member of the epidermal growth factor (EGF) receptor family, encodes a 
transmembrane tyrosine kinase receptor. Her-2/neu activates nuclear factor (NF)- B via a 
phosphatidylinositol 3 kinase (PI3-K)-Akt kinase signaling pathway in mouse mammary 
tumor virus (MMTV)-Her-2/neu NF639 mouse breast cancer cells. Because  ectopic CK2 
activity appears sufficient to induce NF- B, the elevated CK2 activity observed in many 
primary human breast cancers likely plays a role in aberrant activation of NF- B and, 
suggesting that CK2 represents a potential therapeutic target, in breast cancer [16]. 
Human SIX1 (HSIX1) is a protein implicated in muscle, eye, head, and brain 
development. CK2 and HSIX1 have both been implicated in cancer and in cell cycle 
control, it was proposed that HSIX1, whose activity is regulated by CK2, is an important 
target of CK2 in G(2)/M checkpoint control and that both molecules participate in the 
same pathway whose dysregulation leads to cancer, in MCF-7 cells [17]. Ultimately 
TNF-α was found to induce apoptosis in breast cancer cells. CK2 amplifies the effect of 
TNF-α [18]. 
SW480 colon cancer cell line. 
SW480 is a colorectal adenocarcinoma from Duke’s type B tumor stage. This cell 
ine secretes TGFβ, keratin and carcinoembrionic antigen (CEA).[19] 
To identify mechanisms by which CK2 promotes survival, specific CK2 inhibitors 
TBB and DMAT were used to treat colon cancer cells. TBB and DMAT significantly 
decreased proliferation and increased apoptosis of HT29(US) colon cancer cells. These 
authors concluded that CK2 kinase activity promotes survival by increasing survivin 
expression via β-catenin–Tcf/Lef-mediated transcription [20]. Mutations in the 
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adenomatous polyposis coli (APC) gene are responsible for familial adenomatous 
polyposis coli and colorectal cancer development. The tumor suppressor protein APC and 
CK2 interaction discovery suggests that growth-inhibitory effects of APC may be 
regulated by inhibition of CK2 [21]. 
WM164 melanoma cell line. 
WM164 is a nodular melanoma in vertical growth phase cell line. The WM164 line 
was established from a metastatic melanoma from a lymph node from a 21 year old male. 
This cell line is highly agressive and develops tumors in nude mice.[22, 23] 
A proteomics study performed in several melanoma cell lines, found that a 
nucleolar and centrosome associated protein named nucleophosmin B23 is responsible 
for the malignant phenotype in melanoma. B23 is a target for cyclin E/CDK2 thus 
affecting cell cycle control. B23 is up-regulated and shows enhanced phosphorylation in 
tumor cells [24]. B23 was found to be mainly phosphorylated by CK2 and this 
phosphorylation was inhibited by heparin, apigenin and DRB in vitro and in vivo.[25-29] 
p53 protein is a tumor suppressor and its gene disruption is associated with 
approximately 55% of human cancers. The p53 protein is a regulatory cell cycle protein, 
either preventing or initiating apoptosis. Phosphorylation by CK2 activates the specific 
DNA binding of p53 and stimulates its ability to suppress cellular growth. [30-33] 
The PTEN tumor suppressor gene encodes a phosphatidylinositol 3'-phosphatase 
that is inactivated in human tumors, like glioblastoma, melanoma, and prostate and 
endometrial carcinoma. PTEN is a seryl phosphoprotein and a substrate of the kinase 
CK2. CK2 inhibits the PTEN kinase, and this plays a role in oncogenesis [34]. 
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Considering all the possibilities of action of CK2 on various cancers, all finalizing 
with the same effect, inhibition of CK2 proves to be of clinical importance. 
 
4.3. EXPERIMENTAL DESIGN 
Materials used in these experiments were previously described in the Chapters II and III. 
4.3.1. Cell Culture  
MCF-7 breast cancer, SW-480 colon cancer and WM-164 cell lines were a 
generous gift from Dr. D.J. Lindner (Taussig Cancer Center, Cleveland Clinic). Cells 
were maintained in an incubator, with humidified atmosphere of CO2 5%, and at 37 0C. 
Cell culture media was DMEM F12 with L-Glutamine (2mM), containing 10 mM 
HEPES, and 1.0 mM Sodium Pyruvate  and 10% heat-inactivated fetal bovine serum 
(FBS) and 5U Penicillin/Streptomycin were used to grow all these cell lines.  
When cells reached 70-80 % confluence were splitted accordingly.  
4.3.2. Apoptosis Assays using Flow Cytometry with AnnexinV-FITC and 
propidium iodide (PI).  
For induction of typical apoptosis, cells were grown in the presence of 1µM 
staurosporine for 6 hours. The staurosporine treated cells were stained as follows: control 
1 with PI, control 2 with AnnexinV-FITC and control 3 with both PI and AnnexinV-
FITC, in order to have the brightest controls for compensation and proper collection of 
the flow cytometry data. Cell necrosis was induced by heat shock (650C for 30 minutes). 
Controls for necrosis were stained in the same way as for the Staurosporine treated cells. 
The unstained control signal was subtracted by gating from the stained control and the 
rest of stained samples, to get only the positive cells signal (stained). The stained control 
 186 
 
 
(PI and AnnexinV-FITC labeled), was then used as the reference in establishing the level 
of apoptosis induced by the treatments. Data was collected on logarithmic modes, two-
colors. AnnexinV-FITC corresponds to FL1H channel, and PI to FL3H or FL2H 
channels. Cells were gated out from debris on FSCH and SSCH histogram using 
appropriate flow cytometry software (WinMDI 2.8 or Flow Jo ver 6.2). 
AnnexinV-FITC and PI staining protocol  
Apoptosis AnnexinV-FITC and PI kit from BD Biosciences was used. 105 – 106 
cells were stained with 50 µg/ml PI and with 0.5 µg/ml FITC-labeled Annexin V using 
the staining protocol provided by the supplier. Briefly, after trypsinization, cells were 
counted using a Neubauer hemacytometer, then washed by centrifugation (400g, 5 
minutes) and resuspended in the appropriate amount of AnnexinV-binding buffer 1X 
(provided in the kit), in order to have 106 cells in 100 µl buffer. Then PI and AnnexinV-
FITC were added to the cells (5 µl each). Incubation was performed for 15 minutes in the 
dark at room temperature. Samples were then analyzed immediately by flow cytometry. 
4.3.3. Viability (proliferation) assay 
Cells were counted using a Neubauer hemacytometer. Trypan blue dye was used 
according to the manufacturer (Sigma-Aldrich). DMSO, which is the vehicle for DMAT 
was used as a mock control, considering the highest amount that was used as a vehicle for 
DMAT. Phase-contrast micrographs of cells were taken using an inverted microscope 
Olympus CK40, using monochromatic settings, in order to correlate the effect of DMAT 
on proliferation with pictures. 
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4.3.4. Anchorage independence in “soft agar” assay  
Agarose was mixed with MCF-7, SW-480 and WM-164 growth media DMEM F12 
with 10% FBS. Cells were grown in 12 wells dishes at 37 0C, 5% CO2, 90% humidity in 
a VWR incubator. Colonies formation was observed and micrograph images were taken 
using an Olympus CK40 microscope. Cells were observed after one week. We compared 
the control (DMSO) samples with the samples grown in the presence of 10 µM DMAT. 
Media was renewed on the top of the agar every 4 days and DMAT treatment was 
performed every time. 50 colonies from 20 images were analyzed.  Measurements of the 
colonies areas were performed using the NIH Image software ver.1.63 for MacOS 9.  
4.3.5. Creation of the MCF-7, SW-480, and WM-164 xenografts 
Materials 
17-beta-estradiol - 0.36 mg E2/90-day release pellet-  Innovative Research of 
America (Sarasota, FL, USA) 
Method 
Immunodeficient male and female athymic nude nu/nu mice were used, provided 
and housed by Dr. Lindner, DJ from Taussig Cancer Center, Cleveland Clinic and Case 
Western Reserve University. Mice were checked every day and were housed in filtered 
air flow cabinets with autoclaved bedding at a density of 5 mice/cage. They were fed 
autoclaved Purina Lab Rodent Chow 5010 and HCl-acidified distilled water ad libitum 
and were placed in rooms with controlled temperature, humidity and 12-hr light-dark 
cycles. Procedures involving animals and their care were conducted in conformity with 
the institutional guidelines that are in compliance with national and international laws and 
policies (EEC Council Directive 86/609, OJL 358, December 1, 1987, and the National 
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Institutes of Health Guide for the Care and Use of Laboratory), Animals, NIH Publication 
85-23, 1985).  
For engraftment, cells were resuspended in cell culture media. A specific number of 
cells (depending on the cell line) were injected in each flank of the mouse (left and right) 
subcutaneous. Colon cancer cells SW-480 were injected at 2 X 106 cells/100 µl. 
Melanoma WM-164 and breast cancer cells MCF-7 were injected at 3 X 106 cells/100 µl. 
Cells were counted with a hemacytometer using Trypan blue (only live cells were 
counted). 
The average weight of the mice used in these sets of experiments was 30-35 g for 
male mice and 20-25 g for female mice. Female mice weree used for MCF-7 xenografts, 
because MCF-7 is female hormone depended, thus these mice require hormone 
supplementation (17β-estradiol). This hormone was provided in drinking water with 
glucose to be more paleatable.  
Treatment with DMAT was started when tumors were at least 100-200 mm3 
volumes (prolate spheroid). Tumor volumes were calculated as prolate spheroid shown 
bellow: 
V = (4/3*π*(a)2*(b) 
were „a” is half of the minor axis and „b” is half of the major axis of  the prolate 
spheroid. The prolate sheroid axes were measured with a caliper (mm). Animals were 
treated with DMAT for approximately two weeks (when tumor volumes reached a size 
unacceptable with the IACUC protocols, animals were sacrificed in a CO2 euthanasia 
chamber). Tumors were collected for further histological analysis.  
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4.3.6. In vivo therapy with DMAT of MCF-7 xenografts  
Therapy with DMAT was done in two trials (n = 4 both, with 2 tumors per mice). 
The drinking water for mice was supplemented with 17-beta-estradiol. Tumor diameters 
were measured using a caliper and tumor volume was calculated using the prolate-
spheroid formula. DMAT in DMSO as well as just DMSO as a control were administered 
by injection subcutaneous in the neck (exogenous from the tumor).  
4.3.7. In vivo therapy with DMAT of SW-480 xenografts  
Therapy with DMAT was done in one trial (n = 4 both, with 2 tumors per mice). 
Tumor diameters were measured using a caliper and tumor volume was calculated using 
the prolate-spheroid formula. DMAT in DMSO as well as just DMSO as a control were 
administered by injection subcutaneous in the neck (exogenous from the tumor).  
4.3.8. In vivo therapy with DMAT of WM-164 xenografts  
Therapy with DMAT was done in one trial (n = 4 both, with 2 tumors per mice). 
Tumor diameters were measured using a caliper and tumor volume was calculated using 
the prolate-spheroid formula. DMAT in DMSO as well as just DMSO as a control were 
administered by injection subcutaneous in the neck (exogenous from the tumor).  
Tumor measurements will show if DMAT induces tumor ablation in the previously 
described murine xenografts.  
4.3.9. Hematoxylin & eosin staining of tumor tissue and organs 
After euthanasia with CO2, mice were  supposed to necropsy. Tumors were 
collected from both flanks from under the skin and were measured for the last time and 
then fixed in formalin fixative. Various organs (spleen, liver, kidney, brain, lungs and 
legs) were collected and fixed. Spleens were also measured (as lenght, mm). Fresh tissue 
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was immersed immediatly into liquid nitrogen and kept frozen at -800C. Fixed tissue was 
embedded in parafin. Sections (4-µm thick) were stained with hematoxylin and eosin and 
evaluated for pathologic changes in a blinded fashion. The protocol for processing and 
staining tissue with hematoxylin and eosin was described in detail in Chapter III. 
4.3.10. Statistical analysis. 
Statistical analysis was performed as described at Chapters II and III. Briefly 
student t-test and Anova One-Way test were performed depending on the sample type 
(parametric or non-parametric).  p < 0.05 (*) represents significantly diferent values. 
 
4.4. RESULTS 
CK2 is implicated in cellular transformation and development of tumorigenesis and 
aggressive tumor behavior.  CK2 is over-expressed in cancers of mammary gland, lung, 
kidney, colon, head and neck, just to mention a few more studied. Various mechanisms 
are responsible for the effects of CK2 in these cancers. Based on these facts and our 
preliminary data with chronic myelogenous leukemia cells, we decided to test the effects 
of the CK2 inhibitor DMAT on hormone dependent human breast cancer cells (MCF-7), 
colorectal adenocarcinoma cells (SW-480) and  melanoma cells (WM-164). Our first 
finding was that DMAT induces proliferation arrest in vitro in MCF-7 cells, dose and 
time dependent. This proliferation arrest can be observed in figure 4.1 (proliferation assay 
with Trypan blue) and figure 4.2 (phase-contrast micrographs of MCF-7 cells). The 
figure 4.1 shows that the effects of DMAT on MCF-7 cells are dose and time dependent, 
and these results are sustained by the results from figure 4.2. In the figure 4.2, panels A 
and B show control MCF-7 cells (DMSO), 5X magnification and 10X magnification 
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respectively. Difference in confluence (showing inhibition) is observed in figure 4.2 
panel C and D, were cells were treated with DMAT 10 µM. The effect of DMAT is more 
pronounced with the doubling of the dose of DMAT (20 µM), figure 4.2 panels E and F.  
Figure 4.3 shows that DMAT induces apoptosis dose dependent in MCF-7 cells in 
culture. Figure 4.3 represents results from flow cytometric apoptosis assay (AnnexinV-
FITC and PI) of MCF-7 cells after 24 hours of treatment with DMAT 10 and 20 µM. 
Control (DMSO), has 4.1 % apoptotic cells, whereas DMAT 10 µM  treatment of MCF-7 
cells for 24 hours induced 28% apoptosis and DMAT 20 µM  treatment of MCF-7 cells 
for 24 hours induced 49% apoptosis. From these results we can tell by comparison with 
MEG-01 cells analyzed in Chapter II, that MCF-7 are much more sensitive to DMAT 
than the chronic myelogenous leukemia cells. This maybe due to different mechanisms of 
CK2 action specific to MCF-7 cells, like hormone related involved pathways. MCF-7 
cells are known to present the anchorage independence feature, due to activation of 
MAPK through phosphatidylinositol-3 kinase by insulin-like growth factor I [35]. Based 
on the fact that CK2 is involved in this pathway [36], we decided to test the effects of 
CK2 inhibition with DMAT on anchorage independence in soft agar assay of MCF-7 
cells.  
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Figure 4.1. Proliferation assay of MCF-7 cells treated with DMAT 10 and 20 µM.  
 
Squares - control (DMSO), triangles - DMAT 10 µM, stars - DMAT 20 µM.  Treatments 
length was four days.  
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Figure 4.2. Phase-contrast micrographs of MCF-7 cells after 24 hours of treatment 
with DMAT 10 and 20 µM.  
 
A. Control treated only with the vehicle DMSO, 5X magnification, B. Control treated 
only with the vehicle DMSO, 10X magnification, C. DMAT 10 µM  treatment of MCF-7 
cells, 5X magnification D. DMAT 10 µM  treatment of MCF-7 cells, 10X magnification, 
E. DMAT 20 µM  treatment of MCF-7 cells, 5X magnification, F. DMAT 20 µM  
treatment of MCF-7 cells, 10X magnification. 
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The results are summarized in the figure 4.4, for one week treatment with DMAT 
10 µM. From this figure we can conclude that DMAT inhibits anchorage independence in 
MCF-7 cell line. This is most probably due to the inhibition of action of CK2 on the 
MAPK and PI3K pathway. Having these results in MCF-7 cells in culture, next step was 
to test DMAT in a hormone-dependent in vivo model, to see if female hormone 
mechanisms makes a difference. So DMAT was administered to MCF-7 xenografts 
(which received 17-beta-estradiol supplementation daily). Figure 4.5 shows the effects of 
DMAT in vivo in the first trial that we performed. A low amount of DMAT induces 
proliferation arrest in vivo in MCF-7 xenografts, as seen in the figure 4.5. Figure 4.5 
shows MCF-7 xenograft treated with 0.25 mg DMAT/animal/day (10 mg/kg DMAT) for 
two weeks. In the figures 4.5 and figure 4.5, black filled squares are averaged values of 
tumor volumes for control batch (DMSO, 8 tumors) versus tumor volumes from DMAT 
treated batch (8 tumors) represented with filled triangles. Figure 4.6 shows that very low 
amount of DMAT is necessary to induce proliferation arrest in vivo in MCF-7 xenografts 
and tumor ablation if the tumors growth rate is decreased (versus figure 4.5). Figure 4.6 
shows MCF-7 xenograft treated with 0.25 mg DMAT/animal/day (10 mg/kg DMAT) for 
two weeks. These two trials had different growth of tumors due to different 17-beta-
estradiol amount administered to the animals (lower dosage). 
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Figure 4.3. Results from flow cytometric apoptosis assay (AnnexinV-FITC and PI) 
of MCF-7 cells after 24 hours of treatment with DMAT 10 and 20 µM.  
 
A. Control( DMSO) B. DMAT 10 µM  C. DMAT 20 µM, D. Quantification of apoptosis 
induced by DMAT after one day (triplicates).  
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Figure 4.4. Soft agar anchorage independence assay (one week treatment with 
DMAT 10 µM).  
 
A. Control (DMSO) MCF-7 colonies, B. DMAT treated, MCF-7 colonies, C. Colonies 
areas from various images were measured and quantified. 
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Figure 4.5. MCF-7 xenograft treated with 0.25 mg DMAT/animal/day (10 mg/kg 
DMAT) for two weeks. 17-beta-estradiol (0.04 mg/day) was supplemented in water. 
 
Tumors were 200 mm3 in volume at start. Black filled squares - Control batch (DMSO) 
versus tumor volumes from DMAT treated batch represented with filled triangles. * 
represent p < 0.01 as assessed daily with student t-test. 
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Figure 4.6. MCF-7 xenograft treated with 0.25 mg DMAT/animal/day (10 mg/kg 
DMAT) for two weeks. 17-beta-estradiol (0.02 mg/day) was supplemented in water. 
 
Tumors were 200 mm3 in volume at start. Black filled squares - average of tumor 
volumes for Control batch (DMSO) versus tumor volumes from DMAT treated batch 
represented with filled triangles. * represent p < 0.01 as assessed daily with student t-test. 
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Figure 4.7. Hematoxylin and eosin staining of MCF-7 tumors.  
 
A. Control (DMSO), MCF-7 tumor, B. Tumor from MCF-7 DMAT treated mice, C. 
MCF-7 H&E apoptotic-necrotic areas, D. MCF-7 H&E angiogenesis areas. 
Magnification 10X. 
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Figure 4.8. Hematoxylin and eosin staining of MCF-7 livers.  
 
A. Control (DMSO), liver from MCF-7 tumor bearing mouse B. Liver from MCF-7, 
DMAT treated mice, C. Liver from normal healthy wild type mouse C57BL (horizontal 
section), D. Liver from normal healthy wild type mouse C57BL (transversal section). 
Magnification 10X. 
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Figure 4.9. Hematoxylin and eosin staining of MCF-7 spleens.  
 
A. Control (DMSO), spleen from MCF-7 tumor bearing mouse B. Spleen from MCF-7 
DMAT treated mice, C. Spleen from normal healthy wild type mouse C57BL (horizontal 
section), D. Spleen from normal healthy wild type mouse C57BL (transversal section). 
Magnification 10X. 
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Observing such effects in vitro and in vivo, we analyzed the tissues from MCF-7 
xenografts in order to see if there is apoptosis or necrosis in the tumor tissues from 
DMAT treated animals. Organs were also examined (H&E) in order to see if they are 
affected in any way by these treatments. Thus histological analysis was performed. The 
figure 4.7 shows hematoxylin and eosin staining of MCF-7 tumors. The control (DMSO) 
tumor (figure 4.7, panel A) was compared with a tumor from MCF-7 DMAT treated 
mouse (figure 4.7, panel B). Necrosis and apoptosis are induced by DMAT in MCF-7 
tumors as observed and this areas were quantified as averaged data from all the tumor 
samples, see figure 4.7 panel C. Organs samples did not show tumor infiltration or other 
abnormalities in MCF-7 tumor bearing mice (both treated and untreated). Normal liver 
and spleen phenotypes were observed in comparison with wild type C57BL healthy 
tissues. Figure 4.8 and figure 4.9  show that DMAT does not affect these organs in MCF-
7 xenografts and that MCF-7 cells does not infiltrate the spleen and the liver of the MCF-
7 xenograft. 
In colon cancer cells, increased expression of casein kinase 2 (CK2) is associated 
with hyper-proliferation and suppression of apoptosis. One such mechanism is due to the 
fact that CK2 increases survivin expression, which causes the malignant transformation 
of colon cells. CK2 inhibitor TBB was found to inhibit this signaling  [20]. If TBB affects 
this surviving expression, it is normal to presume that DMAT which is a better CK2 
inhibitor than DMAT will have similar or better effects and thus DMAT will inhibit SW-
480 colon cancer cells growth. Figure 4.10 shows the effects of CK2α inhibitor (DMAT) 
on the proliferation rate of SW-480 cells using Trypan blue proliferation assay. DMAT 
 204 
 
 
was found to induce proliferation arrest in vitro in SW-480 cells dose and time 
dependent.  
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Figure 4.10. Proliferation assay of SW-480 cells treated with DMAT 10 and 20 µM 
(Trypan Blue exclusion).  
 
Squares - control (DMSO), triangles - DMAT 10 µM, stars - DMAT 20 µM  Treatment 
of SW-480 cells was for four days. 
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Figure 4.11. Phase-contrast micrographs of SW-480 cells after 24 hours of treatment 
with DMAT 10 and 20 µM.  
 
A. Control treated only with the vehicle DMSO, 5X magnification, B. Control (DMSO), 
10X magnification, C. DMAT 10 µM  treatment of SW-480 cells, 5X magnification D. 
DMAT 10 µM  treatment of SW-480 cells, 10X magnification, E. DMAT 20 µM  
treatment of SW-480 cells, 5X magnification, F. DMAT 20 µM  treatment of SW-480 
cells, 10X magnification. 
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Figure 4.12. Results from flow cytometric apoptosis assay (AnnexinV-FITC and PI) 
of SW-480 cells after 24 hours of treatment with DMAT 10 and 20 µM.  
 
A. DMAT 10 µM, B. DMAT 20 µM, C. Control (DMSO), D. Treatment of SW-480 cells 
with DMAT for one day, quantification of apoptosis (triplicates). 
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This proliferation arrest can be observed better in the figure 4.11, in the phase-contrast 
micrographs of SW-480 cells. Figure 4.11, panel A and B shows control (DMSO) SW-
480 versus panels C and D, which shows SW-480 cells incubated with DMAT 10 µM  
for 24 hours. Figure 4.11 panels E and F show DMAT 20 µM  treatment of SW-480 cells 
for 24 hours. Corresponding to the proliferation arrest we observed that DMAT induces 
apoptosis dose dependent in SW-480 cells in culture. Figure 4.12 summarizes results 
from flow cytometric apoptosis assay (AnnexinV-FITC and PI) of SW-480 cells after 24 
hours of treatment with DMAT 10 and 20 µM. Control (DMSO) has 3 % apoptotic cells, 
whereas DMAT 10 µM treatment of SW-480 cells for 24 hours induced 19% apoptosis 
and DMAT 20 µM treatment of SW-480 cells for 24 hours induced 48% apoptosis. These 
results are comparable with the ones obtained with  MCF-7 cells. Over-expression of  
PKC beta1 and adenomatous polyposis coli (APC) signaling in the SW-480 colon cancer 
cell line are responsible for the anchorage independence growth in soft agar. CK2 is 
involved in these pathways and thus DMAT which is a potent CK2 inhibitor should 
inhibit the anchorage independence phenotype of SW-480 cells. Figure 4.13, soft agar 
anchorage independence assay (one week treatment with DMAT 10 µM) shows that 
indeed DMAT inhibits anchorage independence in SW-480 cell line. If DMAT represses 
malignant proliferation in vitro it should have similar effects in vivo. Therefore DMAT 
was used as a treatment of SW-480 tumor bearing mice. As expected we found that 
DMAT induces proliferation arrest in vivo in SW-480 xenografts. Figure 4.14 shows 
SW-480 xenograft treated with 1 mg DMAT/animal/day (10 mg/kg DMAT) for two 
weeks.  
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Figure 4.13. Soft agar anchorage independence assay for SW-480 cells (one week 
treatment with DMAT 10 µM).  
 
A. Control (DMSO) SW-480 colonies, B. DMAT treated, SW-480 colonies, C. Colonies 
areas measured and quantified from several pictures. 
Magnification 10X. 
 211 
 
 
 
 
 
 
SW-480 xenograft treated with 40 mg/kg DMAT (in DMSO) per animal, daily
animal weight was averaged at 35 g at the start of treatment
0 1 2 3 4 5 6 7 8 9 10 11 12 13
0
250
500
750
1000
1250
1500
1750
2000
2250
2500
DMAT Treated SW-480
SW-480 Control
n = 8
*
*
*
*
*
*
*
*
*
*
*
days
tu
m
or
 v
ol
um
e 
(p
ro
la
te
 s
ph
er
oi
d)
 m
m
3
 
Figure 4.14. SW-480 xenograft treated with 1 mg DMAT/animal/day (40 mg/kg 
DMAT) for two weeks.  
 
Tumors were 200 mm3 in volume at start. Filled squares - average of tumor volumes for 
Control batch (DMSO) versus tumor volumes from DMAT treated batch represented 
with filled triangles. * represent p < 0.01 as assessed daily with student t-test. 
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Figure 4.15. Hematoxylin and eosin staining of SW-480 tumors.  
 
A. Control (DMSO) tumor SW-480, B. Tumor from SW-480 DMAT treated mice, C. 
SW-480 H&E apoptotic-necrotic areas, D. SW-480 H&E angiogenesis areas 
Magnification 10X. 
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Figure 4.16. Hematoxylin and eosin staining of SW-480 livers.  
 
A. Control (DMSO), SW-480 xenograft, liver B. Liver from SW-480 DMAT treated 
mice, C. Liver from normal healthy wild type mouse C57BL (horizontal section), D. 
Liver from normal healthy wild type mouse C57BL (transversal section). Magnification 
10X. 
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Figure 4.17. Hematoxylin and eosin staining of SW-480 spleens.  
 
A. Control (DMSO), SW-480 tumor bearing, spleen B. Spleen from SW-480 DMAT 
treated mice C. Spleen from normal healthy wild type mouse C57BL (horizontal section), 
D. Spleen from normal healthy wild type mouse C57BL (transversal section). 
Magnification 10X. 
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The effect less stronger than in the MCF-7 xenografts (we used four times more DMAT), 
suggesting potential involvement of different mechanisms of action, especially female 
hormone pathways (due to CK2 signaling). Tumor sections were analyzed (histology) for 
necrosis and apoptosis. Figure 4.15 show hematoxylin and eosin staining of SW-480 
tumors. Figure 4.15, panel A, Control tumor (DMSO) is compared with panel B (tumor 
from SW-480 DMAT treated mice). This figure shows that necrosis and apoptosis are 
induced by DMAT in SW-480 tumors to an even higher extent than in MCF-7 
xenografts. Organs were checked (H&E) and as seen in the figure 4.16 (spleen) and 
figure 4.17 (liver) show that DMAT does not affect these organs in SW-480 xenografts. 
SW-480 cells did not infiltrate the spleen and liver of SW-480 xenografts.   
CK2 maybe involved in the development of melanoma cells due to its action on 
B23 nuclear protein, as well as due to its effects on AKT/PI3K pathways. First things that 
were tested were effects of DMAT on proliferation and apoptosis in vitro in WM-164 
melanoma cells. Results were like expected, DMAT induced proliferation arrest in 
melanoma cells, dose and time dependent, maybe due to a dominant mechanism different 
than in breast cancer cells, for example the VEGF signaling. In the figure 4.18 we can 
observe that DMAT induces proliferation arrest in melanoma cells dose and time 
dependent. Figure 4.19 show that DMAT induces apoptosis dose dependent in WM-164 
cells in culture. In the figure 4.19 are results from flow cytometric apoptosis assay 
(AnnexinV-FITC and PI) of WM-164 cells after 24 hours of treatment with DMAT 10 
and 20 µM. Control (DMSO) has 4.2 % apoptotic cells, whereas DMAT 10 µM treatment 
of WM-164 cells for 24 hours induced 30% apoptosis and DMAT 20 µM for 24 hours 
induced 50% apoptosis.  
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Figure 4.18. Proliferation assay of WM-164 cells treated with DMAT 10 and 20 µM 
(Trypan Blue exclusion).  
 
Squares – Control (DMSO), triangles - DMAT 10 µM, Stars - DMAT 20 µM  Treatment 
length was four days.  
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Figure 4.19. Phase-contrast micrographs of WM-164 cells after 24 hours of 
treatment with DMAT 10 and 20 µM.  
 
A. Control (DMSO), 5X magnification, B. Control (DMSO), 10X magnification, C. 
DMAT 10 µM  treatment of WM-164 cells, 5X magnification D. DMAT 10 µM  
treatment of WM-164 cells, 10X magnification, E. DMAT 20 µM  treatment of WM-164 
cells, 5X magnification, F. DMAT 20 µM  treatment of WM-164 cells, 10X 
magnification. 
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Figure 4.20. Results from flow cytometric apoptosis assay (AnnexinV-FITC and PI) 
of WM-164 cells after 24 hours of treatment with DMAT 10 and 20 µM.  
 
A. Control (DMSO) B. DMAT 10 µM  treatment of WM-164 cells, C. DMAT 20 µM, D. 
Quantification of the results from diferent apoptosis assays performed after one day of 
treatment with DMAT (triplicates). 
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Figure 4.21. Soft agar anchorage independence assay for WM-164 cells (one week 
treatment with DMAT 10 µM).  
 
A. Control (DMSO) MCF-7 colonies, B. DMAT treated, WM-164 colonies, C. Colonies 
areas were measured from several images. 
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These results are comparable with the ones obtained with MCF-7 cells and SW-
480 cells (about 20% induced apoptosis after 24 hours and 50% apoptosis after 48 hours). 
WM-164 cells also present the characteristic feature of malignant cells, which is growth 
independence. In melanoma, deregulations of growth regulatory pathways have been 
described and are responsible for the anchorage independence of these cells [37, 38]. We 
analyzed the effects of DMAT (and thus CK2) in an anchorage independence soft agar 
assay, see figure 4.20. The soft agar anchorage independence assay (one week treatment 
with DMAT 10 µM) shows that DMAT inhibits anchorage independence in WM-164 cell 
line. We found that DMAT induces proliferation arrest in vivo in WM-164 xenografts, 
this effect was not as strong as observed in the MCF-7 cells, but still significant at the end 
of the two weeks of treatment. Figure 4.21 shows WM-164 xenograft treated with 1 mg 
DMAT/animal/day (10 mg/kg DMAT) for two weeks. Tumors and organs from theses 
mice were analyzed histologically (H&E). Figure 4.22 shows hematoxylin and eosin 
staining of WM-164 tumors. Figure 4.23, panel A. Control (DMSO only treated), 
magnification 10X can be compared with panel B, tumor from WM-164 DMAT treated 
mice. This figure shows that necrosis and apoptosis are induced by DMAT in WM-164 
tumors extensively. Organs examined in the same manner show that  DMAT does not 
affect organs in the WM-164 xenografts and that WM-164 cells do not infiltrate the 
spleen and the liver. Figure 4.23 and 4.24 are H&E micrographs of staining for WM-164 
liver and spleen tissues (control-DMSO versus DMAT treated). 
We can conclude that DMAT at this amount is not toxic to mice and it has real 
potential to be used as a starting point in developing an anti-cancer therapy. 
 
 223 
 
 
 
 
 
 
 
 
WM-164 xenograft treated with DMAT 10 mg/kg (in DMSO) per animal, daily,
animal weight was averaged at 35 g
4 5 6 7 8 9 10 11 12 13 14
0
250
500
750
1000
1250
1500 Control WM-164 Both
Treated WM-164 Both
*
n = 8
days
tu
m
or
 v
ol
um
e 
(p
ro
la
te
 s
ph
er
oi
d)
 m
m
3
 
 
Figure 4.22. WM-164 xenograft treated with 0.25 mg DMAT/animal/day (10 mg/kg 
DMAT) for two weeks.  
 
Tumors were 200 mm3 in volume at start. Filled squares - average of tumor volumes for 
Control batch (DMSO) versus tumor volumes from DMAT treated batch (8 tumors) 
represented with filled triangles. * represent p < 0.01 as assessed daily with student t-test. 
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Figure 4.23. Hematoxylin and eosin staining of WM-164 tumors.  
 
A. Control WM-164 tumor (DMSO), B. Tumor from WM-164 DMAT treated mice, C. 
WM-164 H&E apoptotic-necrotic areas, D. WM-164 H&E angiogenesis areas. 
Magnification 10X. 
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Figure 4.24. Hematoxylin and eosin staining of WM-164 livers.  
 
A. Control (DMSO) liver, WM-164 tumor bearing mouse, B. Liver from WM-164 
DMAT treated mice, C. Liver from healthy normal wild type mouse C57BL (horizontal 
section), D. Liver from healthy normal wild type mouse C57BL (transversal section). 
Magnification 10X. 
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Figure 4.25. Hematoxylin and eosin staining of WM-164 spleens.  
 
A. Control (DMSO) spleen, WM-164 tumor bearing mouse, B. Spleen from WM-164 
DMAT treated mice, C. Spleen from healthy normal wild type mouse C57BL (horizontal 
section), D. Spleen from healthy normal wild type mouse C57BL (transversal section). 
Magnification 10X. 
 
 227 
 
 
4.5. DISCUSSION 
CK2 is involved in many human cancers causing cellular transformation and 
development of tumorigenesis and aggressive tumor behavior. CK2 is up-regulated in 
cancers of mammary gland, lung, kidney, colon, head and neck and serves as an 
oncogene in lymphocytes. Various mechanisms and intricate signaling are responsible for 
the effects of CK2 in these cancers [39]. Based on all the evidence from literature and our 
preliminary data with chronic myelogenous leukemia cells, we decided to test the effects 
of the CK2 inhibitor DMAT on hormone dependent human breast cancer cells (MCF-7), 
colorectal adenocarcinoma cells (SW-480) and melanoma cells (WM-164). 
CK2 enhances Wnt-β-catenin signaling in mammary epithelial cells. NFκ-B 
activation and up-regulation of c-myc are another mechanism through which CK2 
induces malignant transformation of breast cells [1, 40]. MCF-7 cells are known to 
present the anchorage independence feature, due to activation of MAPK through 
phosphatidylinositol-3 kinase by insulin-like growth factor I [35]. Based on the fact that 
CK2 is involved in this pathway [36], we decided to test the effects of CK2 inhibition 
with DMAT on MCF-7 cells first on proliferation and anchorage independence assay in 
soft agar. Results were astonishing. Proliferation and colony formation were strongly 
inhibited, much better than of the megakaryoblastic leukemia cells, that we tested 
previously, see Chapter II and Chapter III.  We also found that DMAT induces apoptosis 
in MCF-7 after 24 hours and that the level of apoptotic cells doubles in 48 hours. The 
percentage of apoptotic cells produced by DMAT treatment is much higher than in the 
megakaryoblastic cells. If we have such a strong apoptotic response, most probably this is 
due also to caspase activation combined with the previously described mechanisms. 
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MCF-7 cells form tumors in vivo only if they are stimulated with feminine hormone 
estrogen. We created MCF-7 xenografts which were treated with the hormone precursor 
17-β-estradiol. Tumor growth was monitored and histological analysis of the tissue 
samples from tumors (treated and non-treated with DMAT) was performed. From these 
experiments we found that DMAT induced tumor growth arrest, ablation in smaller 
tumors and these were due to apoptosis and necrosis in the tumor. Tumor growth varies 
with the amounts of hormone administered and we observed that effects of DMAT were 
more pronounced in smaller tumors (less hormone) sustaining the idea that CK2 
inhibitors maybe developed to create adjuvant therapy for breast cancer. Organ tissue 
samples were analyzed and were normal from both tumor bearing mice treated and non-
treated suggesting that DMAT does not have toxic effects at the amounts administered. 
For variety, other completely different cancer cell lines were treated with DMAT 
and analyzed in the same manner. 
In colon cancer cells, increased expression of casein kinase 2 (CK2) is associated 
with hyperproliferation and suppression of apoptosis. Mutations in the tumor suppressor 
APC (adenomatous polyposis coli) are frequent in colon cancer and often increase levels 
of β-catenin–T cell factor (Tcf)/lymphoid enhancer binding factor (Lef)-dependent 
transcription of genes such as c-myc and cyclin-D1. CK2 increases survivin expression 
via these signaling mechanisms, which provokes in this way the malignant transformation 
of colon cells. CK2 inhibitor TBB was found to inhibit this signaling [20]. If TBB affects 
this survivin expression, it is normal to presume that DMAT which is a better CK2 
inhibitor than DMAT will have similar or better effects and thus DMAT will inhibit SW-
480 colon cancer cells growth. Over-expression of  PKC beta1 and adenomatous 
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polyposis coli (APC) signaling in the SW-480 colon cancer cell line are also responsible 
for the anchorage independence growth in soft agar. CK2 is involved in these pathways 
and thus DMAT which is a potent CK2 inhibitor should inhibit the anchorage 
independence phenotype of SW-480 cells. Therefore, we tested effects of DMAT on 
apoptosis, proliferation and anchorage independence in soft agar and we found that 
DMAT inhibits all these processes almost as at the same level as in MCF-7 cells, in vitro. 
We had to use a much higher amount of DMAT in vivo, to observe tumor proliferation 
arrest and necrosis/apoptosis in the SW-480 tumors treated with DMAT. One reason 
could be that the animals that we used for these experiments were males whereas the 
MCF-7 xenografts were females treated with feminine hormone. These difference 
suggests that CK2 maybe involved in the hormone metabolism or defective function of 
receptors for estrogen, or at least that DMAT acts on such pathways. 
CK2 maybe involved in the development of melanoma cells due to its action on 
B23 nuclear protein, as well as due to its effects on AKT/PI3K pathways. WM164 
melanoma growth is modulated by VEGF and BFGF factors [37]. These factors induce 
angiogenic and tumorogenicity characteristics to melanoma cells. VEGF and BFGF 
activate PI3K/AKT signaling [38]. Thus it was interesting to see whether DMAT affects 
angiogenesis and tumor development in melanoma. Deregulation of growth regulatory 
pathways has been described on four levels and are responsible for the anchorage 
independence of melanoma cells: aberrant production of autocrine growth factors, 
alterations in the response to negative autocrine growth factors, interleukine-6 (IL-6) and 
transforming growth factor (TGF-beta), over-expression of epidermal growth factor 
receptors (EGF-R) and alterations of cellular oncogenes involved in signal transduction 
 230 
 
 
(RAS, MYB) and growth suppression (p53) [41]. In in vitro cellular assays (apoptosis, 
proliferation, anchorage independence in soft agar) DMAT had similar effects on WM-
164 cells as on MCF-7 and SW-480 suggesting that just in the cellular environment, 
defective mechanisms in which CK2 is involved maybe common. We speculate that the 
mechanism that involves cell cycle and the defective extrinsic apoptotic pathway will 
cooperate to have similar results in all cancer cell lines tested.  The melanoma xenografts, 
treated with the same amount of DMAT, as MCF-7 cells, responded to these treatment 
only at the end of the study (after two weeks). These results suggest that in body, where 
various stimuli and signals modulate tumor growth, there are other mechanisms involved 
which create the unique characteristics and variety of pathways of each cancer type.  
  To conclude, all tumors from treated mice showed high necrotic and apoptotic 
areas versus untreated (DMSO) tumors and tumor growth was arrested. All organs seem 
to look normal based on the hematoxylin-eosin pictures. Therefore, DMAT and in 
general CK2 inhibition prove of utmost importance as tools in developing new cancer 
therapies. 
 231 
 
 
4.5. REFERENCES 
1. Landesman-Bollag, E., R. Romieu-Mourez, D.H. Song, G.E. Sonenshein, 
R.D. Cardiff, and D.C. Seldin, Protein kinase CK2 in mammary gland tumorigenesis. 
Oncogene, 2001. 20: p. 3247-3257. 
2. Seldin, D.C., E. Landesman-Bollag, M. Farago, N. Currier, D. Lou, and I. 
Dominguez, CK2 as a positive regulator of Wnt signalling and tumourigenesis. Mol. Cell 
Biochem., 2005. 274: p. 63-67. 
3. Slaton, J.W., G.M. Unger, D.T. Sloper, A.T. Davis, and K. Ahmed, 
Induction of apoptosis by antisense CK2 in human prostate cancer xenograft model. Mol. 
Cancer Res., 2004. 2: p. 712-721. 
4. Unger, G.M., A.T. Davis, J.W. Slaton, and K. Ahmed, Protein kinase CK2 
as regulator of cell survival: implications for cancer therapy. Curr. Cancer Drug Targets, 
2004. 4: p. 77-84. 
5. Wang, H., A. Davis, S. Yu, and K. Ahmed, Response of cancer cells to 
molecular interruption of the CK2 signal. Mol. Cell Biochem., 2001. 227: p. 167-174. 
6. Ravi, R. and A. Bedi, Sensitization of tumor cells to Apo2 ligand/TRAIL-
induced apoptosis by inhibition of casein kinase II. Cancer Res., 2002. 62: p. 4180-4185. 
7. Ahmed, K., D. Gerber, and C. Cochet, Joining the cell survival squad: an 
emerging role for protein kinase CK2. Trends Cell Biol., 2002. 12(5): p. 226-230. 
 232 
 
 
8. Phan-Dinh-Tuy, F., J. Henry, C. Boucheix, J.Y. Perrot, C. Rosenfeld, and 
A. Kahn, Protein kinases in human leukemic cells. Am. J. Hematol., 1985. 19: p. 209-
218. 
9. Yu, S., H. Wang, A. Davis, and K. Ahmed, Consequences of CK2 
signaling to the nuclear matrix. Mol Cell Biochem, 2001. 227(1-2): p. 67-71. 
10. Faust, R.A., S. Tawfic, A.T. Davis, L.A. Bubash, and K. Ahmed, 
Antisense oligonucleotides against protein kinase CK2-alpha inhibit growth of squamous 
cell carcinoma of the head and neck in vitro. Head Neck, 2000. 22(4): p. 341-346. 
11. Izeradjene, K., L. Douglas, A. Delaney, and J.A. Houghton, Casein kinase 
II (CK2) enhances death-inducing signaling complex (DISC) activity in TRAIL-induced 
apoptosis in human colon carcinoma cell lines. Oncogene, 2005. 24(12): p. 2050-2058. 
12. Soule, H.D., J. Vazguez, A. Long, S. Albert, and M. Brennan, A human 
cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst, 
1973. 51(5): p. 1409-16. 
13. Huguet, E.L., J.A. McMahon, A.P. McMahon, R. Bicknell, and A.L. 
Harris, Differential expression of human Wnt genes 2, 3, 4, and 7B in human breast cell 
lines and normal and disease states of human breast tissue. Cancer Res, 1994. 54(10): p. 
2615-21. 
14. Sugarman, B.J., B.B. Aggarwal, P.E. Hass, I.S. Figari, M.A. Palladino, Jr., 
and H.M. Shepard, Recombinant human tumor necrosis factor-alpha: effects on 
 233 
 
 
proliferation of normal and transformed cells in vitro. Science, 1985. 230(4728): p. 943-
5. 
15. Pratt, S.E. and M.N. Pollak, Estrogen and antiestrogen modulation of 
MCF7 human breast cancer cell proliferation is associated with specific alterations in 
accumulation of insulin-like growth factor-binding proteins in conditioned media. Cancer 
Res, 1993. 53(21): p. 5193-8. 
16. Romieu-Mourez, R., E. Landesman-Bollag, D. Seldin, and G. Sonenshein, 
Protein Kinase CK2 Promotes Aberrant Activation of Nuclear Factor-B, Transformed 
Phenotype, and Survival of Breast Cancer Cells. Cancer Research, 2002: p. 6770-6778. 
17. Ford, H., E. Landesman-Bollag, C. Dacwag, P. Stukenberg, A. Pardee, and 
D. Seldin, Cell cycle-regulated phosphorylation of the human SIX1 homeodomain 
protein. J Biol Chem, 2000. 275: p. 22245-22254. 
18. Izeradjene, K., L. Douglas, A. Delaney, and J.A. Houghton, Influence of 
casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced 
apoptosis in human rhabdomyosarcoma cells. Clin. Cancer Res., 2004. 10: p. 6650-6660. 
19. Leibovitz, A., J.C. Stinson, W.B. McCombs, 3rd, C.E. McCoy, K.C. 
Mazur, and N.D. Mabry, Classification of human colorectal adenocarcinoma cell lines. 
Cancer Res, 1976. 36(12): p. 4562-9. 
20. Tapia, J.C., V.A. Torres, D.A. Rodriguez, L. Leyton, and A.F. Quest, 
Casein kinase 2 (CK2) increases survivin expression via enhanced beta-catenin-T cell 
 234 
 
 
factor/lymphoid enhancer binding factor-dependent transcription. Proc Natl Acad Sci U 
S A, 2006. 103(41): p. 15079-84. 
21. Homma, M.K., D. Li, E.G. Krebs, Y. Yuasa, and Y. Homma, Association 
and regulation of casein kinase 2 activity by adenomatous polyposis coli protein. Proc 
Natl Acad Sci U S A, 2002. 99(9): p. 5959-64. 
22. Herlyn, D., D. Iliopoulos, P.J. Jensen, A. Parmiter, J. Baird, H. Hotta, K. 
Adachi, A.H. Ross, J. Jambrosic, H. Koprowski, and et al., In vitro properties of human 
melanoma cells metastatic in nude mice. Cancer Res, 1990. 50(8): p. 2296-302. 
23. Graeven, U., W. Fiedler, S. Karpinski, S. Ergun, N. Kilic, U. Rodeck, W. 
Schmiegel, and D.K. Hossfeld, Melanoma-associated expression of vascular endothelial 
growth factor and its receptors FLT-1 and KDR. J Cancer Res Clin Oncol, 1999. 
125(11): p. 621-9. 
24. Bernard, K., E. Litman, J.L. Fitzpatrick, Y.G. Shellman, G. Argast, K. 
Polvinen, A.D. Everett, K. Fukasawa, D.A. Norris, N.G. Ahn, and K.A. Resing, 
Functional proteomic analysis of melanoma progression. Cancer Res, 2003. 63(20): p. 
6716-25. 
25. Negi, S.S. and M.O. Olson, Effects of interphase and mitotic 
phosphorylation on the mobility and location of nucleolar protein B23. J Cell Sci, 2006. 
119(Pt 17): p. 3676-85. 
 235 
 
 
26. Louvet, E., H.R. Junera, I. Berthuy, and D. Hernandez-Verdun, 
Compartmentation of the nucleolar processing proteins in the granular component is a 
CK2-driven process. Mol Biol Cell, 2006. 17(6): p. 2537-46. 
27. Lawson, K., L. Larentowicz, L. Laury-Kleintop, and S.K. Gilmour, B23 is 
a downstream target of polyamine-modulated CK2. Mol Cell Biochem, 2005. 274(1-2): 
p. 103-14. 
28. Szebeni, A., K. Hingorani, S. Negi, and M.O. Olson, Role of protein 
kinase CK2 phosphorylation in the molecular chaperone activity of nucleolar protein 
b23. J Biol Chem, 2003. 278(11): p. 9107-15. 
29. Siemer, S., S. Kriener, J. Konig, K. Remberger, and O.G. Issinger, 
Influence of indomethacin and difluoromethylornithine on human tumour growth in nude 
mice. Eur J Cancer, 1995. 31A(6): p. 976-81. 
30. Xu, X., E. Landesman-Bollag, P.L. Channavajhala, and D.C. Seldin, 
Murine protein kinase CK2: gene and oncogene. Mol Cell Biochem, 1999. 191(1-2): p. 
65-74. 
31. McKendrick, L., D. Milne, and D. Meek, Protein kinase CK2-dependent 
regulation of p53 function: evidence that the phosphorylation status of the serine 386 
(CK2) site of p53 is constitutive and stable. Mol Cell Biochem, 1999. 191(1-2): p. 187-
99. 
32. Blaydes, J.P. and T.R. Hupp, DNA damage triggers DRB-resistant 
phosphorylation of human p53 at the CK2 site. Oncogene, 1998. 17(8): p. 1045-52. 
 236 
 
 
33. Olsten, M.E., J.E. Weber, and D.W. Litchfield, CK2 interacting proteins: 
emerging paradigms for CK2 regulation? Mol Cell Biochem, 2005. 274(1-2): p. 115-24. 
34. Miller, S.J., D.Y. Lou, D.C. Seldin, W.S. Lane, and B.G. Neel, Direct 
identification of PTEN phosphorylation sites. FEBS Lett, 2002. 528(1-3): p. 145-53. 
35. Suzuki, K. and K. Takahashi, Anchorage-independent activation of 
mitogen-activated protein kinase through phosphatidylinositol-3 kinase by insulin-like 
growth factor I. Biochem Biophys Res Commun, 2000. 272(1): p. 111-5. 
36. Le Page, C., I.H. Koumakpayi, L. Lessard, F. Saad, and A.M. Mes-
Masson, Independent role of phosphoinositol-3-kinase (PI3K) and casein kinase II (CK-
2) in EGFR and Her-2-mediated constitutive NF-kappaB activation in prostate cancer 
cells. Prostate, 2005. 65(4): p. 306-15. 
37. Graeven, U., U. Rodeck, S. Karpinski, M. Jost, S. Philippou, and W. 
Schmiegel, Modulation of angiogenesis and tumorigenicity of human melanocytic cells 
by vascular endothelial growth factor and basic fibroblast growth factor. Cancer Res, 
2001. 61(19): p. 7282-90. 
38. Abid, M.R., S. Guo, T. Minami, K.C. Spokes, K. Ueki, C. Skurk, K. 
Walsh, and W.C. Aird, Vascular endothelial growth factor activates PI3K/Akt/forkhead 
signaling in endothelial cells. Arterioscler Thromb Vasc Biol, 2004. 24(2): p. 294-300. 
39. Duncan, J.S. and D.W. Litchfield, Too much of a good thing: the role of 
protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2. 
Biochim Biophys Acta, 2008. 1784(1): p. 33-47. 
 237 
 
 
40. Landesman-Bollag, E., D.H. Song, R. Romieu-Mourez, D.J. Sussman, 
R.D. Cardiff, G.E. Sonenshein, and D.C. Seldin, Protein kinase CK2: signaling and 
tumorigenesis in the mammary gland. Mol Cell Biochem, 2001. 227(1-2): p. 153-65. 
41. Rodeck, U., Growth factor independence and growth regulatory pathways 
in human melanoma development. Cancer Metastasis Rev, 1993. 12(3-4): p. 219-26. 
 
 
 238 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER V 
OVERALL CONCLUSIONS AND FUTURE DIRECTIONS 
5.1. OVERALL CONCLUSIONS 
Cancer is one of the major health problems of this century. The variety of cancer 
types and complex mechanisms and various molecular and genetic defects that cause 
cancer makes drug development a real challenge for researchers today. Different 
strategies were developed by focusing on specific molecules involved in cancer 
development. It is extremely hard to find specific molecules that are entirely the cause of 
the cancer development, but there are a lot that are deregulated, therefore they are 
targeted for drug design. 
A protein named casein kinase 2 (CK2) was found deregulated in several types of 
cancer. CK2 controls both cell cycle [1-3] and apoptotic pathways [4-6]. This kinase has 
dual localization: cytoplasmic and nuclear. In different cancer types examined, CK2 was 
found to be up-regulated and constitutively activated. CK2 started to become an 
interesting cancer target, especially after various inhibitors were developed and studies in 
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cells and animals (mice) were done [4, 6]. Knockout CK2 alpha [7-11] and beta mice and 
silencing of CK2 alpha in mice were studied [12, 13]. CK2 has a highly conserved 
aminoacid sequence between the species suggesting that may have a fundamental role in 
cell function. Our studies sustain these data and bring novel observations that promote the 
idea of using CK2 inhibitors as a potential drug for various types of cancer. 
We observed for the first time that the use of the CK2 inhibitor DMAT in the 
human malignant megakaryoblastic cell line (MEG-01) induces proliferation arrest and 
apoptosis. A very unique observation was that DMAT enhances platelets production from 
these cells in vitro (we characterized this process in detail) and in vivo. I consider this 
observation the most important of my entire work because it opens up various 
possibilities, just for basic research. We have a model of platelets production in vitro, 
easy to obtain and fast. These platelets were characterized as normal and have a normal 
function. Other models of platelets production in vitro were developed, like the one using 
CD34+ stem cells. In this model, CD34+ stem cells are stimulated to become 
megakaryocytes with specific cytokine cocktails and then these megakaryocytes are 
stimulated to release platelets. These procedures are time (months) and money 
consuming. The CD34+ cells are primary cells and thus they need to be isolated each 
time from bone marrow aspirates or they need to be purchased. We can use MEG-01 
platelets for studying various proteins by using genetic engineering of megakaryocytes so 
that the platelets will express the engineered protein. Platelets do not have nucleus and 
thus they cannot produce their own proteins, they need them to be produced in 
megakaryocytes. Such models were created using CD34+ cells and their platelets. 
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An amazing observation that I made is that MEG-01 cells form tumors in 
immunodeficient mice and these tumors release platelets in vivo. This release seem to be 
stimulated by DMAT. These animals show spleen infiltration with megakaryocytic cells 
and have splenomegaly, as well as high platelets counts. This creates an easy to obtain 
model of chronic myelogenous leukemia, in which anti-leukemia drugs can be tested.  
Another possibility, on the long run, for the applicability of this present work is 
the use of such inhibitors as developing adjuvant therapy for chronic myelogenous 
leukemia patients. We are targeting specifically the patients with resistance to the actual 
therapies (imatinib, and imatinib –like drugs). 
DMAT was tested in various cellular and murine xenograft models. This work 
brings a few more cell lines that were not studied previously into the cohort of others that 
were tested up to date with other CK2 inhibitors. We found (like expected) that DMAT 
inhibits malignant cell growth in vitro and in vivo by inducing apoptosis in these cells 
(breast cancer, colon cancer and melanoma). Effects of DMAT on cancer cells, in vitro, 
were similar with all the cell lines tested, but in vivo results were different (tumor growth 
was inhibited with different amounts of DMAT), suggesting that the organism milieu 
creates signaling mechanisms that may stimulate more the malignant cells growth. Such 
stimuli are hormones. MCF-7 (breast cancer) xenografts were treated with 17-beta-
estradiol. When hormone level was decreased, tumor growth was slower and thus DMAT 
had a better effect than in the exponentially growing tumors. DMAT had the best effect 
on breast cancer, very good on colon cancer and good on melanoma. 
A pilot toxicity study was performed with DMAT. A male immunodeficient mouse 
received a high quantity of DMAT for a period of two weeks. The animal behavior was 
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observed and after two weeks was euthanized and histological analysis was performed on 
its organs. The animal did not present any abnormal behavior and he ate and drunk water 
regularly. He presented soreness and a big cyst formation at the injection site, which was 
due to deposits of DMAT. DMAT is not soluble in polar solvents (only DMSO) and that 
was the reason for this cyst formation. This maybe the reason that even at this high 
amount it was not lethal. However it seems that somehow DMAT maybe absorbable up 
to a point that it has effect from an exogenous tumor site. DMAT was injected into the 
neck fat pad subcutaneous, far from the tumors. From this study, the first conclusion to 
draw would be that DMAT is not toxic at the level tested. 
Overall from all the studies performed in this work we can conclude that a CK2 
inhibitor, DMAT is a potent candidate for anti-cancer drug development. 
 
5.2. FUTURE DIRECTIONS 
The first thing that I would do to continue this work, would be to administer 
DMAT to animals by gavage. This can be done by using oil-emulsion (sesame-seed oil). 
Insoluble substances can be administered in this way on the oral route. I will repeat the 
toxicity study with more animals, considering that one animal is not enough. More 
animals are also needed for the tail-bleeding study, in order to withdraw any clear 
conclusions from it. For the tail-bleeding study, I would also perform a clot retraction 
tail-bleeding time. The xenografts studies performed until now need to be repeated with a 
higher animal number. 
As a more tangible and immediate direction of this research, I would analyze 
more in detail the platelets production from MEG-01 tumor bearing mice. First thing that 
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needs to be done is to assess if we have circulating MEG-01 blasts. This can be easily 
done by blood smear. Blood smears will show all the blood cells and the abnormal cells 
can be easily spotted. With blood smears, accurate cell counts can be performed based on 
cell density per field. This is a very common practice in clinical laboratories. I would also 
examine lungs for megakaryocytic infiltration, because it was proposed that platelets 
production may not take only in the bone marrow but also in the lungs from migrated 
megakaryocytes.  
Another way, more complicated but more elegant, to study blast and platelets 
circulation would be to transfect MEG-01 cells with green fluorescent protein (GFP) or 
luciferase and to examine if platelets from these cells are “green”, in vitro (fluorescence 
microscopy and flow cytometry). If these platelets are green, then GFP MEG-01 cells 
could be used to create xenografts with green tumors. In this way we can quantify exactly 
how many platelets are human and how many are murine, how they get activated and 
where they go. We can also monitor tumor infiltration and have a possible metastasis 
model. This model can prove useful in studies like platelets involvement in angiogenic 
response in ischemia conditions. 
It would be interesting to see what effects has DMAT on CD34+ megakaryocytes 
(normal and from patients with chronic myelogenous leukemia). A murine model of 
chronic myelogenous leukemia [14] is available from the Jackson Laboratory and it can 
be used to study DMAT in the context of the real disease in animal. 
A mechanistic study is also required. One direction would be to consider the 
cytoplasmic localization of CK2 and another to consider the nuclear site. For the 
cytoplasmic study it seems that CK2 controls apoptotic pathways preponderantly through 
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Bid protein as a common mechanism in all cancers. CK2 phosphorylates Bid and 
phosphorylated Bid is less sensitive to cleavage by caspase-8 and caspase-3. The active 
form of Bid is the truncated one, tBid. tBid will relocate to mithocondria and start the 
mitochondrial apoptotic pathway [5, 15-18]. I would use western blot analysis of cell 
lysates (cancer cells treated and not-treated with DMAT and as a control cell lysates 
where silencing of CK2α was performed) to quantify amounts of various apoptotic 
proteins and first ones to quantify would be tBid and Bid. Mitochondrial membrane 
potential changes could be assess using flow cytometry (JC-1, Mitotrack). Cytochrome c 
release can be quantified by western blot and also caspase-3, caspase-9 and caspase-7 and 
other apoptotic proteins levels can be observed. A second direction in an mechanistic 
approach would be to understand the events that involve CK2 and control cell cycle [1, 3, 
19-22]. For this normal, cancer cells (diploid and polyploid) will be used. Cyclins, cdk’s 
and B23 protein levels can be assess by western blotting and cell cycle can be analyzed 
for both diploid and polyploid cells by flow cytometry. 
There are a few strategies that can be followed up in order to obtain a cancer drug 
starting with DMAT. 
One possibility (the least desirable) is to cling to DMAT like it is. In order to 
become a drug this substance needs to be soluble and absorbable, thus it needs a drug 
delivery strategy. This can be done by sonication with a delivery vehicle (nano-particles) 
or by using liposome drug delivery [23].  
As a second possibility, other CK2 inhibitors are continuously developed [24-28] 
and therefore options are endless. As a chemist I would change the structure of DMAT to 
make it first of all soluble, even more specific and also original. 
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The third possibility would be to test other potent CK2 inhibitors, that are naturally 
occurring like ellagic acid and cinnamic acid. Such acids can be purchased from Sigma. 
Ellagic acid, for example, is a polysaccharide and thus is soluble in polar solvents. 
Ellagic acid is a polyphenol antioxidant found in berries, various nuts, pomegranates and 
interestingly was found to act on factor XII and stimulate blood clotting. These natural 
occurring substances are sold as natural extracts (remedies), not approved by FDA, in 
natural stores and can be also purchased from internet stores. Cancer patients that used 
them claim very good results. If we as scientists would test more this compounds and 
push for clinical studies, maybe FDA would approve their use and standardize it so they 
can be prescribed by doctors to all patients and this would be of great benefit to so many 
people. Unfortunately patent and financial issues may hinder such developments. 
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